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Abstract
This thesis describes the structural and functional analysis o f two related proteins, PI31 
and Fbxo7, both of which act within the ubiquitin-proteasome system. This system is 
involved in a wide variety o f cellular processes. Proteins modified with ubiquitin are 
often targeted for degradation by the proteasome, an ATP-dependent multi-subunit 
complex. Specificity for ubiquitin transfer is controlled by the E3 ubiquitin ligases. 
The multi-subunit SCF E3 ubiquitin ligases use their F-box domain protein to engage 
substrates.
Analysis of possible binding partners of the novel F-box protein Fbxo7 using an affinity 
pull-down in Jurkat cell lysates identified PI31, a putative proteasome inhibitor. Fbxo7 
was also shown to bind Skpl, Cullinl and Rbxl inferring that it forms part of a 
functional E3 ubiquitin ligase. Crystallisation of the Fbxo7-Skpl complex yielded 
poorly diffracting crystals with a maximum resolution o f 8 A.
The PI31 N-terminal domain (NTD) shows significant sequence similarity to a globular 
domain o f Fbxo7. The PI31-NTD structure was obtained at 2.64A by MAD phasing 
after introducing an additional methionine to engineer a non-centrosymmetric selenium 
substructure. The structure reveals a homodimer o f novel a/p topology, which we 
define as the FP (Fbxo7 -  PI31) domain since its distribution is limited to Fbxo7 and 
PI31 proteins in higher eukaryotes.
Biophysical analysis o f structure-based mutations identified the relevant residues in the 
homodimer interface by confirming the production of a monomeric form of PI31. 
Further mutations also revealed the binding surface between Fbxo7 and PI31 by using 
isothermal calorimetry.
Fbxo7 and PI31 were shown to interact in vivo by co-immunoprecipitation and yeast 
two-hybrid screens using either PI31 or Fbxo7 as bait. Fbxo7 was shown to 
ubiquitinate FLAG-tagged PI31 in vivo. Abolishing the interaction between Fbxo7 and 
PI31 by mutations in PI31 prevents this ubiquitination. A model for the interaction 
between PI31 and Fbxo7 is presented.
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Chapter 1: Introduction
1 Introduction
1.1 Protein degradation through the ubiquitin-proteasome pathway
Since the discovery in 1979 that a specific protein marker, called ubiquitin, tags and 
targets proteins for degradation (Ciechanover et a l  1980; Hershko et a l  1980) it has 
become clear that the degradation of cellular proteins is a highly complex, temporally 
controlled, and tightly regulated process. The ubiquitin-proteasome system plays major 
roles in a variety o f basic pathways during cell life and death through cellular processes 
such as transcription regulation (Muratani and Tansey 2003) and antigen presentation 
(Shastri et a l 2002). In 2004 the Nobel Prize in Chemistry was awarded to Aaron 
Ciechanover, Avram Hershko and Irwin Rose in recognition of their initial discovery of 
this process.
Protein ubiquitination is a tightly controlled process, which is required to target proteins 
for destruction by a multi-subunit ATP-dependent protease called the proteasome. The 
proteasome consists of a central catalytic machine, known as the 20S proteasome and 
two terminal regulatory sub-complexes that are attached to both ends o f the central 
portion to form the active proteasome. Structure determination o f the 20S proteasome 
and its regulators has revealed much o f its function (for a review of this see (Bochtler et 
al. 1999)). Regulation of the proteasome itself is achieved by restricting the proteolytic 
activity to specific locations that can be accessed only by those polypeptides destined 
for destruction. The best characterised chambered protease is the proteasome but 
bacteria, archaea and eukaryotes all use the simple method o f restrictive access for 
regulation of proteases (Groll and Clausen 2003).
Synthetic inhibitors of the proteasome, such as the drug Bortezomib, have been shown 
to have in vivo anti-tumour efficacy (Voorhees et a l 2003) and have recently been 
given approval for use in the treatment of multiple myeloma. It appears that 
transformed cells are more susceptible to proteasome inhibition than normal cells. A 
key factor in the ability to kill certain cancer cells appears to be the ability to block 
activation of NF-kB, which is constitutively active in myeloma cells. NF-kB has anti- 
apoptotic effects and so treatment with proteasome inhibitors can sensitise cells to other 
anti-cancer treatments (Goldberg and Rock 2002).
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The ubiquitin-proteasome system is involved in many cellular processes and one well 
characterised example is the cell cycle (Figure 1.1). For the cell cycle to proceed 
correctly specific proteins must be produced at critical times, these proteins must be 
localised correctly (Moore et al. 2003) and then degraded at specific points in the cell 
cycle in a ubiquitin-dependent manner (Evans et al. 1983; Glotzer et al. 1991). The 
periodic but complete destruction of signalling proteins during this process ensures that 
the cycle continues in its progression in a timely manner without returning to previous 
phases.
Figure 1.1 - Cyclins targeted by ubiquitin-mcdiated proteolysis.
The G1 (gap phase 1), S (DNA synthesis), G2 (gap phase 2) and M (mitosis) phases of the 
mammalian cell cycle are depicted. Positive cell-cycle regulators are shown as green rectangles, 
whereas negative regulators are depicted as red circles.
Proteins in sea urchins and clam embryos, called cyclins, were found to be continuously 
synthesized and accumulated throughout the cell cycle but abruptly disappeared during 
mitosis (Evans et al. 1983). The striking behaviour of these proteins indicated that 
cyclins might be involved in the regulation of cell division. The importance of this 
discovery was recognised in 2001 by the joint award of the Nobel Prize in physiology 
and medicine to Tim Hunt. The rapid disappearance of one of these cyclins, cyclin B, 
was later revealed to be dependent on the ubiquitin system (Glotzer et al. 1991). 
Though cyclin B is a positive regulator of the G2-M phase transition of the cell cycle 
the degradation of this protein is required for exit from mitosis (Glotzer et al. 1991). 
The rapid exit from mitosis that is afforded by the irreversible destruction of cyclin B is 
crucial for cellular and genomic integrity (Wheatley et al. 1997; Jin et al. 1998).
APC
cyclin8
©  APC
M
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The D type cyclins are also regulated by the ubiquitin system. D type cyclins are rate- 
limiting controllers of G1 phase progression. The elimination of the intrinsically 
instable D cyclins is initiated by phosphorylation on a specific site (reviewed in (Lee 
and Yang 2003) and (Sherr 1995)). In addition to this it has been shown that cyclins A 
and E are also substrates of the ubiquitin-proteasome system. Despite the apparent 
complexity of the cell cycle the underlying control is through phosphorylation and 
phosphorylation-dependent degradation through the ubiquitin-proteasome system.
1.2 Ubiquitin and ubiquitin-like proteins
Proteins are targeted to the proteasome for destruction by covalent ligation to ubiquitin, 
a 76 amino acid protein (Hershko et al. 1980). The role of ubiquitin in protein 
degradation was discovered and the main enzymatic reactions of the process elucidated 
by biochemical studies using a cell free system ((Ciechanover et al. 1980) and 
reviewed in (Hershko and Ciechanover 1998)). The ligation of ubiquitin to a protein 
requires the sequential action o f three enzymes (E l, E2 and E3). These enzymes were 
originally identified by affinity chromatography of a crude reticulocyte extract on 
ubiquitin-Sepharose by Hershko et al in 1983 (Hershko et al. 1983). The C-terminal 
glycine residue of ubiquitin is activated by an activating enzyme (E l) in a step that 
requires ATP (Step 1, Figure 1.2). This step involves the intermediate formation of a 
ubiquitin adenylate in which the carboxyl-terminal glycine of ubiquitin and AMP are in 
an acyl-phosphate linkage (Haas and Rose 1982; Haas et al. 1983) along with release of 
PPi and the binding of ubiquitin to a cysteine residue of the El enzyme by a thiolester 
linkage and the release of AMP. This activated ubiquitin is then transferred to the 
active site cysteine residue of a ubiquitin conjugating enzyme (E2) (Step 2, Figure 1.2). 
In the final step, which is catalysed by a ubiquitin-protein ligase (E3), ubiquitin is 
linked by its C-terminus in an amide isopeptide linkage to a s-amino group of the 
substrate protein’s lysine residues (Step 3, Figure 1.2). In rare cases ubiquitin can be 
conjugated to the N-terminal amino group of the substrate (reviewed in (Ciechanover 
and Ben-Saadon 2004)). By successively adding activated ubiquitin moieties to lysine 
residues on the previously conjugated ubiquitin molecule, a polyubiquitin chain is 
synthesised. The three steps outlined in Figure 1.2 are the simple, progressive 
mechanism used in the ubiquitination cascade independently of whether the substrate 
bound ubiquitin(s) signal proteasomal proteolysis or directs the protein to another fate.
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Figure 1.2 -  Enzymatic reactions of the ubiquitin system.
Step 1. El enzyme activates ubiquitin in an ATP-dependent reaction. Step 2. El enzyme 
transfers the activated ubiquitin to the E2 ubiquitin conjugating enzyme. Step 3. E2 transfers the 
ubiquitin to the substrate protein in cooperation with the E3 ubiquitin ligase. SH refers to the free 
form of catalytic cysteine and PPj to inorganic pyrophosphate.
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It has been recently proposed that in addition to the well established E1-E2-E3 cascade 
a supplementary enzyme may be required in some cases. This enzyme would allow the 
elongation of ubiquitin chains on monoubiquitinated substrates to achieve the 
polyubiquitin chains required for recognition by the proteasome. These enzymes have 
been termed E4 enzymes and are reviewed in (Hoppe 2005).
Ubiquitin has a number of related homologues known collectively as ubiquitin-like 
proteins (referred to here as UbLPs) some of which also use the basic set o f catalytic 
reactions that are involved in ubiquitination (outlined in Figure 1.2). Not all UbLPs 
require an E3-like ligase to assist the binding of the UbLP to its target substrate for 
example the E2 enzyme for SUMO-1 can directly both bind and sumoylate its substrate 
in vitro although whether this occurs in vivo is not clear (Schwartz and Hochstrasser 
2003).
By tagging proteins with ubiquitin or ubiquitin-like proteins the cell can create a diverse 
family of post translationally modified proteins that can be identified by downstream 
protein receptors and used to control many regulatory pathways in the cell (Glickman 
and Ciechanover 2002).
Figure 1.3 -  The ubiquitin superfold
An overlay of ubiquitin (blue; PDB accession code 10GW (Vijay-Kumar et al. 1987)), SUMO-1 
(cyan; PDB accession code 1WYW (Baba et al. 2005)) and NEDD8 (green; PDB accession code 
1R4M (Walden et al. 2003)), produced using PyMol (DeLano 2004).
Ubiquitin and ubiquitin-like proteins all contain the ubiquitin superfold (Figure 1.3), 
which is a P-grasp fold, but sequence homology between the proteins varies 
considerably. In the course of evolution UbLPs have evolved to give the present
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repertoire of small proteins with distinct functions, which are only now starting to be 
understood.
Substrate targeting to the proteasome requires the assembly of a polyubiquitin chain 
formed by an isopeptide bond between Lys48 of one ubiquitin moiety and the C- 
terminal carboxyl group of the next ubiquitin in the chain. By contrast, ubiquitin chains 
with non-Lys48 linkages or even a single ubiquitin can sometimes be attached to a 
substrate and may direct its target to a different fate. The most common alternative to 
Lys48 is Lys63 and Lys63-linked polyubiquitination has been implicated in many 
cellular events that do not require destruction via the proteasome (reviewed in 
(Hochstrasser 2004)).
Lys48-linked polyubiquitin chains themselves do not always target the substrate protein 
for destruction (Hochstrasser 2004). The transcription factor Met4 is a stable protein 
even after Lys48-linked polyubiquitination and indeed transcriptional repression of 
Met4 target genes is dependent on the ubiquitination of Met4 (Kaiser et al. 2000; Flick 
et a l 2004). This reveals a proteolysis-independent function for Lys48-linked 
polyubiquitin chains.
Modification of substrate proteins by other UbLPs also has a wide variety of functions 
within the cell by changing the stability, localisation or activity of the target protein. 
Most of these functions are only starting to be established, with SUMO-1 and NEDD8 
being perhaps the best understood UbLPs at this time (Aguilar and Wendland 2003).
In addition to ubiquitin and UbLPs, which are small single subunit proteins, ubiquitin- 
like (Ubl) domains can also occur as stable elements within multi-domain proteins, 
although these Ubl domains cannot be processed or conjugated. Ubl domains, which 
usually have an N-terminal location, have significant sequence similarity to ubiquitin 
and display its characteristic fold. These Ubls can often function as targeting elements 
and have been shown to bind to the proteasome (Walters et al. 2002).
1.3 E3 ubiquitin ligases
There is a hierarchical structure within the ubiquitin cascade: there is one El enzyme 
(McGrath et al. 1991); a limited number of E2 enzymes each of which may interact with 
several E3 enzymes (Pickart and Rose 1985); and a much larger number o f E3 enzymes.
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The level of complexity of control of this system therefore increases throughout the 
pathway.
The large number of E3 ubiquitin ligases confer the specificity, regulation and 
complexity on this pathway by mediating the transfer of ubiquitin from the E2 ubiquitin 
conjugating enzyme to the substrate protein. The ability of E3 proteins to recognise and 
catalyse the processive polyubiquitination of their substrate protein(s) is vital for the 
protein to be targeted to the proteasome because if the correct number of ubiquitin 
moieties is not transferred to the substrate it will not be recognised by the proteasome 
for degradation.
Almost all known E3 ligases contain either a HECT domain or a RING domain (Figure 
1.4) and are classified accordingly. The major difference between these ligases is that 
the HECT domain E3 ubiquitin ligases form a covalent bond with ubiquitin through an 
active site cysteine (Huibregtse et al. 1995) whereas RING domain E3 ubiquitin ligases 
do not. A further sub-classification within the RING E3 ubiquitin ligases can be made 
between single subunit RING E3 ubiquitin ligases, the multi-subunit SCF-like RING E3 
ubiquitin ligases and the multi-subunit APC RING E3 ubiquitin ligases.
El - S -  Ub El - s -  Ub
- S — Ub0  ub j 0
HECT - S -  Ub ^  RING
substrate . . .  substrate . . .
Ub . Ub
protein protein
Figure 1.4 -  Two families of ubiquitin protein ligases
HECT domain E3 ubiquitin ligases form a covalent bond with ubiquitin through an active site 
cysteine whereas RING domain E3 ligases mediate the transfer of ubiquitin to the substrate 
through a different mechanism.
The focus of this introduction is on the SCF subgroup of the RING E3 ubiquitin ligases. 
Excellent reviews have been published elsewhere on the HECT E3 ligases (Pickart 
2001), the single subunit RING E3 ubiquitin ligases (Jackson et al. 2000) and the multi­
subunit APC RING E3 ubiquitin ligases (Vodermaier 2004; Castro et al. 2005).
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1.3.1 SCF-Iike E3 ubiquitin ligases
All non-HECT domain E3 ligases promote the transfer of ubiquitin from the E2 without 
forming a covalent interaction with ubiquitin and they all contain either a RING finger 
domain or the structurally equivalent U-box domain (Hatakeyama and Nakayama 
2003). The RING (really interesting new gene) finger domain displays a series of 
histidine and cysteine residues with a characteristic spacing (Lovering et al. 1993) that 
allows for the co-ordination of two zinc ions in a cross-brace structure. Whereas 
spacing of the two ions is conserved throughout the family, which consists of many 
hundreds of proteins, the primary sequence is not conserved. RING finger proteins act 
as molecular scaffolds that bring other proteins together (Pickart 2001). The RING 
finger domain is thought to bring the E2 enzyme into contact with the RING domain E3 
ligases (Zheng et a l 2000).
The largest subgroup of the RING finger containing E3 ligases is the SCF-like E3 
ligases (reviewed in (Deshaies 1999)). The SCF E3 ubiquitin ligases consist of a 
complex of the Skpl-Cullinl-F-box proteins bound to the E2 binding RING finger 
protein Rbxl (Kamurae/a/. 1999) (Figure 1.5).
O E2 wi t h ubiquit in b o u n d  
•  ■  Cullin h o m o l o g y  
Adapter protein(s)
RING finger protein
€ 3  Substrate r e cogn i t ion  
protein
Figure 1.5 -  The SCF RING E3 ligase
The interaction between Skpl and F-box proteins was first observed between Skpl and 
cyclin F. A 40 amino acid motif was identified in cyclin F that mediates the interaction 
with Skpl by Bai and co-workers (Bai et al. 1996). This 40 amino acid motif is known 
as the F-box domain and it is present in a large family of multi-domain F-box proteins 
that also contain protein-protein interaction domains. The most common protein- 
protein interaction domains in F-box proteins are WD40 domains and leucine rich 
repeats (LRR) and so the nomenclature for newly discovered F-box proteins is Fbxw 
(for WD40 repeat containing proteins), Fbxl (for LRR containing proteins) and Fbxo 
(for all other F-box proteins) (Cenciarelli et al. 1999; Winston et al. 1999). The large
F-box
protein
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numbers of F-box proteins in all the genomes predicted that these proteins conferred 
specificity on the SCF ligase and add to the complexity of the pathway. Skowyra et al 
(Skowyra et al. 1997) showed that this is true in yeast for the F-box protein cdc4 and its 
substrate protein phosphorylated Sicl. Each F-box protein binds to several substrates 
and so many hundreds of proteins can be targeted to the proteasome by interaction with 
the SCF E3 ubiquitin ligase through the variable F-box domain. The specific 
complexes were designated SCF for Skpl-Cullinl-F-box protein, with the F-box protein 
indicated by a superscript, as in SCFcdc4 or SCFcyclm F.
Rbx1
Figure 1.6 -  Model of the SCFskp2-E2 complex
Cull (green), Rbxl (red), Skpl (blue), Skp2 (pink), E2 (yellow) are shown in cartoon 
representation. The zinc atoms in the Rbxl are shown as yellow spheres and the active site 
cysteine of the E2 enzyme where the ubiquitin would be attached is shown in space filling 
representation and coloured in cyan. The grey arrow indicates the 50A gap between the F-box 
protein and the active site cysteine where the substrate is thought to bind. Figure reproduced from 
(Zheng et al. 2002).
The structure solution of the Cull-Rbxl-Skpl-F-boxSkp2 revealed the organisation of the 
SCF ligase and provided valuable insights into the mechanism of ubiquitin transfer 
(Zheng et al. 2002). Cullinl is an elongated protein that consists of a long stalk made of 
three repeats of a five helix bundle called the cullin-repeat motif and a globular domain 
that binds the RING finger protein Rbxl through an intermolecular P-sheet. The Skpl- 
F-box substrate recognition complex binds to the tip of the Cullinl stalk. Cullinl is a 
rigid scaffold that organises the Rbxl, Skpl and F-box protein subunits, positioning the 
substrate for optimal ubiquitin transfer. This crystal structure was used to produce a 
model using the previously solved Skpl-Skp2 complex (Schulman et al. 2000) and the
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RING finger -  E2 complex (Zheng et al. 2000) to reveal the overall structure of the E2- 
SCFSkp2 interaction (Figure 1.6). The model revealed a 50A gap between the F-box 
protein and the active site cysteine o f the E2 enzyme to allow the binding of the 
substrate and presentation to the E2 ligase for the transfer of ubiquitin to the substrate 
protein. This proposed mechanism was further revealed by two crystal structures of 
Skpl-F-box protein complexes which contained peptides o f the substrates (SCFcdc4 
(Orlicky et al. 2003) and SCF*3'11^  (Wu et al. 2003)) which both show that a peptide of 
the substrate protein is bound to the F-box protein in a position to allow access to the 
active site cysteine of the E2.
The SCF is not constitutively active and it is controlled by NEDD8 modification 
(neddylation) of Cullinl (Read et al. 2000). Candl protein binds to the unmodified 
Cullinl-Rbxl complex and occludes Skpl, thereby preventing the assembly of an active 
SCF complex. Neddylation o f Cullinl prevents the binding of Candl and stabilises the 
active Skpl-Cull-Rbxl complex. Candl can dissociate Skpl and NEDD8 can 
dissociate Candl and so the inactive and active complexes exist in equilibrium (Zheng 
et al. 2 0 0 2 ).
The Cullin-RING-adaptor theme is repeated in at least five other multi-subunit ubiquitin 
ligases. The complicated combinations of proteins belie a coherent nomenclature and 
so here SCF-like ubiquitin ligases will be named with the original nomenclature for the 
SCF. This is based on the order of the Skpl-like linker, Cullin and the adaptor class for 
example, an EloC-EloB-Cul2-Rbxl-SOCS box protein complex is called EC2S. An 
outline of all the SCF-like protein complexes is given in Table 1.1 and each of these 
will be discussed briefly, for a more complete review see (Willems et al. 2004).
SCF e c 2s b c 3b SC4F? s c 7f ?
Cullin domain 
protein
Cull Cul2 or Cul5 Cul3 Cul4 Cul7
Adaptor proteins Skpl Elongin C, 
Elongin B
BTB/POZ domain 
proteins
? Skpl
Substrate 
binding proteins
F-box
proteins
SOCS box 
proteins
BTB/POZ domain 
proteins
? F-box proteins 
(Fbxw6, Fbxo29)
Activator
proteins
NEDD8 NEDD8 NEDD8 NEDD8 NEDD8
Table 1.1 -  Components of SCF-like ubiquitin E3 ligases
Information taken from (Passmore and Barford 2004) with BTB meaning Broad complex, 
Tramtrack, Brick-a-brack and POZ Poxvirus and Zinc finger.
26
Chapter 1: Introduction
A class of SCF-like complexes that has been shown to be closely related to the SCF is 
built on the Elongin C (EloC)-Cul2 core complex. The EloC forms a heterodimer 
complex with the ubiquitin-like protein Elongin B (EloB) and these two proteins act as 
an adaptor between the substrate binding proteins and the Cul2-Rbxl complex. The 
substrate binding proteins contain a 40 amino acid motif called the SOCS box as well as 
further protein-protein interaction domains which is reminiscent of the F-box proteins. 
The crystal structures of the SOCS box protein VHL bound to EloB/C (Stcbbins et a l  
1999) and the F-box protein Skp2 bound to Skpl (Schulman et al. 2000) reveal striking 
similarities (Figure 1.7). The SOCS box and F-box both consist of a three helix bundle, 
the N-terminus of Skpl resembles the structure of Elongin C. The overall layout of the 
adaptor proteins is the same and therefore substrate binding to the protein is likely to be 
similar (Kile et al. 2002).
Elongin C
Elongin B
SOCS box com plex F-box com plex
Figure 1.7 -  Structural comparison of EC2S and SCF complexes
Elongin C and Skpl are shown in blue, Elongin B is shown in green and the SOCS and F-box 
proteins are shown in red. The boxed area highlights the structural similarity between the N- 
terminus of Skpl and Elongin C. Figure adapted from (Kile et al. 2002).
A third type of SCF-like E3 ligases consist of BTB-containing proteins acting as both a 
Skpl-like adaptor and F-box protein-like substrate specificity factors in association with 
Cul3 and Rbxl (Pintard et al. 2003; Xu et al. 2003). These complexes are termed BC3B 
for BTB-Cul3-BTB reflecting the dual role of the BTB protein. A structural
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comparison of the Skpl and EloC structures revealed that there is a BTB fold embedded 
within them (Stebbins et al. 1999; Schulman et al. 2000) emphasising the structural link 
between all these SCF-like E3 ubiquitin ligases. BTB proteins can also contain protein- 
protein interaction domains, which could interact with substrate proteins in a way 
homologous to F-box proteins (Stogios and Prive 2004).
The other possible SCF-like E3 ligases are less well characterised with, for example, 
several SOCS box proteins (including VHL) binding Cul5 as well as Cul2. Cul4A may 
also act in E3 ligases and Cul7 forms an SCF-like E3 ligase with Rbxl, Skpl and the F- 
box protein Fbxw6/Fbxo29. This interaction between the subunits o f the different 
RING E3 ligases reveals the possibility for cross-talk between these ligases. These 
interactions add an additional layer of complexity to this system, which is required 
because aberrant degradation of proteins might have serious consequences.
1.3.2 Signals that target proteins for ubiquitination
The E3 ubiquitin-protein ligases use different substrate specificity factors to bind to 
their substrates. These differences allow specific proteins to be conjugated with 
ubiquitin at the required time and place. The substrate recognition proteins identify 
signals within the substrate that include post-translational modifications and motifs 
within the protein itself. In contrast to the complexity of the enzymes involved in the 
recognition of these substrates the protein signals themselves are very simple.
Of the SCF-like E3 ligases the best understood is the SCF itself and some o f the signals 
recognised by this ligase are well characterised. The F-box proteins recognise at least 
two different forms of post-translational modification in substrate proteins. F-box 
proteins were originally thought to bind only phosphorylated substrates through their C- 
terminal protein-protein interaction domains (Skowyra et al. 1997). This is an elegant 
and simple solution as SCF complexes can be thought of as coupling protein kinase 
signalling to control the abundance of active proteins. More recently it has been 
reported that some o f the Fbxo type F-box proteins interact with their substrates by 
recognising sugar chains on the substrate protein with the substrates o f these F-box 
proteins being recognised in an N-glycosylation-dependent manner (Yoshida et al. 
2002; Mizushima et al. 2004). The discovery of this mechanism for one class o f Fbxo 
type F-box proteins indicates that there are likely to be other signals recognised by F- 
box proteins that are, as yet, uncharacterised.
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Studies o f the other classes of SCF-like ligases implicate phosphorylation as a targeting 
signal. In the EC2S protein ligase the substrate proteins are only recognised following 
post-translational modification by phosphorylation (Kile et a l 2002) and in the BC3B 
protein ligase it is also possible that phosphorylation is required for substrate 
recognition as in the case o f the BTB protein Mel26 and its substrate M eil (Willems et 
a l 2004).
1.3.3 F-box protein, Fbxo7
Fbxo7 is an F-box protein o f the Fbxo7 class which Cenciarelli and co-workers 
(Cenciarelli et a l 1999) first identified in a yeast two-hybrid screen using human Skpl 
as bait. Biomolecular analysis revealed that Fbxo7 contained the F-box domain and in 
addition to this it also contained proline rich regions (PRR) and a leucine zipper, which 
are both potential protein-protein interaction domains. They went on to show that 
FLAG-tagged Fbxo7 is a component of an SCF complex in vivo by 
immunoprecipitation with anti-FLAG antibody. This interaction is dependent on the 
presence of a functional F-box domain in Fbxo7. SCFFbxo7 was also shown to have 
ubiquitin ligase activity in the presence of an El and E2 enzyme. This was the first 
demonstration that F-box proteins from the Fbxo family could associate with ubiquitin 
ligase activity.
Independently of the work done by Cenciarelli et al, another group identified Fbxo7 to 
be a predicted Fbxo type F-box protein with 522 amino acids and an F-box motif 
located in the C-terminal half of the protein (Ilyin et a l  2000). Fbxo7 mRNA was 
reported to be ubiquitously expressed but enriched in bone marrow, foetal liver, testis 
and thyroid glands. This led Ilyin et al (Ilyin et a l 2000) to suggest that, as the highest 
expression is in the main hematopoietic tissues, this could imply a role for Fbxo7 in the 
regulation of hematopoiesis.
The work by Cenciarelli et al, which showed that Fbxo7 is part o f a functional E3 
ligase, did not point to any substrate proteins for this complex. The first reported 
substrate for SCFFbxo7 was the Cdkl-cyclin B-phosphorylated hepatoma up-regulated 
protein (HURP) (FIsu et a l  2004). Hsu et al (Hsu et a l 2004) demonstrated that Fbxo7 
functions as an adaptor linking the core SCF complex with its substrate, HURP, through 
the PRR of Fbxo7. They were also able to show that this interaction is dependent on the 
phosphorylation of HURP on multiple sites by Cdkl-cyclin B. The kinase Aurora A
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has also been shown to phosphorylate HURP (Yu et a l 2005) and so may also be able 
to target HURP for binding to SCFFbxo7. HURP is a cell cycle regulated gene that is 
over expressed in hepatocellular carcinoma (Tsou et al. 2003). The endogenous levels 
of HURP mRNA are tightly regulated during the cell cycle and its expression is 
elevated in the G2-M phase. Cells stably transfected with HURP appear to have the 
characteristics of tumour cells with a reduced dependence on extra cellular growth 
factors and the potential to exhibit anchorage-independent growth. Tsou et al (Tsou et 
al. 2003) suggested that over expression of HURP in hepatocellular carcinoma may be a 
consequence of deregulation which can lead to cancer by allowing cells to progress 
through the cell cycle. This protein has also been associated with colon cancer, breast 
cancer (Bassal et al. 2001) and transitional cell carcinoma (Chiu et a l 2002). This 
uncontrolled expression of HURP means that the identification o f the SCF ligase 
responsible for the timed degradation of the protein could reveal a possible way to 
revert these cancer cells to a more normal phenotype. These results are further 
encouraging as Ilyin et al (Ilyin et al. 2000) reported Fbxo7 expression in the liver 
which could imply that one possible in vivo role of SCFFbxo7 could be the control of 
HURP protein levels.
Fbxo7 was also reported to be a putative oncogene by our collaborators Laman et al 
(Laman et a l 2005). This work identified Fbxo7 as interacting with viral D-type 
cyclins in a yeast two-hybrid screen of a human cDNA library using a viral D-type 
cyclin as bait. Fbxo7 interacts with both cellular and viral D cyclins and specifically 
binds Cdk6 , in vitro and in vivo. The interaction with Fbxo7 is specific to D 
cyclin/Cdk6  complexes, as Fbxo7 does not interact with either cyclin E or Cdk4. An 
Fbxo7 knockdown decreased Cdk6  association with cyclin D and over expression of 
Fbxo7 increased D cyclin/Cdk6  activity. Over expression of Fbxo7 transformed murine 
fibroblasts and rendered them tumorigenic in athymic nude mice. These transformed 
phenotypes were dependent on Cdk6  activity, as concomitant knockdown o f Cdk6 
eliminated the changes. Fbxo7 was shown to be highly expressed in epithelial tumours, 
but not in normal tissues, suggesting it may have a proto-oncogenic role in human 
cancers (Laman et a l 2005).
The connection between F-box proteins and cancer has been well established through 
the study of other F-box proteins such as Skp2. Skp2 has been shown to be responsible 
for the activation and stabilisation of an oncogene, c-Myc (Kim et a l  2003; von der
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Lehr et al. 2003), as well as playing a role in the degradation o f the tumour suppressors 
p27 (Carrano et al. 1999; Tsvetkov et al. 1999), p21 (Bomstein et al. 2003), p57 
(Kamura et al. 2003) and p i 30 (Tedasco et al. 2002). These latter interactions indicate 
that the Skp2 protein itself may be the product of a proto-oncogene. Several studies 
have revealed that Skp2 expression significantly and directly correlates with tumour 
malignancy and aggressiveness and is associated with poor prognosis in human 
lymphomas, prostate cancers and ovarian adenocarcinomas ((Guardavaccaro and 
Pagano 2004) and references therein).
It has been suggested as a consequence of the strong link between the SCF complexes 
and cancer that individual F-box proteins such as Skp2 may be a target for treatment as 
well as being an effective prognostic marker (Guardavaccaro and Pagano 2004). The 
diversity of pathways regulated by the ubiquitination system means that targeting the 
proteins higher in the chain would be likely to disrupt too many essential processes and 
so the substrate specificity factors, the F-box proteins, would be ideal drug targets for 
new cancer therapies. As discussed previously Fbxo7 has been shown in two different 
reports to be implicated in the control of cell cycle proteins, HURP and cyclin D/Cdk6 , 
and in both reports Fbxo7 displayed proto-oncogenic behaviour. It is possible that 
Fbxo7 represents one such suitable cancer drug target. Further work would be required 
to assess the suitability of Fbxo7 as a drug target as protein-protein interactions are 
complex targets. The structure determination of Fbxo7 would greatly assist this 
analysis as well as facilitating any possible drug design.
1.4 Structure and function o f the proteasome
1.4.1 Architecture of the proteasome
After proteins are modified by ubiquitin they can be targeted for destruction by the 
proteasome. The proteasome is found throughout all three kingdoms, bacteria, archaea 
and eukaryotes, and has a similar core structure. The archaeal proteasome complex 
consists of two different subunits, a  and p, which form a barrel-shaped structure of four 
stacked rings (Lowe et al. 1995) (Figure 1.8). The two inner rings consist o f seven p 
subunits each and the two outer rings consist of seven a subunits each. The overall 
architecture of the proteasome reveals an elongated cylinder with a central penetrating 
channel with large cavities and narrow constrictions.
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Structural studies on the Thermoplasma acidophilum proteasome (Lowe et a l 1995) 
have shown that the a and P subunits are similar, consisting of a core of two five- 
stranded anti-parallel P-sheets that is flanked by three a helices on the top and two on 
the bottom (Figure 1.8). Sequence analysis of the a and p subunits indicates that they 
evolved from a common ancestral gene with the main difference being the N-terminal 
extension of ~35 amino acids (Lowe et al. 1995). These amino acids form the 
additional N-terminal a helix seen in the a subunits and are not present in the p 
subunits. Instead of this N-terminal a helix the P subunits contain a prosequence of 
various lengths, which are removed during proteasome assembly. These prosequences 
aid the efficient incorporation of the P subunits into the proteasome by a co-operative 
mechanism (Schmidt et al. 1999).
(3 s u b u n ita s u b u n it
Figure 1.8 -  Representation o f the 20S proteasome and the a and p subunits
The 20S proteasome consists of four stacked rings of alpha (blue) and beta (green) subunits. The 
20S proteasome of T. acidophilum is shown with each subunit as a sphere. The cartoon 
representations of the alpha and beta subunits show that they are similar in structure with the main 
difference being the N-terminal helix in the alpha subunit (PDB accession code: 1PMA). 
Structural drawing produced using PyMOL (DeLano 2004).
The structural study of the proteasome revealed that it was a previously unclassified 
type of protease, which cleaved in an unspecific way to produce protein fragments with 
a range of six to nine amino acids. The protease activity was described as being an N- 
terminal nucleophile (Ntn) hydrolase (Brannigan et al. 1995).
In eukaryotes such as yeast and mammals, the core proteasomes are more complex than 
the simpler archaeal homologues and they have more than one type of a and P subunits 
and therefore a more complex structure (Groll et al. 1997; Unno et al. 2002). The 28
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subunits of the yeast 20S proteasome are arranged as an (a l ...a7, 01 . . .07)2  complex in 
four stacked rings and occupy unique locations.
1.4.2 Assembly and activation of the proteasome
Five of the 0 type subunits o f the yeast 20S proteasome are synthesised as proproteins 
before being protealytically processed for assembly into the particle. O f particular 
interest is that 01, 02 and 05 autolyse between the final residue in the prosequence (Gly- 
1) and the first residue in the active 0 subunit (Thrl) (Groll et a l 1997). With the 
generation of the N-terminus at Thrl these three 0 subunits become active. The activity 
of these subunits was identified as follows: 05 carries the chymotrypsin-like 
(hydrophobic) and trypsin-like (basic) activity, 01 carries the peptidylglutamyl-peptide 
hydrolytic (PGPH) (acidic) activity, and 02 is suited for very large PI residues of 
neutral, acidic or basic character. Only the 01, 02 and 05 subunits are proteolytically 
active, all other 0  subunits and all the a  subunits are catalytically inactive.
The assembly of the proteasome is thought to start as an assembly o f a precursor 
complex (called the 16S) consisting o f a  and unprocessed 0 subunits. The propeptides 
of the 0  subunits are thought to prevent the premature conversion of the precursor 
complex into matured, active, particles (Kruger et a l  2001). The proposed mechanism 
for the formation of the mature 20S proteasome is that during 16S precursor formation a 
subunits spontaneously oligomerise into seven-membered rings, onto which the 0 
subunits assemble. After the formation of this 16S complex the 0 subunits must 
undergo a conformational change and rotate upwards, towards a second 16S complex 
undergoing the same conformational change. This rearrangement is induced either by 
the completed 0 ring or by the second 16S complex, possibly supported by chaperone 
proteins. After this conformational change has completed the 0 subunits from each 16S 
complex can bind to the other and so form an inactive 20S complex. The prosequence 
of the active 0  subunits would then be auto-catalytically cleaved to allow the activation 
of the complex (Mullapudi et a l  2004).
In the T. acidophilum proteasome structure entry ports with a diameter of ~13A at each 
end of the cylindrical particles are open, however the N-terminal 12 residues are 
disordered in the structure. In the yeast 20S proteasome the N-termini o f the subunits 
a l ,  a2, a3, a 6  and a7 project into the opening and fill it completely with several layers 
of tightly interacting side-chains. This means that there can be no access for substrates
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to the proteolytic chamber by this route without substantial conformational re­
arrangement and thus, without activation, the cell is protected from the proteolytic 
activity of the proteasome.
Additional proteins are required to mediate proteasome function by overcoming the 
restrictions on substrate access imposed by the structure of the 20S proteasome and are 
therefore considered proteasome activators. The 20S proteasome forms complexes with 
different proteins and, thus, it is the centre o f a modular system where different 
regulatory proteins confer unique catalytic and regulatory properties upon the 
proteasome. O f these proteasome activators the best studied are the 19S and 11S 
complexes and these will be discussed in turn here.
The asymmetric 19S activator binds to one or both o f the a  subunit disks of the 20S 
proteasome in a defined alignment and they face in opposite directions (Kopp and 
Kuehn 2003). When both ends of the 20S proteasome are bound to the 19S proteasome 
this complex is known as the 26S proteasome.
The 19S complex has a molecular weight of approximately 700 kDa and serves to 
recognise polyubiquitinated proteins and to convert them into a form suitable for 
degradation by the 20S core complex. Each 19S complex contains at least 17 different 
subunits and is assembled from two subcomplexes. An eight-subunit subcomplex of the 
19S, the lid, can be dissociated from proteasomes prepared from a deletion mutant for 
RpnlO, a 19S subunit (Glickman et a l  1998). A second subcomplex, the base, contains 
all six proteasomal ATPases and links the 19S regulatory complex to the 20S 
proteasome. The base is sufficient to activate the 20S proteasome for degradation of 
peptides or a nonubiquitinated protein, whereas the lid is required for ubiquitin- 
dependent degradation (Glickman et a l 1998).
The yeast 19S subunit RpnlO (S5a in humans) is involved in the recognition of 
polyubiquitinated substrates through its ubiquitin-interacting motif (UIM) (Deveraux et 
a l 1994; Fujiwara et a l 2004). The recognition of polyubiquitinated proteins is an 
important function as at this stage the specificity o f the degradation o f substrate proteins 
depends upon the correct recognition by the proteasome of targeted proteins. RpnlO is 
not an essential gene in S. cerevisiae (Van Nocker et a l 1996) and so there is expected 
to be some redundancy in its function. This is surprising as the deletion of this subunit 
encourages the dissociation of the lid and base of the 19S complex. The ubiquitin
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recognition function of the RpnlO protein may be supplemented by the reversibly bound 
proteasome co-factor Rad23 that also recognises ubiquitin chains (Elsasser et al. 2004).
Figure 1.9 -  20S-11S proteasom e complex
Ribbon representation of the structure of the 20S-1 IS complex (PDB accession code: 1FNT). The 
figure has been cut away to reveal the internal features and the gated access between the 11S and 
the antechamber of the 20S. 1 IS coloured in blue and 20S in grey. Figure produced using PyMol 
(DeLano 2004).
Another type of 20S proteasome activator is the non-ATP dependent activator, the 1 IS. 
This activator does not enable the proteasome to process proteins, only peptides, as it 
does not recognise ubiquitinated substrates. The crystal structure of the yeast 20S 
proteasome bound to the 11S activator complex from Trypanosoma brucei showed that 
the 11S activation loops induces conformational changes in the a subunits of the 20S 
proteasome that open the gate separating the proteasome interior from the intracellular 
environment (Whitby et al. 2000). In addition to this the activation loops also impose a 
more stringent sevenfold symmetry on the 20S proteasome thereby straightening the 
asymmetrically oriented tails of the a subunits and moving them away from the 
entrance/exit gates (Forster et al. 2003). This ordered open conformation is required for
Antechamber
Proteolytic
chamber
Antechamber
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proteolysis and its formation is likely to be triggered by outward displacement o f the a 
subunit residues in all activators, both ATP-dependent and -independent (Forster et al. 
2005).
1.4.3 The immunoproteasome
In addition to the constitutively active 20S proteasome described above, in mammalian 
cells the three catalytically active proteasomal subunits many be further regulated by the 
immunomodulatory cytokine, interferon-y (IFN-y) (Yang et al. 1992). These IFN-y 
induced P subunits incorporate into the proteasome in the place o f the active P subunits 
and are termed p ii (or LMP2), p2i (or MECL1) and p5i (or LMP7) and replace the pi, 
P2 and p5 subunits o f the constitutively active proteasome in a controlled way (Friih et 
al. 1994). The modified proteasome is known as the immunoproteasome. The 
introduction of p ii and P5i was shown to be responsible for a change in the cleavage 
specificity of the proteasome (Driscoll et al. 1993; Gaczynska et al. 1993). The 
incorporation of the IFN-y inducible subunits into the proteasome favours the 
production of the types of peptides found on MHC class I molecules, which terminate 
almost exclusively with hydrophobic or basic residues (Gaczynska et al. 1993) and so 
the immunoproteasome plays a role in the immune response o f the cell.
The structure o f the mammalian proteasome allowed the prediction o f the structure of 
the immunoproteasome (Unno et al. 2002). The sequence identities o f the human pii, 
P2i and P5i subunits to the human p i, p2 and p5 are 59.2%, 57.7% and 6 8 .6 % 
respectively. The remaining 11 subunits are not changed between the proteasome and 
immunoproteasome. In the predicted immunoproteasome structure the SI pocket o f p ii 
was more apolar than that o f p i, making it likely that the PGPH activity o f this subunit 
would be reduced and chymotrypsin-like activity enhanced. There was no large 
structural change predicted for the P2 replacement with p2i. This change fits with the 
observed change in specificities for the cleavage of the polypeptides.
The formation o f the immunoproteasome must occur in such a way as to prevent the 
formation of hybrid proteasomes that contain both the constitutively active p subunits 
and the inducible immuno p subunits. During immunoproteasome formation the 
incorporation and processing of inducible proteasome P subunits are cooperative 
processes. Subunit p ii is essential for the incorporation of P2i. The contribution o f P5i 
appears to be to accelerate the p ii and P2i processing kinetics. This cooperative
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behaviour is not dependent on the active sites of the subunits and has the end result of 
creating a homogenous proteasome population (Schmidt et al. 1999).
The proteasome plays a vital role in our immune system by generating peptides from 
intracellular antigens that are then presented to T cells at the cell surface. In response to 
viral attack the specially adapted immunoproteasome is a more efficient protease for the 
production of the peptides for presentation by the MHC class I molecules than the 
constitutively active proteasome (Kloetzel 2004). Bioinformatic study showed that the 
immunoproteasome is a more specific enzyme than the constitutively active proteasome 
and produces better ligands for MHC class I presentation when analysing the 
degradation of pathogen proteomes (Kesmir et al. 2003). The MHC class I presentation 
pathway enables T cells to distinguish between intracellular self-antigens and cellular 
pathogens. It is likely that the immunoproteasome has co-evolved with the major 
histocompatibility complex to optimise antigen presentation (Kesmir et al. 2003).
Figure 1.10 -  The proteasome and antigen processing
Substrates that contain MHC class I epitopes are tagged with a polyubiquitin chain and targeted to 
the proteasome for destruction. Proteasomal processing results in the generation of small peptides 
that are transported to the ER by TAP. For N-terminal extensions the peptides may be trimmed in 
the cytosol or ER by aminopeptidases. In the ER peptides bind and stabilise the appropriate MHC 
class I molecule with the help of chaperones. Fully loaded and assembled MHC class I molecules 
are translocated to the cell surface. By binding specifically to an MHC class I molecule loaded 
with a unique peptide, cytotoxic CD8+ T cells with complementary T cell receptors (TCRs) are 
stimulated to proliferate and destroy infected cells. Figure reproduced from (Kloetzel 2004).
Ub-protem substrates
Aminopeptidases
26S proteasome
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1.4.4 Proteasome inhibitor protein 31, PI31
In addition to activators o f the proteasome natural inhibitors have also been identified. 
PI31 was first identified as an inhibitor o f the proteasome after purification from bovine 
red blood cells (Chu-Ping et al. 1992). PI31 was found to be a protein o f about 31kDa, 
which may be present in cells in different multimeric forms and was shown in vitro to 
be a specific non-competitive inhibitor of the 20S proteasome but not o f the 26S 
proteasome.
Studies of recombinant PI31 in the Sijts lab (Zaiss et al. 1999) and the DeMartino lab 
(McCutchen-Maloney et a l  2000) revealed more of the function o f this protein. PI31 is 
a proline rich protein, particularly at its C-terminus where 26% of the amino acids are 
prolines (McCutchen-Maloney et al. 2000). PI31 was shown to inhibit both the 
constitutively active 20S proteasome and the immunoproteasome with the same kinetics 
when analysing the degradation of short fluorogenic peptides in vitro and it does not 
influence cleavage specificity (Zaiss et al. 1999). Competition experiments revealed 
that PI31 mediated inhibition o f 20S proteasomes by competing directly with 11S 
mediated activation. The authors proposed that as the 11S binds to the a  subunits of the 
20S proteasome that this is also the binding site of PI31. PI31 was also reported to 
inhibit the activation o f the 20S proteasome by the 19S complex but not to completely 
ablate the function o f the 26S proteasome. It was reported by both McCuthchen- 
Maloney et al (McCutchen-Maloney et al. 2000) and Zaiss et al (Zaiss et al. 1999) that 
the proteasome inhibition activity o f PI31 was conferred on the protein by the C- 
terminal proline rich region and it was suggested that this protrudes into the cavity of 
the 20S proteasome, thus preventing access to proteins targeted for degradation.
Further experiments carried out in the Sijts lab revealed that PI31 induced inhibition of 
the proteasome could not be observed in vivo (Zaiss et al. 2002) and so another role for 
PI31 was sought. Over expression of PI31 in mouse embryonic cells has no impact on 
either proteasome mediated proteolysis or upon cell cycle progression. Instead PI31, 
when up regulated, interferes with the maturation of the immunoproteasome. Over 
expression of PI31 abrogates MHC class I presentation o f an immunoproteasome 
dependent cytotoxic T lymphocyte epitope and reduces the surface MHC class I levels 
on IFN-y treated mouse embryonic cells in culture. The authors suggested that the 
function of PI31 may be that of interference with the processing of the prosequences of
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the IFN-y inducible subunits thus preventing the formation of fully mature 
immunoproteasomes.
In addition to its role interacting with the proteasome PI31 has also been linked to 
CD2BP2 protein (Kofler et al. In Press), which is a cellular adapter protein that was 
originally identified as a binding partner of the T cell adhesion protein CD2 in the 
context of T cell signalling. A small a/p protein, the GYF domain of the protein 
CD2BP2, serves as an adapter that recognizes proline-rich sequences in intracellular 
proteins. This GYF domain has been shown to interact with a C-terminal motif in PI31 
by spot analysis and yeast two-hybrid (Kofler et al. In Press). PI31 contains both types 
of binding motifs identified to be the consensus motifs required for interaction with the 
GYF domain that is; PPG[W,F,Y,M,L] and PPGx[R,K]. The implications o f this new 
interaction on the function of PI31 have yet to be uncovered and indeed this interaction 
has not yet been demonstrated in vivo.
The successful use o f synthetic proteasome inhibitors in the treatment o f cancer implies 
that the naturally occurring PI31 may be amenable to manipulation for the same 
purpose. This may warrant further investigation into the function of this protein in vivo.
1.5 Aims and objectives o f this thesis
• Structural characterisation of the Fbxo7-Skpl complex, its homologues and 
interaction partners.
• Identification of the substrates and binding partners for SCFFbxo7 and validation 
of the interaction.
By investigating the F-box protein Fbxo7 I hoped to employ several strategies to learn 
more about the structure of Fbxo7 and its interaction with Skpl. I also hoped to 
undertake biochemical screens to find interacting proteins and therefore potential 
substrates. These proteins could, in turn, provide some insight into the molecular and 
cellular function o f Fbxo7.
Ultimately I hoped to reconstitute the SCF^ 07 E3 ligase in vitro and determine its 3D 
structure.
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2 Preparation and characterisation  o f the F b xo7-S k p l 
com plex and its b inding partners
The protein Fbxo7 has been shown to be a proto-oncogene (Laman et al. 2005) but 
much of its structure and function remain uncharacterised. This chapter describes the 
bioinformatic analysis o f Fbxo7 leading to the identification of previously unidentified 
domains within this protein. These domain boundaries were confirmed by limited 
proteolysis and used to direct the production of recombinant Fbxo7-Skpl complex for 
crystallisation trials. In vivo and in vitro characterisation of Fbxo7 revealed that it is a 
subunit of an SCF complex and identified a novel binding partner for Fbxo7. A 
flowchart describing the experiments performed can be found below (Figure 2.1).
Analysis of Fbxo7- 
Skp1 crystals
Crystallisation of 
Fbxo7-Skp1
Protein expression 
and purification 
trials
Preparation of 
di-cistronic 
constructs
Yeast two-hybdrid 
with Fbxo7 as bait 
and PI31 as prey
Further protein 
purification by size 
exclusion 
chromatography
Confirmation of 
domain 
boundaries using 
limited proteolysis
Identification of 
domains within 
Fbxo7 using 3D- 
PSSM
Identification of 
Fbxo7 as a 
subunit of an SCF 
complex in vivo
Identification of 
Fbxo7-Skp1 
binding partners 
from Jurkat cells
Confirmation of 
Fbxo7 as a 
subunit of an SCF 
using recombinant 
proteins
Co-immunoprecipitation 
of FLAG-tagged PI31 
with over expressed 
Fbxo7
Figure 2.1 -  Flowchart of the experim ents described in chapter two.
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2.1 Preparation of recombinant Fbxo7-Skpl complexes
2.1.1 General aspects o f recombinant protein production
Many biologically interesting proteins are present in such low quantities under 
endogenous conditions within cells that extracting sufficient quantities o f these proteins 
for analysis from their naturally producing organisms would be difficult. Recombinant 
DNA techniques originally developed in the 1970s by Cohen et al (Cohen et a l  1973) 
and developed since have helped to overcome this problem. Our increased 
understanding o f the molecular mechanisms o f gene expression in bacteria has enabled 
the manipulation o f this system to express foreign proteins from cloned genes at high 
levels (Appelbaum and Shatzman 1999). Several different types of host cells can be 
used in this way including mammalian cells and insect cells but in this study E. coli has 
been used exclusively as the expression host throughout and so only methods 
appropriate for E. coli are described.
In order to manipulate bacterial cells to produce human proteins extra-chromosomal 
plasmids have been designed to transcribe and translate large amounts of heterologous 
protein when transformed into bacterial cells. These expression vectors are small 
circular pieces o f DNA (about 5 kb) that have been produced to include; an origin of 
replication (ori) sequence allowing it to be replicated separately from the rest of the 
cellular DNA; a gene encoding antibiotic resistance to maintain the selection of cells 
containing the plasmid; unique restriction enzyme sites to allow the plasmid to be 
readily digested and a non-host DNA fragment inserted and ligated; a strong regulable 
E. coli promoter (lac promoter was used in this study); a ribosome binding site (RBS); a 
start codon spaced to maximise translation initiation and finally a stop codon to prevent 
read through o f the remaining vector.
The DNA fragment o f interest is amplified by polymerase chain reaction (PCR) from a 
template or a cDNA library, ligated into the previously digested plasmid and then used 
to transform the host cell (as described in appendix A) (Old and Primrose 1994). 
Transformed cells are grown to exponential growth phase prior to induction to obtain a 
large number o f cells containing the plasmid o f choice. The expression o f proteins that 
can be toxic to the bacteria is controlled using the bacterial lac operator. The lac 
repressor is bound under normal growth conditions and prevents transcription.
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Induction o f expression is achieved by the addition of Isopropyl-P-d-Thiogalacto- 
Pyranoside (IPTG), which binds to the lac repressor, which thus dissociates from the 
operator allowing translation to proceed (Appelbaum and Shatzman 1999).
To facilitate rapid purification o f recombinant protein produced in this way a variety of 
tags are employed. These tags consist either of peptides, such as a poly-histidine (His) 
tag, or o f globular proteins, such as glutathione S-transferase (GST) and maltose 
binding protein. These tags bind to small molecule ligands, which can be immobilised 
on Sepharose beads to form an affinity column and can then be used to separate the 
tagged recombinant proteins from the bacterial proteins under non-denaturing 
conditions. Recombinant proteins are readily eluted from the affinity column by the 
addition of a site specific protease site between the tag and protein of interest. A 
method originally described by Smith and Johnson (Smith and Johnson 1988) for 
expression of all GST fusion proteins was used in this thesis. This method was 
improved by Guan and Dixon (Guan and Dixon 1991) by the addition to the original 
vector of a poly-glycine linker inserted after the thrombin cleavage site, which 
improved cleavage efficiency. The linker allows cleavage while attached to the affinity 
resin and therefore efficient single step purification. The purification procedure 
outlined by Guan and Dixon (Guan and Dixon 1991) and described in appendix A was 
employed for all GST fusion proteins described here.
This method for producing recombinant protein allows the adaptation o f the proteins to 
contain the optimal domains for either structural or functional characterisation. For 
functional characterisation it is preferable to analyse the full length protein however in 
crystallography the identification and removal of flexible regions o f proteins can greatly 
improve the quality o f crystals. Using secondary structure prediction servers to identify 
structured domains within a protein can identify flexible regions and limited proteolysis 
on full length proteins can also identify the minimal structured domain o f the protein.
2.1.2 Identification of domains within Fbxo7
Identification o f the regions o f Fbxo7 that are likely to be globular domains and 
therefore represent good crystallisation targets was performed by domain analysis. The 
biomolecular modelling server 3D-PSSM (3 dimensional position specific scoring 
matrix) (Kelley A.L. 2000) was used to predict the secondary structure o f Fbxo7 and to 
identify domains with remote sequence similarity which are below the threshold of
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sequence alignment servers. This analysis revealed an N-terminal ubiquitin like domain 
(Ubl) spanning amino acids 1-78 with an E-value of 1.6 and an estimated precision of 
65% (Figure 2.2a). The F-box domain itself was shown to span residues 329-375 with 
an E-value of 2 and an estimated precision of 60% (Figure 2.2c). A further unknown 
globular domain was identified preceding the F-box domain with a predicted a/p 
structure but with no known function (Figure 2.2b). This domain spanned residues 173- 
324. 3D-PSSM also revealed a predicted unstructured C-terminal after the F-box 
domain, which on analysis of the sequence was revealed to be a proline-rich region 
(PRR) and would be unlikely to crystallise. The domains identified in this search are 
outlined in Figure 2.2 with the sequence alignment o f the different domains within 
Fbxo7 proteins from all species. The secondary structure predicted from 3D-PSSM 
shows that the Ubl domain is predicted to have a a/p fold and the F-box domain is 
predicted to contain three helices, consistent with previous structural information (see 
chapter one for details of these domains).
Having identified the likely domain boundaries o f Fbxo7 using bioinformatics Phillip 
Knowles (Structural Biology Laboratory, Cancer Research UK) carried out limited 
proteolysis on Fbxo7-Skpl (Koth et al. 2003) (Figure 2.3). Recombinant Fbxo7(129- 
398)-Skpl(1-146) was used because Fbxo7( 129-398) had been shown by Laman et al 
(Laman et a l  2005) to interact with viral cyclin by yeast two-hybrid and so it is likely 
that Fbxo7( 129-398) represents a functionally relevant domain. Limited proteolysis can 
be used to reveal the areas o f a protein that are more susceptible to proteolysis and are 
therefore more likely to be flexible or exposed regions o f the protein. Structured 
regions are less susceptible to proteolysis and therefore would not be degraded by this 
method and so can be identified. The analysis of the protein fragments produced by 
limited proteolysis was performed by N-terminal Edman sequencing by Nick Totty 
(Protein Analysis Laboratory, Cancer Research UK). Fbxo7(l 31-C-terminal truncation) 
and Fbxo7(171-398) were revealed to be likely to have defined secondary structure by 
this method. The latter correlates well with the results from the bioinformatic analysis, 
amino acids 171-398 include both the novel domain and the F-box domain. S kp l(l-
146) shows no sign o f proteolysis and therefore is likely to be a globular domain.
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Figure 2.2 -  Sequence alignm ent of Fbxo7 domains identified by 3D-PSSM
3D-PSSM (Kelley A.L. 2000) was used to identify all globular domains within Fbxo7. The 
secondary structure prediction revealed both the Ubl domain and the novel domain to have a 
predicted a/p fold. The F-box domain is likely to be a  helical. Sequence alignments of Fbxo7: A) 
Ubl domain, B) Uncharacterised globular domain, C) F-box domain. Sequence alignment was 
performed using ClustalX (Thompson et al. 1997) and figure produced using ESPript (Gouet et al.
1999).
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Figure 2.3 -  Limited proteolysis o f Fbxo7(129-398)-Skpl(l-146)
Left: SDS-PAGE of Fbxo7(129-398)-Skpl(l-146) prior to limited proteolysis. Right: SDS-PAGE 
of limited proteolysis carried out by Phillip Knowles, protein fragments and sequence identified by 
N-terminal Edman sequencing by Nick Totty (Protein Analysis Laboratory, Cancer Research UK). 
Fbxo7(l31-C-terminal truncation) and Fbxo7(171-398) were revealed to be likely globular 
domains.
2.1.3 Cloning strategy for Fbxo7-Skpl expression vectors.
The structure o f a Skpl-F-box complex had previously been solved by Schulman et al 
(Schulman et a l 2000) for the leucine rich repeat F-box protein Skp2 complexed to 
Skpl. For these studies human Skp2 and Skpl were cloned as a di-cistronic message 
into a commercially available vector with the GST tagged Skp2 open reading frame 
preceding that of un-tagged Skpl (Schulman et a l  2000). Using this type of vector in 
E. coli for protein production encourages a stoichiometric protein complex to form as 
the proteins are synthesised with their cognate binding partners. By allowing 
simultaneous expression any problems with mis-folding and aggregation due to exposed 
hydrophobic contact interfaces are reduced due to the presence of the physiological 
binding partner. As only one o f the proteins was expressed as a GST fusion protein, 
purification by affinity chromatography allows for the detection of a properly folded 
partner protein.
To produce sufficient recombinant Fbxo7 for crystallisation we co-expressed Fbxo7 
with Skpl, its in vivo partner, in order to mimic in vivo conditions and enhance the 
stability of Fbxo7. Many F-box proteins have been shown to interact directly with Skpl 
(Bai et a l 1996) and Fbxo7 in particular was shown to bind to Skpl in vivo in HeLa 
cells (Cenciarelli et a l 1999).
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Bam H1 RBS
GC GGG ATC CAA GAA GGA GAT ATA ATG CCTTCA ATT A AG TTG CAG AGTTCT G 
Figure 2.4 -  5 ’ prim er for PCR o f Skpl containing a ribosome-binding site
pGEX-KG
T
r r r  r  r t  v t  7" t  t  r *
pBluescript KS(
Hindi 4 SamHI digestion
p. *■
TGCMbCTCCACCGCGOTGGCGOCCOaaAOAAaAGrOGATCCAAGAAOGAGAIAT 1= ?
pBluescript KS(-) 
RBS- SkplSKt & HindM digestion
BamHI HindlHFbxo7
thrombin stop codonstart codon
stop codons 
Tht 1 1 1 1 
Aat II
pGEX-KG
F b xo7F1-RBS-Skpl
BssHII' AlwNI
pBR322
orl
Figure 2.5 -  Construction o f expression plasmids
Fbxo7 (blue bar) was inserted into pGEX(KG) and Skpl (green bar) was inserted into pBluescript. 
Fragments from these two plasmids were then ligated to produce pGEX(KG) Fbxo7F1-RBS-Skpl. 
Constructs were produced by Heike Laman. The thick filled arrow (* )  represents the coding 
sequence for GST. Unique restriction sites are indicated. The locations of the genes for ampicilin 
resistance (Amp1) and the lac repressors (laclq, lac Z and P lac) are indicated by thin arrows (-+).
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At the start o f this study there were only limited commercially available di-cistronic 
constructs and so we adapted pGEX(KG) from Guan and Dixon (Guan and Dixon 1991) 
to contain an additional RBS. Heike Laman (Wolfson Institute, UCL) produced all 
Fbxo7 - Skpl constructs using the following procedure (outlined for full length Fbxo7 
here and in Figure 2.5); Fbxo7 full length protein (Fbxo7Fl) was cloned into pGEX(KG) 
using EcoRl and Xhol restriction sites to produce pGEX(KG) Fbxo7F1. Skpl was 
amplified by PCR from a human foetal cDNA library using the primer containing a 
RBS shown in Figure 2.4. Skpl DNA was then cloned into BlueScript (Stratagene) 
using the BamHI and HindlH restriction sites to produce pBluescriptKS(-) RBS-Skpl. 
The Skpl insert was then shuttled into the pGEX(KG) Fbxo7F1 using Sacl and HindlH 
restriction sites to produce pGEX(KG) Fbxo7F1-RBS-Skpl. The restriction sites used to 
shuttle the Skpl DNA into the final vector were designed to allow a sufficient spacer 
between the stop codon o f the Fbxo7 and the second RBS to maximise the translation 
efficiency. If they are too close together this can reduce or prevent the translation o f the 
second protein.
2.2 Fbxo7-Skpl com plexes
2.2.1 Screening for an optimal expression construct of Fbxo7-Skpl for 
structural and function analysis
In designing the constructs for use in this project it was possible to combine the 
information obtained from the domain analysis with the published experience o f the 
original Skpl-F-box protein structure. Two out o f the three constructs used for the 
original Skpl-Skp2 structure (Schulman et a l 2000) used a truncated form of Skpl (1-
147), which removes a  helix eight o f the Skpl structure. This construct was designed 
using limited proteolysis and represents an efficient expression construct and also a 
good crystallisation target. In all the constructs of Fbxo7-Skpl produced for this project 
the truncated form of Skpl (1-146) has been used and will be referred to as Skpl AH8 .
Eleven different constructs o f human Fbxo7-SkplAH8 were produced, sequenced and 
expression trials were performed in E. coli under standard protocol conditions, outlined 
in appendix A (Figure 2.6 and Figure 2.7). Throughout this chapter all constructs will 
be referred to using the labelling assigned in Figure 2.6 and Figure 2.7 as a superscript 
e.g. Fbxo7F1- Skpl.
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Figure 2.6 -  Constructs produced and expression trials for Fbxo7-Skpl com plexes
Expected positions of Fbxo7 (blue) and SkplAH8 (green) generated by the expression constructs 
shown are marked with arrows. Fbxo7F7 is shown as the un-cleaved GST fusion protein. FI 
produced very little detectable protein, SDS-PAGE provided by Phillip Knowles, and neither F8 
nor F9 produced any detectable protein. F4 and F5 have both been adapted to contain a TEV 
protease site by Phillip Knowles and this has been used for cleavage of the GST moiety. Skpl is 
not a fusion protein and so was only detectable when Fbxo7 binds correctly to it indicating that 
both proteins had folded correctly.
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All of the constructs produced except Fbxo7F9 contain the F-box domain of Fbxo7 and 
therefore can bind to Skpl. Binding to Skpl has been used as a positive control for 
correctly folded Fbxo7 in all constructs containing an intact F-box domain. 
Unfortunately Fbxo7F1 -  Skpl (Full length Fbxo7 -  SkplAH8 ) expresses very poorly 
and so further analysis o f the other constructs was needed to identify the optimal 
construct to use for both crystallisation and functional experiments.
The Fbxo7F2-Skpl and Fbxo7F3-Skpl constructs express both Fbxo7 and Skpl proteins 
indicating that these constructs can be used to produce recombinant protein complexes 
for biochemical analysis and are also potential crystallisation targets. The overall 
expression for these constructs was l-2mg of protein per litre of E. coli under the 
standard protocol conditions outlined in appendix A.
Fbxo7F4-Skpl and Fbxo7F5-Skpl were adapted to contain a TEV protease site by Phillip 
Knowles to attempt to improve the cleavage efficiency o f GST from Fbxo7. An 
additional advantage of using recombinant TEV protease is that the protease itself 
contains an N-terminal His-tag and so all o f the protease can be removed by passage 
through Ni-NTA upon completion of cleavage. The TEV cleavage o f GST was less 
efficient than thrombin. After a 4°C overnight incubation with thrombin the cleavage of 
GST-Fbxo7 was 80% complete while TEV required 48 hours to achieve the same 
cleavage levels (data not shown).
Fbxo7F6-Skpl, Fbxo7F7-Skpl and Fbxo7F8-Skpl all disrupt regions within the globular 
domain preceding the F-box domain that, as would be expected, causes the expression 
levels to drop. There is significantly less expression o f Fbxo7 protein using these three 
constructs and there is very little SkplAH8 bound to the Fbxo7 indicating that these 
proteins may not be correctly folded.
The constructs previously described only varied the Fbxo7 sequence and SkplAH8  was 
kept constant. It was also important to identify the optimum Skpl construct to use for 
efficient translation. When Schulman et al (Schulman et a l  2000) identified SkplAH8 
as an appropriate construct they also performed two loop deletions in their construct 
design. They solved three versions of the Skpl-F-box protein complex and all three of 
the constructs that were used to produce the proteins lack a six residue internal loop of 
Skpl (38-43). This region was determined to be unstructured on the basis of limited 
proteolysis and is absent from several Skpl orthologues. One o f the three structures
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solved also lacked a protease sensitive loop (71-82), which was disordered in the other 
two Skpl crystal structures. After identification of the optimal region of Fbxo7 for 
expression as amino acids 169 to 398 (Fbxo7F3) this construct was adapted to remove 
the two loop regions identified by Schulman et al (Schulman et al. 2000) (Figure 2.7).
1 78 173 324 329 375 423 522 1 163
Ubl | g lobu lar d o m ain  F-box]— Proline Rich Region Skpl
F10. Fbxo7 (169-398)-Skpl (1-146 A38-43) f ~ H Skpl I
FI 1. Fbxo7 (169-398)-Skpl (1-146 A38-43, A70-81) ■  | WHskpl |
97
66
45
30
20
14
F10 FI 1
Figure 2.7 -  Fbxo7F3-Sk pl construct adapted to contain loop deletions of Skpl
Expected positions of Fbxo7 (blue) and SkplAH8 (green) generated by the expression constructs 
shown are marked with arrows. F10 shows low expression and F ll  Skpl appears to show 
evidence of proteolytic clipping. Fbxo7F3-Skpl was adapted to contain the Skpl loop deletions by 
Heike Laman.
Fbxo7-SkplK1° contains the 38-43 loop deletion used in all the previous Skpl structures. 
Skpl protein is visible on SDS-PAGE indicating that this deletion does not interfere 
with the binding between Skpl and the F-box domain o f Fbxo7. As this loop deletion 
of Skpl had been used successfully in three other structure determinations it was 
unfortunate that the expression of Fbxo7-SkplF10 was not high enough to continue to 
use this construct for crystal trials.
Fbxo7-SkplFU contains the double loop deletion used in the Skpl-Skp2 structure for 
one of their datasets (38-43 and 71-82) (Schulman et al. 2000). The expression of the 
protein complex from this construct appears to produce two discrete Skpl bands 
although these have not been identified by mass spectrometry or Westem-blot analysis. 
The expression of this construct was again too low to follow up in our crystal trials at 
less than 0.5mg/l.
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On completion o f all the initial construct expression trials two constructs were revealed 
to produce reasonable yields o f protein complex, Fbxo7F2-Skpl and Fbxo7F3-Skpl. The 
two complexes both contain the full globular domain immediately preceding the F-box 
and the complete F-box domain with some residues after the C-terminus o f the F-box. 
Fbxo7F2-Skpl also contains a region preceding the globular domain predicted to be 
unstructured by 3D-PSSM.
The stoichiometry o f Fbxo7 and Skpl does not appear to be 1:1 when analysed by SDS- 
PAGE (Figure 2.6 and Figure 2.7). This is surprising as the di-cistronic expression 
construct is designed to produce the physiologically relevant complex.
2.2.2 Fbxo7F3-Skpl expression optimisation
During the original expression trials of the different constructs the expression conditions 
were kept constant in order to be able to quantitatively compare them. After identifying 
the most efficient expression constructs optimisation was used to enhance the protein 
yield.
Variables that can be used to improve protein expression in E. coli include the type of 
media used, temperature o f cell growth and induction, and the concentration of IPTG 
used for protein expression induction. An expression trial was performed varying each 
of these variables in turn. Trials were performed at an induction temperature o f 18°C, 
25°C and 37°C using LB, TB and NZY media. IPTG concentration was varied 
dependent on the temperature, 50pM and lOOpM final concentration used at 18°C and 
lOOpM, 250pM and 500pM final concentration used at both other temperatures (Figure 
2 .8).
The expression trials produced high yields of Fbxo7 in all conditions tested; 
unfortunately this was not matched by SkplAH8  expression. This is surprising as the 
stoichiometry o f the proteins would be expected to be 1:1 due to their relationship as an 
obligate heterodimer. The yields o f SkplAH8  were dependant on all three of the 
variables tested as can be seen in Figure 2.8. There was a reasonable yield o f Skpl AH8 
using TB media at both concentrations o f IPTG at 18°C while using either LB or NZY 
medias under any conditions there were considerably reduced yields. Growing up E. 
coli using TB media generally produces a larger cell pellet than LB media, as it is a 
richer food source, which could account for some of the difference in expression seen.
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There was a higher protein complex yield using TB media at all temperatures tested but 
the most efficient production o f protein occurs using TB as the media at 18°C with an
IPTG concentration o f 50pM. This method was used alongside the LB protein
production described in appendix A to produce protein complexes for experimental 
analysis.
TB LB NZY Media
50 100 50 100 50 100 [IPTG] (gM)
I B  I B  I B I B  I B  I B  lnsoluble(l)/Bound to  Resin(B)
GST-Fbxo7F3
3  *  9t
SkplA H8
Figure 2.8 -  Expression trials o f Fbxo7F3-S k p l
Typical SDS-PAGE of an expression trial showing three different media tested with varying 
concentrations of IPTG at 18°C. All lanes other than those using TB media at 18°C contained 
similar amounts of Fbxo7F3-Skpl (other temperatures not shown). Expected positions of 
expressed proteins are marked with arrows, GST-Fbxo7F3 fusion protein (blue), SkplAH8 (green) 
and free GST (black). The insoluble lanes (I) represent equal volumes of insoluble E. coli cell 
pellet and the bound to resin lanes (B) represent equal volumes of purified protein bound to 
glutathione Sepharose affinity resin.
2.3 C rysta llisa tion  o f  F b x o 7 -S k p l com p lexes
Fbxo7F2-Skpl and Fbxo7F3-Skpl were both submitted to crystal trials by Philip 
Knowles and myself. Initial trials were performed using both vapour diffusion and 
microbatch methods as described in appendix B. There is no known a priori way of 
predicting which condition any given protein or complex will crystallise in. Targeted 
trial and error experiments were performed using sparse matrix screens based on the 
conditions used previously to successfully crystallise proteins.
Crystals were obtained from both Fbxo7F2-Skpl and Fbxo7F3-Skpl after considerable 
screening of conditions. The initial trials used commercially available sparse matrix 
screens from Hampton (Jancarik and Kim 1991; Cudney et al. 1994) and Emerald
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BioSystems and a protein complex screen made using the instructions in Radaev and 
Sun (Radaev and Sun 2002). These screens gave an indication of which conditions to 
follow up with grid screens and additive screens. Crystals of Fbxo7F2-Skpl originally 
formed in Flampton crystal screen 2 condition 22 and those of Fbxo7F3-Skpl formed in 
Hampton crystal screen 2 in conditions 35 and 39. To improve the quality and size of 
these crystals variables were tested including temperature, pH, concentration of the 
protein and the precipitant, and additives including salts and detergents. Fbxo7F2-Skpl 
crystals were showers of small crystals and it was not possible to improve their quality 
using the conditions tested. Fbxo7F3-Skpl crystallised within two to three days under 
vapour diffusion at a protein concentration of 16mg/ml using hanging drops at room 
temperature. The well solution consisted of 6 % PEG 20K, 0.1M MES pH 6.5 and 
0.005% Zwittergen 3.12 and produced the diamond shaped crystals shown in Figure 
2.9a.
Micro-batch grown crystals grew much quicker than the vapour diffusion crystals taking 
only 15 minutes to appear and did not require the addition of detergent to form ordered 
crystals. It was not possible to produce large enough crystals to handle using this 
method.
A.
Figure 2.9 -  Crystals o f Fbxo7F3-S k p l
A. Diamond shaped crystals typical of the morphology of Fbxo7F3-Skpl crystals grown under 
vapour diffusion in 6% PEG 20K, 0.1 M MES pH 6.5 and 0.005% Zwittergen 3.12. B. SDS-PAGE 
of protein used to grow crystals shows that this protein complex does not have a 1:1 stoichiometry 
when stained with Coomassie brilliant blue. Crystal photograph provided by Phillip Knowles.
^ —  F bxo7F3 
Skpl AH8
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2.4 Data collection from  Fbxo7F3-Sk p l crystals
The protein complex crystals described above are reproducible but they displayed 
anisotropic diffraction to only 8 - 12A using a rotating anode X-ray generator as the X- 
ray source. This level o f diffraction was not high enough to extract any information 
about these crystals.
Paratone was used as the main cryo-protectant for Fbxo7F3-Skpl crystals and produced 
a good glassy freeze with no ice rings visible. Cryo-protectant screens were also carried 
out using various concentrations o f glycerol, PEG 400 and ethylene glycol to attempt to 
improve the diffraction o f the crystals. Flash cooling in liquid nitrogen was also 
attempted in order to minimise the chance that the crystals were becoming disordered 
during the freezing process. None of these changes in cryo-protectant changed the 
diffraction quality o f the crystals.
One explanation for the poor diffraction quality of these crystals is that the protein used 
to produce the crystals contained a number o f high molecular weight contaminants 
(Figure 2.9b) at a low concentration, which could have been poisoning the crystal 
lattice. It is also clear from the SDS-PAGE that either SkplAH8  does not stain well 
with Coomassie brilliant blue or that Fbxo7F3 and Skpl AH8 are not being produced in a 
1:1 complex under these expression and purification procedures. If the latter is true 
then it is possible that the protein used for crystallisation is not mono-disperse and 
homogeneous and this would explain the difficulty in achieving crystals that diffract 
well.
In order to test the likelihood of the sample containing non-homogeneous material it 
was analysed by size exclusion chromatography as described in appendix A. All 
concentrated Fbxo7F3-Skpl samples analysed produced two peaks, one representing 
high molecular weight aggregates and the second a complex of 43-45kDa (Figure 2.10a 
and b). The anticipated molecular weight of a 1:1 complex of Fbxo7F3-SkplAH8 is 
43kDa. SDS-PAGE (Figure 2.10c) shows that the protein eluted in the high molecular 
weight fractions consists o f Fbxo7 and high molecular weight contaminants, which are 
likely to be E. coli heat shock proteins. The elution profile shown in Figure 2.10 is 
typical of all Fbxo7-Skpl samples produced and analysed in this way. Figure 2.10a and 
b demonstrate that the extent of aggregation of Fbxo7 varies in different protein 
preparations however sample b is the most representative o f the majority o f samples.
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Figure 2.10 -  Gel filtration profile o f Fbxo7F3-Sk pl used in crystallisation
Gel filtration performed using a Superdex 75 HR 10/30 column (Amersham Biosciences) at a rate 
of 0.4 ml/min using 20mM Tris-HCl pH 8.0 and 50mM NaCl as buffer. 500pl of protein sample 
was loaded onto the column. A) Gel filtration profile of Fbxo7F3-Skpl used in crystallisation 
showing a large molecular weight aggregate, likely to be Fbxo7F3 bound to an E. coli heat shock 
protein (identified as HSP60 by mass spectrometry and shown in Figure 2.12). B) Typical gel 
filtration profile, the ratios of the aggregate to complex are more typical here. C) SDS-PAGE of 
fractions from (A). This shows a high molecular weight contaminant in the aggregated fractions 
and a 1:1 ratio of Fbxo7-Skpl in the complex fraction.
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Gel filtered samples o f the 43kDa Fbxo7F3-Skpl complex were concentrated to 
16mg/ml and subjected to crystal trials. No crystals were obtained using this method of 
purification suggesting that the crystals obtained previously are o f Fbxo7F3 alone. The 
detergent in the crystallisation solution might reduce the extent o f Fbxo7F3 aggregation 
allowing crystals to form.
2.5 Functional characterisation o f Fbxo7-Skpl
2.5.1 Fbxo7 is a subunit of an E3 ligase
In parallel with the crystallisation experiments biochemical and cell biology 
experiments were performed to analyse the molecular function o f Fbxo7.
Heike Laman repeated the experiments o f Cenciarelli et al (Cenciarelli et al. 1999) 
using FLAG-tagged Fbxo7, His-tagged Cull and T7-tagged Rbxl in HeLa cells to 
confirm that Fbxo7 forms part o f an E3 ligase. Immunoprecipitation with an anti- 
FLAG antibody revealed that Fbxo7 co-precipitated with endogenous Skpl, His-tagged 
Cull and T7-tagged Rbxl as identified by Western blot (Figure 2.1 la).
In order to determine if this result is dependent on the interaction between Fbxo7 and 
Skpl FLAG-tagged Fbxo7 and FLAG-tagged Fbxo7 with the F-box domain deleted 
(Fbxo7AF-box) were transfected into HeLa cells and immunoprecipitated with anti- 
FLAG antibody. Endogenous Skpl co-precipitated with full length Fbxo7 but not with 
Fbxo7AF-box or vector alone (Figure 2.11a). These results show that a complete SCF 
complex containing Fbxo7 forms in vivo and that complex formation is dependent on an 
intact F-box domain.
The interaction between Fbxo7 and the other components o f the SCF has not previously 
been shown in vitro. In order to show this interaction in vitro Cull-NTD (14-312) was 
applied to a glutathione Sepharose column charged with GST-Fbxo7F2-Skpl (data not 
shown) or GST-Fbxo7F3-Skpl. The column was then fully washed and the resulting 
complex cleaved from the resin with thrombin. All proteins were expressed in E. coli 
and purified using standard protocols. In both constructs examined Cull-NTD forms a 
complex with Fbxo7-Skpl in the supernatant (Figure 2.11b). There is no difference 
between the constructs as would be expected as Cull-NTD binds to Skpl (Zheng et al. 
2 0 0 2 ) which is invariant in the two constructs.
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The resulting Fbxo7-Skpl-Cull complexes were both submitted to crystal trials as 
described for the Fbxo7-Skpl complex above. There were no crystals obtained from 
these screens. This could be because the samples were not applied to the additional gel 
filtration purification step that has been shown to be required for the Fbxo7-Skpl 
complex alone to be homogeneous.
A. B.IP: a n t i- f la g
WB: Skpl
WB: His
WB: T7
S k p l
■ H is-C u llin l
■T7-Rbx1
C ullin  1 (1 4 -3 1 2 )
F b xo7F 3
S k p l A H 8
WB:Skp1 S k p l
Figure 2.11 -  Fbxo7 forms a com plex with S k p l, C ull and Rbxl
A. Coimmunoprecipitation of FLAG-tagged Fbxo7 with endogenous Skpl, His-tagged Cull and 
T7-tagged Rbxl. When the F-box is deleted from Fbxo7 it no longer co-precipitates with Skpl. 
Cull contains a large non-specific band lower than His-Cull which is present in both vector alone 
control and Fbxo7 lanes. T7-Rbxl also shows some non-specific binding of the antibody. B. 
Cull-NTD binds to GST-Fbxo7F3-Skpl when immobilised on a glutathione Sepharose column. 
These three proteins co-elute in the supernatant, as seen by SDS-PAGE, when submitted to 
thrombin cleavage of the GST moiety. This shows that they form a ternary complex in vitro. 
Coimmunoprecipitation performed by Heike Laman.
2.5.2 Identification of Fbxo7-Skpl binding partners from Jurkat cell 
lysates
One of the main challenges facing the study of E3 ubiquitin ligases is the identification 
of substrate proteins. At the start of this project no substrate or binding partner for 
Fbxo7 had been reported in the literature other than Skpl. The identification of proteins 
that interact with Fbxo7 would be an important step in the functional analysis of the 
SCF^ 07 complex.
57
Chapter 2: Preparation and characterisation o f  the Fbxo7-Skpl complex and binding
partners
Our collaborator Heike Laman identified that Fbxo7 interacts with a viral D-type cyclin 
by yeast two-hybrid interaction. When the cyclin encoded by Herpesvirus samurai 
(HVS) was used as bait a clone was isolated encoding the amino acids 129-393 of 
Fbxo7, a region containing both the F-box domain and the undefined globular domain. 
This interaction had not been confirmed as a direct interaction by in vitro analysis 
therefore a GST pull down assay was performed against Jurkat cells (Schneider et al. 
1977) using GST-Fbxo7F2-Skpl as bait. Jurkat cells were chosen as in this leukaemia 
cell line cell cycle control protein levels are high, which would increase the chance of 
observing whether Fbxo7 binds to the D-type cyclins or their interacting proteins.
The pull-down experiment was performed using the longest Fbxo7-Skpl construct that
F2gave good yields o f recombinant protein (Fbxo7 -Skpl). This complex mimics as 
closely as possible the endogenous proteins and is also the original clone identified by 
yeast two-hybrid. The GST pull down was performed as described in appendix A using 
GST-Fbxo7F2-Skpl fusion protein affinity resin and GST protein as a control. Proteins 
co-eluted by thrombin treatment of GST-Fbxo7-Skpl were analysed by mass 
spectrometry (Nick Totty, Protein Analysis Lab, Cancer Research UK).
Fbxo7F2-Skpl interacts directly with endogenous Skpl and Cullinl (Figure 2.12a) as 
would be expected. This confirmation of a known interaction indicated that the protein 
binding partner identified by this approach might be physiologically relevant. Fbxo7F2- 
Skpl also binds to the proteasome inhibitor PI31 (and a truncated form o f this protein), 
actin and E. coli HSP60. Actin is also bound in the GST control so this is likely to be 
an artefact of the experiment and E. coli HSP60 is presumably bound to Fbxo7-Skpl 
from the original protein production due to the aggregated Fbxo7. PI31 has not been 
shown to interact with Fbxo7 or Skpl before and so this represents a novel binding 
partner for Fbxo7-Skpl.
The GST pull-down did not reveal any evidence o f interaction with the cell cycle 
control proteins cyclins or cyclin dependent kinases, as might have been expected from 
the yeast two-hybrid results. There is also no binding of the recently reported substrate 
of Fbxo7, HURP (Hsu et al. 2004). The interaction between HURP and Fbxo7 is 
thought to be via the C-terminal PRR of Fbxo7 and as this domain is missing from the 
recombinant protein the interaction is not detected.
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Figure 2.12 -  Identification o f PI31 as a binding partner of Fbxo7.
A. Identification of proteins from Jurkat cell lysates that co-elute with Fbxo7F2-Skpl upon 
thrombin cleavage of the GST-Fbxo7F2-Skpl fusion protein complex. Proteins were identified by 
SDS-PAGE and mass spectrometry. B. Fbxo7 co-immunoprecipitates with PI31. Fbxo7 was 
present in the anti-FLAG immunoprecipitates of PI31 as seen by Western blotting using anti- 
Fbxo7. C. pGAD-PI31 interacts specifically with Fbxo7 bait as shown by growth on media 
selecting for the plasmids (SC-Ura-Leu) and on media selecting for activation of reporter genes 
(SC-Ura-Leu-His-Ade). Coimmunoprecipitation and yeast-2 hybrid performed by Heike Laman.
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The interaction between Fbxo7F2-Skpl and PI31 could be mediated through either 
Fbxo7 alone, Skpl alone or the heterodimeric complex. PI31 does not contain an F-box 
domain and it does not have any homology to Cull and so it is more likely that the 
interaction with PI31 is through Fbxo7 than Skpl. In order to test this hypothesis 
FLAG-tagged full length PI31, Fbxo7( 129-522) and Fbxo7( 1-522) were over expressed 
in HeLa cells and immunoprecipitated with anti-FLAG antibody and then Western 
blotted with anti-Fbxo7 showing that over expressed Fbxo7 binds to PI31 in vivo 
(Figure 2.12b). There is no visible interaction with endogenous Fbxo7, which is likely 
to be because the endogenous levels of protein are not visible at this exposure.
The interaction was further confirmed by a yeast two-hybrid screen o f a human cDNA 
library using Fbxo7(l29-398) and Fbxo7(l-522) as respective baits. PI31 fused with 
Gal4 activation domain (GAD) was isolated on many occasions. Assaying for 
activation of the HIS3 and ADE2 reporter genes tested specificity for the pGAD-PI31 
interaction with the Fbxo7 bait plasmid. Yeast co-transformed with Fbxo7 plasmid and 
pGAD-PI31 grew on media lacking histidine and adenine but plasmid alone or HVS 
cyclin plasmid with pGAD-PI31 failed to grow under the same conditions (Figure 
2 .1 2c).
Taking these data together it appears that Fbxo7 binds to PI31 both in vitro and in vivo. 
PI31 is therefore a novel interaction partner that would benefit from further analysis and 
validation.
2.6 Discussion
The goals for the use o f the recombinant proteins described in this chapter were to 
identify novel binding partners o f Fbxo7 and to crystallise and solve the structure o f the 
Fbxo7-Skpl complex. The purified recombinant proteins Fbxo7-Skpl were produced at 
moderate levels allowing crystallisation trials and biochemical analysis o f the complex. 
These proteins will be useful tools in the analysis of the novel interaction between 
Fbxo7-Skpl andPI31.
The identification of aggregated Fbxo7 in the Fbxo7-Skpl protein complex used to 
obtain Fbxo7-Skpl crystals indicates that this protein was not homogeneous. The 
possibility that Fbxo7 may crystallise in the absence o f Skpl should be considered and 
this may aid the crystallisation o f an Fbxo7-substrate complex.
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The observation that Fbxo7 binds to the Skpl containing the loop deletions used for 
previous structure determination o f Skpl-F-box proteins (section 2.2.1) is important 
since the interaction between Skpl and other F-box proteins is not identical in the three 
previously solved structures. Skp2, a LRR F-box protein (Schulman et al. 2000), and P- 
TRCP, a WD40 F-box protein (Wu et al. 2003), bind to Skpl via a four helix bundle 
with the F-box domain comprising a loop region (LI) and 3 a  helices (a l -  a3). 
However cdc4, another WD40 F-box protein (Orlicky et al. 2003), has a different F-box 
topology comprising five a helices (aO -  a4) and although it interacts with Skpl using a 
similar four helix bundle the Skpl a  helix 8 and F-box a4 deviate significantly. The 
fact that this loop region, when deleted in Skpl, has no effect on the binding o f Skp2, P- 
TRCP, cdc4 and Fbxo7 indicates that although the topology of the F-box itself may vary 
this deletion does not have any effect on Skpl-F-box binding irrespective o f which class 
o f F-box protein is involved. The loop deletion construct with reasonable expression 
(Fbxo7-SkplF10) may be worth re-visiting now that technology has improved and the 
volume o f high concentration protein required for screening 96 crystallisation 
conditions using the mosquito™ robot (TPP Labtech) is only 12pi.
The identification o f the proline rich region at the C-terminus o f Fbxo7 and its reported 
role as a protein-protein interaction domain (Hsu et al. 2004) indicates that this region 
may be important in the function o f Fbxo7. Further work on the analysis of the role of 
this region in vitro with respect to the interaction with PI31 may be valuable. It might 
be useful to identify the minimal region of Fbxo7 that interacts with PI31 and to 
evaluate the role that the PRR may play in this interaction.
The Ubl domain of Fbxo7 may also play a role in the function o f this protein in vivo 
because Ubl domains have previously been shown to interact directly with the 
ubiquitin-interacting motif (UIM) of S5a, a subunit of the 26S proteasome. The 
structure of the UIM of S5a bound to the Ubl of HR23B showed that the Ubl adopts the 
ubiquitin fold and that the UIM contact sites in the Ubl are conserved in ubiquitin 
(Fujiwara et al. 2004). This indicated that the Ubl and ubiquitin make the same contacts 
and so Ubls can mimic ubiquitin in its interactions. It is interesting that Fbxo7, a 
protein involved in the ubiquitination pathway, also contains this motif. In addition to 
this the C-terminal region of the Ubl domain in Fbxo7 is conserved and so it may be 
cleaved at this site and could provide a different regulatory mode. One o f the plant
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Fbxo7 proteins does not contain the Ubl domain and so this form o f the protein could 
represent a function for the Fbxo7 protein in the absence of the Ubl.
The identification o f Fbxo7 as a subunit o f an E3 ligase both in vitro and in vivo reveals 
that this complex can form in the absence o f any co-factors and so is likely to be an 
active E3 ligase although such an activity remains to be reconstituted in vitro. A 
surprising finding was the identification of a novel binding partner for Fbxo7 but not the 
reported interacting partner Cdk6 . Other known interacting partners such as Cullinl 
were identified and so it is likely that this assay is able to detect physiological 
interactions. It is possible that the full length Fbxo7 is required for interaction with 
Cdk6 . The identification o f PI31 as a novel binding partner could indicate several roles 
for this interaction. It is possible that PI31 could be a substrate of SCFFbxo7 or it could 
be a co-factor, binding to Fbxo7 in order to bring another protein into position for 
polyubiquitination and degradation.
The interaction between PI31 and Fbxo7 will be discussed later in this thesis.
This chapter shows that Fbxo7 can form a complete SCF both in vitro and in vivo. It 
was also found that the proteasome inhibitor PI31 acts as a binding partner to Fbxo7 
both in vitro and in vivo and that the domain mediating this interaction is within amino 
acids 129-398 of Fbxo7.
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3 P roduction  and structure determ ination o f  the PI31 N- 
term inal dom ain
Following the identification of the structurally uncharacterised protein PI31 as a binding 
partner for Fbxo7 its suitability as a crystallisation target was assessed. Sequence 
analysis from 3D-PSSM and CD data (McCutchen-Maloney et al. 2000) was used to 
predict that PI31 has a globular domain spanning residues 1-151 which would be a 
suitable crystallisation target. This chapter describes the structure determination of this 
globular domain o f PI31. A flowchart describing the experiments undertaken can be 
found in Figure 3.1.
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Figure 3.1 -  Flowchart of the experiments described in chapter three.
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3.1 Cloning and expression of PI31
Circular dichroism (CD) analysis of recombinant PI31 performed by McCutchen- 
Maloney et al (McCutchen-Maloney et al. 2000) identified two separate domains within 
the protein. PI31 full length protein displayed elements of both a helical and random- 
coil structure whereas PI31 (1-192) showed predominately a helical structure and 
PI31(192-271) exhibited a random-coil structure. The C-terminal domain of PI31 
consists o f a PRR in which 26% of the terminal 117 amino acids are proline residues, 
which is reminiscent o f the C-terminus of Fbxo7. McCutchen-Maloney et al 
(McCutchen-Maloney et al. 2000) previously reported that whereas high expression of 
PI31 protein in E. coli was achieved using the pET expression system other systems did 
not produce the same yields o f recombinant protein. PI31(1-151), referred to in this 
thesis as PI31-NTD, cloned into pET28(a)+ was a gift from Neil McDonald (Structural 
Biology Laboratory, Cancer Research UK) and was generated as follows: PI31 was 
amplified by PCR from an IMAGE clone and the resulting DNA fragment was 
subcloned into Ndel/Hindlll cut pET28(a)+ expression vector (Novagen) and verified 
by DNA sequencing. This vector contains an amino-terminal poly-histidine (His) tag 
for affinity purification, a thrombin cleavage site for removal of the His-tag and a 
kanamycin antibiotic resistance marker.
Expression of PI31-NTD was performed using the standard protocols described in 
appendix A. The recombinant His-tagged PI31 was purified by immobilisation on a Ni- 
NTA column and eluted with imidazole. The His-tag was cleaved overnight with 
thrombin protease and the overall yield of purified protein was about 50mg/l (Figure 
3.2).
1 151  271
1 globular domain \\ Proline Rich Region
Figure 3.2 -  SDS-PAGE showing expression o f PI31-NTD
Expected position of PI31-NTD generated by the expression construct is marked with an arrow. 
This construct produced high yields of pure protein.
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3.2 Crystallisation o f PI31
Crystallisation trials were carried out using PI31-NTD recombinant protein at a 
concentration of 6 -8 mg/ml in 20mM Tris-HCl pH 8.0 and 5mM 2-ME as described in 
appendix B. In Hampton screens 1 and 2 and Wizard screen 1 several conditions 
yielded crystals as listed in Table 3.1.
Screen Name Number Description Time Contents o f Crystallisation solution
Hampton One 10 Showers o f crystals and 
protein precipitate
24 hours 30% w/v PEG 4000, 0.1M sodium acetate trihydrate pH 4.6, 
0.2M ammonium acetate
35 Crystalline needles 1 week 0.8M mono-sodium dihydrogen phosphate, 0.8M mono­
potassium dihydrogen phosphate, 0.1M HEPES pH 7.5
37 Showers o f crystals 1 hour 8% w/v PEG 4000, 0.1M sodium acetate trihydrate pH 4.6
42 Crystalline diamond 
plates
24 hours 20% w/v PEG 8000, 0.05M mono-potassium dihydrogen 
phosphate
Hampton Two 7 Showers o f  crystals 1 week 10% w/v PEG 1000, 10% w/v PEG 8000
Wizard One 17 Showers o f crystals and 
protein precipitate
24 hours 30% w/v PEG 8000, 0.1M sodium acetate pH 4.5, 0.2M Li2S0 4
19 Showers o f  crystals 24 hours 20% w/v PEG 1000, 0 .1M Tris-HCl pH 7.0,
30 Showers o f crystals 1 week 1.26M (NH^SO.*, sodium acetate pH 4.5, 0.2M NaCl
31 Showers o f crystals and 
protein precipitate
1 week 20% w/v PEG 8000, 0.1M HEPES pH 7.5, 0.2M NaCl
Table 3.1 -Initial crystallisation hits from sparse matrix screens using vapour diffusion
Screen Name Number Description Time Contents o f Crystallisation solution
PEG/Ion 7 Crystalline needles 1 week 20% w/v PEG 3350, 0.2M calcium chloride dehydrate
9 Crystalline diamond 
plates
72 hours 20% w/v PEG 3350, 0.2M ammonium chloride
12 Crystalline diamond 
plates
1 week 20% w/v PEG 3350, 0.2M ammonium iodide
16 Showers o f crystals and 
protein precipitate
72 hours 20% w/v PEG 3350, 0.2M magnesium nitrate hexahydrate
39 Showers o f  crystals 72 hours 20% w/v PEG 3350, 0.2M sodium dihydrogren phosphate 
monohydrate
41 Showers o f crystals 72 hours 20% w/v PEG 3350, 0.2 M potassium dihydrogen phosphate
43 Showers o f  crystals 72 hours 20% w/v PEG 3350, 0.2 M ammonium dihydrogen phosphate
Table 3.2 -  Crystallisation hits from Hampton PEG/Ion screen using vapour diffusion
PI31-NTD crystallised readily in a variety of conditions indicating that the domain 
boundaries used represent a folded globular domain as predicted. 7 o f the 9 conditions 
that generated crystals o f PI31-NTD in the original sparse matrix screens contained 
PEG and in order to improve the quality o f these crystals the Hampton PEG/Ion™ 
screen was carried out. As would be expected from the results o f the sparse-matrix 
screen several conditions yielded crystals within a week of setting up the vapour 
diffusion experiment (Table 3.2). Optimisation using grid screens designed around the 
conditions highlighted by the PEG/Ion screen produced diffraction-size crystals of 
PI31-NTD with a plate diamond morphology in 0.1 M ammonium iodide (NH4I) and 20- 
22% PEG 3350 (Figure 3.3).
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Figure 3 3  -  Crystals o f PI31-NTD
Protein crystals of PI31-NTD grown in 0.1 M NH4I and 20% PEG 3350. The storage buffer for the 
protein contained 20mM Tris-HCl pH 8.0 and 5mM 2-ME. These crystals were reproducible for 
different preparations of crystal solution and for different protein expression batches.
3.3 Data collection and analysis of PI31-NTD crystals
Data collection was performed on several crystals of PI31-NTD using both rotating 
anode and synchrotron radiation sources. All PI31-NTD data collected had a high 
mosaic spread, which was dependent on the orientation of the crystal and so varied with 
a sinusoidal pattern during the rotation of the crystal. Figure 3.4 shows typical 
diffraction images of a PI31-NTD crystal taken on our home source. There are a 
considerable number of partial reflections visible as clearly weak spots at the edges of 
the lunes.
Figure 3.4 -  Diffraction data im ages o f  PI31-NTD
Data from this crystal was collected on our home source. These images are taken at 0° and 90° 
and show the quality of the diffraction images obtained with a resolution of 2.6A at the edge.
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3.4 Processing and analysis o f PI31-NTD diffraction data
All the PI31-NTD crystals had a monoclinic space group (Hahn 1996). There were two 
different unit cells identified during the data collection (Table 3.3). Crystal parameters 
calculated by the program MOSFLM (described in appendix B and (Leslie 1992)) were 
used to predict diffraction spots. Visual comparison of the observed and predicted spots 
was used to validate the calculated parameters. This revealed that the predicted mosaic 
spread calculated for PI31 -NTD was too low and a new value was applied based on the 
best fit for the data (0.8° - 1.2°). An attempt was made to refine this new value but 
unfortunately due to the large variance in mosaicity (0.5° - 1.5°) this rendered the 
refinement unstable. The mosaic spread was refined for every batch of ten images and 
so varied throughout the integration o f the images. The value chosen by best fit was a 
starting value, which led to a more stable integration than that generated automatically.
Dataset number I II m IV
Data collection site Daresbury 14.2 Home source ESRF BM29 ESRF 14.4
Wavelength (A) 0.971 1.541 0.979 0.979
Space group C2 C2 C2 C2
Unit cell a= 108.5 b=40.8 
c=65.1 0=109.5
a= 109.5 b=45.2 
c=67.3 0=111.5
a=109.2 b=43.0 
c=132.2 0=109.34
a= 108.9 b=43.4 
c=132.3 0=109.4
Resolution range (A) 37.8-2.5 (2.64-2.5) 28.1-2.64 (2.78-2.64) 54.2-2.8 (2.95-2.8) 100-2.1 (2.21-2.1)
Completeness (%) 94.4 99.9 99.7 92.2
Rmeas (%) 9.7 (43.2) 8.5(41.9) 4.5 (9.1) 5.4 (20.7)
<I>/sd 12.7(2.9) 21.1 (4.8) 34.3 (18.5) 14.0 (3.9)
Multiplicity 3.6 (3.7) 7.2 (5.0) 7.1 (6.9) 1.8 (1.7)
Cryo-protectant 20% Ethylene Glycol 20% Ethylene Glycol 15% Ethylene Glycol 20% Glycerol
Table 3 3  - Summary of data collected of wild type PI31-NTD
Value in brackets refer to the highest resolution shell
Although all datasets are in the C2 space group the length of the c axis is variable, 65- 
67A (datasets I and II) or 132-133A (III and IV), with the remaining cell parameters 
remaining reasonably constant. The larger cell was observed when using 20% glycerol 
or 15% ethylene glycol as a cryo-protectant, while the smaller cell was only observed 
using 20% ethylene glycol. The PI31-NTD crystals were very sensitive to different 
cryo-protectant conditions, and additionally if  the crystals were exposed to the air at any 
time during the mounting process all diffraction disappeared. Many different cryo- 
protectant conditions were tested in an attempt to minimise the mosaicity problem, but 
only glycerol and ethylene glycol could be used as a cryo-protectant to obtain
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diffraction to better than 3 A. Analysis o f the Matthew’s co-efficient ((Matthews 1968) 
and appendix B) revealed that the smaller unit cell contained 2 molecules per AU and 
the larger unit cell contained 4 molecules per AU.
Native Patterson map analysis o f the large cell data shows a clear peak at 
u=0,v=0,w=0.5 indicating translational non-crystallographic symmetry (NCS). The 
small and large unit cell crystal forms may be dependent on whether the symmetry is 
NCS (large cell) or crystallographic (small cell).
_ C L
Figure 3.5 -  Native Patterson map on the Harker section (v=0) for large c cell axis.
This Patterson map includes data from 20 -  6A, it is contoured at 2a with an interval of la . The 
large peak at u=0, v=0, w=0.5 indicates the NCS along this axis.
The completeness as calculated by SC ALA (Evans 1993, 1997) is adequate for all the 
datasets collected (varying from 99.9 - 92.2%) and the multiplicity (measure for the 
number of times each reflection is measured) is high for all datasets except for that 
dataset collected at ESRF 14.4 where the multiplicity is only 1.8. <I>/sd is a measure of 
the signal to noise ratio and it is above the recommended value o f 2  for all o f the 
datasets with the lowest value being 2.9 in the highest resolution shell o f dataset I.
O f the two datasets (I and II) collected containing 2 molecules per AU, the data 
collected at the home source (II) has a similar resolution to that collected at Daresbury
(I). However the remaining statistics are better for dataset II with a completeness of 
99.9%, a multiplicity o f 7.2 and a higher <I>/sd in the highest resolution shell, 
indicating that the data is stronger and more redundant and therefore a good dataset for 
refinement. The crystallisation condition for this crystal contained a peptide from the 
C-terminus of PI31, which is not visible in the electron density. Subsequent 
biochemical work showed that this peptide did not bind to PI31-NTD (data not shown).
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Due to the superior quality o f the data all data analysis o f native datasets was performed 
on dataset II.
The program TRUNCATE (French and Wilson 1978) was used to calculate the 
structure factor amplitudes from the average intensities from the PI31-NTD crystals. 
The corresponding Wilson plot is shown in Figure 3.6 and the values calculated for the 
scale factor (C) and the temperature factor (B) were C = 11.0 and B = 60.7A2. The 
structure factor amplitudes calculated in this process were used in all following 
crystallographic analysis.
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Figure 3.6 - Wilson plot of PI31-NTD diffraction data (dataset II)
Wilson plot calculated for dataset II using TRUNCATE (Collaborative Computational Project 
1994). A straight line was fitted to the plot above 3A where the linear relationship is valid and the 
intercept and gradient of this used to estimate the scale factor and temperature factor.
3.5 Phase determ ination
3.5.1 Heavy atom soaks
Having obtained reasonable resolution native data the phase problem needed to be 
addressed. The first method attempted was SIR but since PI31-NTD crystallised in 
NH4I a large number o f the frequently used heavy atoms precipitated in the 
crystallisation solution. This is partly because many of the heavy atom compounds used
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reacted with the NH4I to produce insoluble metal compounds. All heavy atom 
compounds that were soluble in the crystallisation solution were tested on PI31-NTD 
crystals. Three compounds which did not cause visible destruction to the crystals were 
ethylmercurithiosalicylic acid (EMTS), mersalyl acid and potassium tetracyanoplatinate
(II). Crystals soaked in each o f these compounds were tested for diffraction at SRS 
Daresbury beamline 14.1 using different concentrations of heavy atom compound and 
different lengths o f soak. This beamline allowed the wavelength to be tuned to obtain 
the highest possible anomalous signal from the heavy atoms. The only crystals that still 
diffracted x-rays were those soaked in EMTS.
The data collected at a wavelength of lA  after soaking crystals at a concentration of 
either ImM or 5mM EMTS for periods o f 1 hour up to 48 hours maintained the same 
space group and unit cell as the native crystal. Unfortunately on analysis of the 
Patterson maps no peaks due to the heavy atoms could be found and so it was unlikely 
that any well ordered Hg atoms existed in the crystal.
After discussion it was thought that the new method of using halides as a phasing 
vehicle could be used in this case as the crystallisation solution contained iodide. It has 
been shown by Dauter et al (Dauter et a l 2000) that protein crystals soaked for a short 
time in a cryo-solution containing iodide ions can lead to the incorporation o f this 
anomalous scatterer into the ordered solvent region and this can then be used in a SAD 
experiment. It is not possible to use iodide in a MAD experiment as synchrotrons 
cannot be tuned to the wavelengths that would be required for this approach because the 
K edge is at 0.37A and Li edge at 2.39A, parameters that are beyond the capability of 
most beamlines (Carugo et al. 2005). Using X-rays with a wavelength of 1.54A, the 
wavelength from a rotating anode, the anomalous signal for iodide is f ' = 6 .8  electrons 
(Dauter and Dauter 2001) which is quite a significant signal and has been used for 
structure solutions. Unfortunately despite the fact that ammonium iodide significantly 
improves the quality o f the PI31-NTD crystals it was not possible to detect any 
anomalous signal using anomalous difference Patterson maps that could be attributed to 
the iodide in the solution, so no iodide ions were sufficiently ordered to be used for 
phasing.
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3.5.2 Selenomethionine phasing using SAD
Production o f protein labelled with heavy atoms such as selenium and subsequent 
crystallisation o f this modified protein introduces anomalously scattering atoms into the 
crystal. Methionine labelled with selenium is commercially available and by using 
supplemented minimal media a selenomethionine labelled PI31-NTD protein was 
produced (appendix A). PI31-NTD Se-Met protein was produced at a concentration of 
about 2 0 mg/l in the form o f a single species of the expected molecular weight when 
analysed by gel filtration (data not shown).
The crystals of PI31 -NTD Se-Met formed in the same conditions as the native protein, 
with a slightly higher concentration o f PEG 3350 producing the best crystals (22% as 
compared to 20% previously). The crystals have the same morphology (Figure 3.7b and 
c) as the wild type protein and the diffraction quality of the Se-Met crystals was 
comparable to the wild type protein at about 2.5A (Table 3.4). An absorbance scan 
performed on the PI31-NTD Se-Met crystal revealed that the selenomethionine had 
incorporated as it produced the characteristic absorbance for selenium (Figure 3.7d). 
The peak energy was revealed to be 12667eV and this value was used to calculate the 
optimum wavelength for data collection.
Dataset number V
Data collection site Daresbury 14.1
W avelength (A) 0.978
Space group C2
Unit cell a = 109.0, b = 43.2, c = 132.6, p = 109.2
Resolution range (A) 48.22 - 2.5 (2.64 - 2.5)
Completeness (%) 98.2
Rmeas (%) 6.5 (15.0)
Rano (%) 4.3 (7.3)
<I>/sd 20.4 (9.2)
M ultiplicity 7 (6.7)
Cryo-protectant 20% Glycerol
Table 3.4 -  Data processing statistics of Se-Met PI31-NTD crystals
Values in brackets refer to the highest resolution shell.
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Figure 3.7 -  Se-M et crystals o f PI31-NTD
A) The black arrow marks the expected position of the His-tagged PI31-NTD Se-Met protein. B) 
Crystals formed in 0.1 M Ammonium iodide and 22% PEG 3350 and have a very similar 
morphology to the wild type protein crystals (C, as in Figure 3.3). D) Absorbance scan of PI31- 
NTD Se-Met crystal showing the characteristic selenium absorbance profile.
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Table 3.4 contains the statistics calculated in SC ALA for one o f the PI31-NTD Se-Met 
crystals. This data is highly redundant, which is a requirement for anomalous phasing. 
360 degrees of data were collected on this crystal; the statistics showed no evidence of 
substantial radiation damage to the crystal, as the data quality appears to be constant 
throughout the data collection (appendix B). On the absorption scan an edge is seen at 
the point expected for a sample containing selenium (Figure 3.7d) and this was an 
indicator that this would prove to be a successful phasing vehicle for the PI31-NTD 
structure solution. The anomalous Patterson map generated at the beam line showed 
strong peaks on the Harker section (Figure 3.9a) but none on the other sections 
indicating that all cross-peaks were on the Harker section where they could not be 
distinguished from self-peaks. Attempts to identify the positions o f the heavy atoms by 
inspection and then refining them using MLPHARE (Otwinowski 1991; Collaborative 
Computational Project 1994) did not yield any electron density maps that could be 
interpreted which was at odds with the seemingly high signal on the Patterson map.
3.5.3 Breaking the centrosymmetric arrangement of the Se substructure
The problem remained to correctly identify the Se substructure positions because the Se 
atoms are in an arrangement where the symmetry of the isolated substructure is higher 
than that o f the crystal. In PI31-NTD all the Se atoms lie on the same y-plane, forming 
a centrosymmetric arrangement. An electron density map obtained by SAD phasing, as 
was attempted in this case, is a superposition of the true electron density and the 
negative inverse of the true electron density convoluted with the Fourier transform of 
exp(2 /^sub) where i is the imaginary number and <psub are the phases o f the heavy atom 
substructure. Equation 3.1 (Grosse-Kunstleve and Adams 2003) gives the Fourier 
coefficients o f this map.
Equation 3.1 F  -  F* exp(2i(psub )
The second term of Equation 3.1 is expected to contribute noise to the background in 
the SAD map that can be identified and removed by density modification and solvent 
flattening. The case o f a centrosymmetric substructure in a non-centrosymmetric space 
group is different. If the centre for inversion of the substructure is placed at the origin 
of the unit cell all phases <pSUb are either 0° or 180° and therefore exp(2/<pSUb) = 1. This 
reduces Equation 3.1 to F - F *  which means that the SAD map will now be the
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superposition o f the true electron density with its exact negative inverse and
interpretation of the map will be very problematic (Grosse-Kunstleve and Adams 2003).
Several strategies were identified to overcome this problem. One approach would be to 
use MAD phasing, in which case the ambiguity in the phases is removed and the true 
phases of the substructure can be found. However this is still a more complex 
procedure than solving a MAD structure without centrosymmetry and so a way to break 
the centrosymmetric arrangement and increase the anomalous signal was sought. It has 
been shown that the addition of a small number o f methionines can simplify the location 
of Se sites for use in MAD phasing (Gassner and Matthews 1999). The optimal amino 
acid for substitution is leucine, followed by isoleucine; neither of these mutations had a 
significant effect on the structure o f lysozyme (Gassner and Matthews 1999; Ohmura et 
a l 2 0 0 1 ).
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L7M 114M
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Arabidopsis_thaliana_PI31 lorSlMSOT
Figure 3.8 -  N-term inal PI31 alignm ent and crystal o f PI31-NTD (L7M )
A. Alignment of amino terminal 14 residues of PI31 with the mutations indicated. Alignment 
produced using ESPript (Gouet et al. 1999) B. Photograph of a PI31-NTD L7M crystal
Sequence comparison of PI31 using the program ClustalX (Thompson et a l 1997)
showed that the conservation and alignment of both Leu7 and lie 14 with methionines 
was maintained in other species including plants (Figure 3.8) and so represented 
possible mutation sites that were likely to maintain the structural integrity o f the 
molecule. Two mutant constructs (PI31-NTD (L7M) and PI31-NTD (I14M)) were 
generated, using the Quikchange protocol outlined in appendix A, and sequence 
confirmed by DNA sequencing. Protein with Se-Met incorporated was produced for 
both mutants with a yield comparable to that of wild type Se-Met protein. The mutant 
proteins were of the expected molecular weight when analysed by gel filtration (data not 
shown). Both proteins were submitted to crystallisation trials but only PI31-NTD 
(L7M) produced crystals (Figure 3.8b) in the same conditions as for the wild type
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V M A M I R L B
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protein. Two Se-Met incorporated PI31-NTD (L7M) crystals were used to collect 
datasets at BM14 at the ESRF and the statistics for these are outlined in Table 3.5.
Dataset number VI VII
Crystal One Two
Space group C2 C2
Unit cell a = 108.4 , b = 42.8, c = 66.6, P = 109.1 a = 108.7, b = 42.3, c = 66.3, p = 109.4
Resolution range (A) 39.75 - 2.5 (2.64 - 2.5) 2 7 .1 2 -2 .5 0 (2 .6 4 -2 .5 )
Cryo-protectant 20% Ethylene Glycol 20% Ethylene Glycol
Wavelength (A) 0.97855 (peak) 0.9790 (inflection) 0.9770 (high energy) 0.97855 (peak)
Rmeas (%) 7.2 (16.9) 6.1 (19.3) 7.1 (18.6) 4.7(15.1)
Rano (%) 4.5 (8.0) 3 .9 (10) 4.8(11.1) 4.7 (8.4)
<I>/sd 25.5 (12.5) 18.1 (8.6) 16.2 (7.3) 31.9(11.8)
Multiplicity 7.3 (7.4) 3.7 (3.7) 3.7 (3.7) 7.2 (7.3)
Completeness (%) 98.4 98.1 98.2 99.9
Table 3.5 -  Table of MAD (VI) and SAD (VII) data collected on PI31-NTD (L7M)
Values in brackets represent the highest resolution shell.
The high energy remote was collected last in the MAD dataset (VI) and although it has 
reduced values for <I>/sd all the remaining statistics are acceptable. The three datasets 
were scaled together in SCALA and the output after truncation was used for further 
analysis. Comparison between the Patterson maps of the wild type PI31 -NTD Se-Met 
protein and the L7M PI31-NTD protein showed that there were new self- and cross­
peaks on the Harker section (Figure 3.9c and d) and cross-peaks were visible on other 
sections showing that the mutated residue was ordered and the Se position could be 
used in the determination o f the phases for the heavy atom substructure (Figure 3.9b).
There are three methionine residues per mutant PI31-NTD molecule. Both the crystals 
from which data were collected were in the smaller space group with 2  molecules per 
AU and therefore there were six Se atoms to locate. SHELXD was used by Judith 
Murray-Rust (Structural Biology Laboratory, Cancer Research UK) to calculate the 
positions of the heavy atoms using the peak data of dataset VI and these positions were 
confirmed by the SAD dataset using SOLVE. The initial graphical inspection o f the 
heavy atom sites from SHELX revealed two constellations o f 3 Se atoms. The 
transformation matrix between these constellations was later used in NCS averaging. 
SHELXE was then used to determine the hand. The final output was a contrast o f 0.403 
and connectivity o f 0.877 for one hand or a contrast of 0.314 and a connectivity of 
0.845 for the other, which is a clear discrimination and a contrast of 0.403 is within the
75
Chapter 3: Production and structure determination o f PI31 N-terminal domain
range found for SAD structures (http://biop.ox.ac.uk/www/shelx/shelx-de.pdf). 
SOLVE was unable to independently identify the positions of all six heavy atoms and 
so the phases from SHELXD/E were used as the starting point for map generation.
A. B.
t
C. D.
E  HI
Figure 3.9 -  Comparison between wild type and L7M mutant
A and B, unit cell shown in blue and selenium sites represented as red spheres produced using 
PyMol. A) native protein, B) mutated L7M protein. The original selenium sites are all on the same 
y-plane; the introduction of additional methionine residues disrupted this arrangement and enabled 
the phase determination to proceed. C and D, Difference Patterson maps at the v =1/2 Harker 
section of Se-Met PI31 peak wavelength data contoured at 0.5c cut at 2a. C) Wild type and D) 
L7M mutant. The peaks boxed in blue are cross-peaks and in green are self-peaks from native 
methionine residues. Those boxed in red are self-peaks and in orange are cross-peaks from the 
mutated residues. Peaks were identified from calculated Patterson maps after the sites were 
determined using dataset VI. A and C represent dataset V and B and D dataset VI.
3.6 Model building and refinement of PI31-NTD
The initial phases were not of sufficient accuracy to provide fully interpretable electron 
density maps. The phases were initially improved using density modification with the 
additional information from the NCS operator between the 2 Se constellations. Both 
RESOLVE (Terwilliger 2000) and DM (Cowtan 1994) were used separately and the 
maps compared in O (Jones et al. 1991). The map output from RESOLVE displayed 
more connectivity and was partially interpretable so some secondary structure elements 
were built in as a C-alpha chain in O. This secondary structure enabled the refinement 
of the NCS operator and a further improvement in the phase estimate.
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In the analyses of the maps only the peak data from dataset VI had contributed to the 
phase calculation (Figure 3.10a). The program DMMULTI (Cowtan 1994) allows data 
from more than one crystal to be combined during density modification. Multi-crystal 
averaging using both the SAD (VII) and MAD (VI) data including NCS was performed 
and produced interpretable electron density maps (Figure 3.10).
Figure 3.10 -  Comparison o f  electron density maps from RESOLVE and DM M ULTI
Electron density maps shown with refined structure. Left) RESOLVE map and Right) DMMULTI 
map. Unexplained connectivity visible in the RESOLVE map has been solvent flattened in the 
DMMULTI map enabling correct placement of amino acids.
The positioning of the Se atoms within the anomalous peaks in the electron density 
assisted chain tracing and the majority o f the chain could be assigned in the map from 
DMMULTI. The program O was used for most of the rebuilding although the final 
cycles used the newer program COOT (Emsley and Cowtan 2004) as it contained 
several useful model validation tools.
REFMAC (Murshudov et al. 1997) was used for refinement using TLS refinement. 
Although the L7M mutant does not appear to have an impact on the structure it was 
thought that the native data would be more valid for future analysis and so the partially 
refined Se-Met derivatised model was used to solve the native structure by molecular 
replacement using MOLREP (Vagin and Teplyakov 1997) using the home source native
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data (II) (Table 3.3) which is of a comparable resolution to the mutant data. Final data 
statistics and the structure are those o f the native data (dataset II). The structure was 
refined to 2.64A and a representative image of the quality of the final electron density 
map can be seen in Figure 3.11.
Figure 3.11 -  Final electron density map (2Fo-Fc) contoured at 1 o with PI31-NTD structure
All figures of this type in this thesis were produced using the program PyMOL (DeLano 2004).
3.7 Structure validation
The final structure of PI31-NTD contains the amino acids 1-143 with the remaining 8 
amino acids at the C-terminus of the protein disordered and not visible in the electron 
density. There are also two amino acids on the N-terminus of chain A and one on the 
N-terminus of chain B that originate from the construct sequence. Whilst they are not 
part of the PI31-NTD sequence these amino acids are visible in the electron density and 
so have been built in. The refinement of the structure was concluded when the Rfact and 
Rfreeconverged at 19.3% and 27.1% respectively (Table 3.6).
The final model has good stereochemistry (Table 3.6) in that the RMSD values from 
target bond lengths and from target bond angles are reasonable at 0 . 0 16A and 1.743° 
respectively.
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Model
Protein atoms present in the structure 2132
Solvent atoms (water oxygen) 39
Protein atoms missing from the structure due to disorder 127
Diffraction Agreement
Resolution limits (A) 20.0 - 2.64
Total reflections (test for Rfree) 8707 (476)
R fa c t(% ) 19.3
R fre e (% ) 27.1
Stereochemistry
RMSD bond lengths (A) 0.016
RMSD bond angles (°) 1.743
Table 3.6 -  Structural quality indicators for PI31-NTD structure output by REFMAC 5.0
During refinement the electron density for several side chains was not complete and so 
these have been modelled as listed in Table 3.7. The majority o f these residues are 
either in flexible loop regions where the electron density was weak or are intrinsically 
flexible sidechains at the protein surface. There are two main flexible loop regions in 
the structure, 72-76 and 95-100. In addition to the missing side-chain density there was 
no main-chain density for Ser75 in chain A and so this has been omitted; Ser75 is 
visible in chain B.
Number Residue Chain A Chain B
-1 Ser CB Not Built
43 Gin CB CB
49 Lys CB CB
50 Lys CB CB
72 Lys CB CA
73 Asp CB CA
75 Ser Not Built CA
76 Arg CB CB
77 Lys CB CB
95 Glu CD
96 Tyr CB CB
98 Ser CB CB
99 Gin CB CB
100 Gin CB CB
122 Arg CB
128 Glu CB CB
132 Ser CB
142 lie CB CB
143 His CB
Table 3.7 - Table listing omitted and truncated amino acids
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Figure 3.12 shows the Ramachandran plot calculated for the PI31-NTD final structure. 
This provides a measure o f the quality of the proteins main-chain geometry with 88.4% 
of residues in the most favoured regions, 1 0 .0 % in additionally allowed regions, 0 .8 % in 
generously allowed regions and 0.8% in disallowed regions. The value within the most 
favoured regions is above the typical value for this resolution (74.0%) and so this is 
considered to be a good model. The two residues within the disallowed regions are both 
in chain A and are Glu8 6  and Ser98. Whilst Glu8 6  in both chains has an unusual 
stereochemistry it is however built into well-defined electron density. Ser98 is in an 
area of poor electron density and so it is very possible that this geometry suffers from 
insufficient knowledge to fully place this residue.
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Figure 3.12 -  Ramachandran plot o f the refined PI31-NTD structure
This plot is calculated using the program PROCHECK (Laskowski et al. 1993) using the final 
refined co-ordinates of the PI31-NTD structure; data from both protomers is shown. Glycine 
residues are shown as black triangles.
The mean temperature factor for the model was given as 32.2A2, which is much lower 
than the value originally given in the Wilson plot produced by TRUNCATE. Since the 
temperature factor from Refmac and TLSANL does not include the contribution made 
by the TLS parameters it is not a directly comparable figure with the Wilson plot. 
There is a wide range o f temperature factors for different residues throughout the 
structure as can be seen in Figure 3.13 but nevertheless the majority are within a small
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range. The residues with high temperature factors (60A2) are all from the vector 
sequence and so are not part o f the PI31 protein.
N-term
Figure 3.13 -  Tem perature factors mapped onto final model
Red represents high B-factors (60A2) and blue represents low B-factors (20A2). The majority of 
the structure is either blue or green representing low to medium temperature factors as would be 
expected. The high (red) amino-acids are at the N-terminus of the protein where the additional 
residues from the vector are present.
3.8 Discussion
The previous identification o f the globular domain of PI31 by CD analysis (McCutchen- 
Maloney et al. 2000) enabled the design of a protein construct that produced large 
quantities of purified recombinant protein suitable for crystallisation. PI31-NTD 
crystallised readily and after some optimisations diffracted to 2.64A. This diffraction 
was highly mosaic, probably due to mechanical weakness of the plate shaped crystals. 
The high sensitivity to air may also have been due to this morphology, weak inter- 
molecular contacts within the crystal or the solvent content o f the crystal. The cryo 
protectant used had an effect on the crystal form and so it is likely that this would have 
had an effect on the internal order of the crystal and so on the resolution and mosaicity. 
The combination of the high mosaicity and the crystal handling procedures adopted to 
avoid contact with the air may have reduced the quality of the data collected. In 
hindsight it would have been preferable to attempt to refine some o f the other PI31-
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NTD crystallisation conditions to attempt to minimise the mosaicity and so improve the 
data quality. It is also possible that some of the other conditions may have produced 
crystals that diffracted to a higher resolution and may have been more amenable to 
heavy atom derivatisation.
The phasing problems encountered during the structure solution o f PI31-NTD required 
the use of several strategies. The heavy atom derivatisation would, if  successful, have 
supplied the information required for phasing, although the presence o f the ammonium 
iodide in the crystallisation condition reduced the number o f derivatives available. In 
the final structure solution some o f the cysteine residues demonstrate a small amount of 
modification, which could have prevented the interaction of the mercury derivatives.
The selenomethionine protein crystallised readily and the Harker section showed peaks 
that should have been interpretable and so it was unfortunate that the selenium atom 
substructure was in a centrosymmetric arrangement. The use o f MAD phasing and the 
introduction of additional methionine residues proved to be a successful method for 
determining the phases in this situation. It is possible that despite the centrosymmetric 
arrangement the phases could have been solved using MAD phasing alone, however it 
is likely that the phase information obtained using this method alone would not have 
been as good and it still may have been difficult to identify the positions o f the selenium 
substructure.
Despite the problems encountered the final structure is a reasonable model for PI31- 
NTD as analysed using PROCHECK (Laskowski et a l 1993) and when using the R 
factors for analysis. The analysis with PROCHECK revealed that the model is better 
than average for the resolution. The difference between the two R factors is larger than 
would be preferable but it is within the limits for data within the resolution range of 
2.5A to 3A as set out by Tickle et al. (Tickle et a l 2000). The other data collected 
remains to be refined and a higher resolution dataset may reveal further information 
about the structure o f PI31 -NTD.
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4 Structural and b ioph ysica l characterisation  o f the FP  
dom ain
The structure o f PI31-NTD is discussed in this chapter along with the sequence and 
structure based analysis o f the previously uncharacterised globular domain in Fbxo7. 
PI31 and Fbxo7 have a common domain that we have called the FP domain, which 
spans residues 1-151 in PI31 and 169-276 in Fbxo7. This domain has a novel a/p fold 
that does not belong to any previously identified family of proteins. The PI31 FP 
domain forms a dimer through an alpha helix interface as identified in this chapter by 
gel filtration and AUC of wild type and mutant proteins. Experiments described in this 
chapter are outlined in a flowchart in Figure 4.1.
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a lign m en t of  
F b xo7 and  PI31
T
Dali serverP roF u nc (S SM )
Identification o f  
PI31 FP dom ain  
a s  a  novel 
structural fold
Identification of 
th e  FP  dom ain  in 
F b xo7 and  PI31
S ea rch  for sim ilar 
p roteins to identify 
function o f FP  
dom ain
A nalysis  o f m utant 
p roteins by s iz e  
exc lu sion  
chrom atography
D etailed  structural 
a n a ly s is  o f  
c o n serv ed  
r e sid u es
Production o f  
m utant proteins to 
disrupt two  
in terfaces
A n a lysis  o f m utant 
p roteins by A UC
A n alysis  o f th e  
PI31 structure
Identification o f  
tw o
crystallographic
d im ers
A n alysis  o f th e  
dim er in terfaces  
u sin g  Protein- 
Protein Interaction  
S erver
Figure 4.1 -  Flowchart of experiments described in chapter four
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4.1 Discussion o f the structure of the P131-NTD
The structure of PI31-NTD consists of an a/p fold (Figure 4.2) with the topology of two 
a helices followed by a five stranded anti-parallel p sheet and then three a helices. All 
the helices are packed against one side of the P sheet.
Figure 4.2 -  Stereo view and topology diagram of a PI31-NTD protomer
Alpha helices shown in blue, beta sheets in yellow and loops in cyan. PI31-NTD has a topology of 
two a helices followed by a five stranded anti-parallel (5 sheet and then three a helices. All the 
helices are packed against one side of the P sheet. Figure produced using PyMOL.
The C-alpha chains of the two protomers of PI31-NTD in the AU have an RMSD of 
0.381 A when superposed using the program LSQKAB (Collaborative Computational 
Project 1994). The areas in which the two protomers are different are residues 73 and 
74, residue 97 and within the C-terminus. These regions are poorly defined in the 
electron density and so these differences are unlikely to be due to any conformational 
changes in PI31 -NTD.
There are two molecules of PI31-NTD in the AU. These two protomers have two 
possible dimer interfaces (Figure 4.3) interface A between the N-terminal a  helices of 
molecule a and b’ and interface B between the P-sheet of molecules a and b. The two 
possible dimers are not formed through crystal contacts and so one of these may 
represent a true dimer in solution.
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Dimer interacting through interface A
Dimer interacting through interface B
Figure 4.3 -  Diagram of the two crystallographic PI31-NTD dimers
Molecule a is coloured from blue at the N-terminus to red at the C-terminus, the two molecule b 
protomers (b and b’) are coloured in blue. Interface A is formed through the N-terminal a  helix of 
molecules a and b ’ and Interface B is formed through the P-sheet of molecules a and b. No 
interactions can be seen between a with a or b with b.
4.2 Structure-based alignment of the FP domain
A PSI-BLAST search with PI31-NTD (Altschul et a l 1997) identifies Fbxo7 to have 
sequence similarity. Human PI31-NTD and Fbxo7( 169-276) have a 24% sequence 
identity and 45% sequence similarity. Further analysis using ClustalX (Thompson et al. 
1997) revealed that PI31 and Fbxo7 contain a common domain that is unique to these 
two proteins and is conserved throughout all organisms where these proteins are present 
(Figure 4.4). This previously undefined domain spans residues 1-151 in human PI31 
and residues 169-276 in human Fbxo7 and we have termed it the FP domain for Fbxo7 
and PI31. This domain was delineated in chapter 2 as being an uncharacterised globular 
domain in Fbxo7 by limited proteolysis and biomolecular modelling.
From analysis of the sequence alignments it was observed that PI31-NTD contains a 
conserved YxLxY motif on the P2 strand. In addition to this motif it was also noticed 
by sequence alignment using ClustalX (Thompson et al. 1997) that Asp20 and His28 on 
the a2 helix were completely conserved through all PI31 proteins indicating a possible 
enzymatic activity for PI31. All o f these residues are buried and form hydrogen bonds 
as can be seen in Figure 4.5 and so they are unlikely to be functionally important 
residues within an enzyme active site although they are important for the conformation 
of the protein.
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Figure 4.4 -  Structure based alignm ent of PI31 and Fbxo7 FP domains
Structural assignment is based on PI31 FP domain structure. Residues coloured in yellow are 
conserved, figure produced using the web server ESPript (Gouet et al. 1999).
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His27
Leu67
J
Figure 4.5 -  Interaction o f  the invariant YxLxY m otif with Asp20 and His28 FP domain  
residues
The YxLxY motif on the P2 strand interacts through hydrogen bonds with the conserved residues 
Asp20 and His28 on the a2 helix. These conserved residues appear to be important in the 
structural arrangement of the FP domain but are not likely to be functionally active residues.
Figure 4.6 -  Salt bridge form ed by Asp48 and Arg68
Asp48 and Arg68 form a salt bridge in the PI31 FP domain, which stabilises a proline rich loop 
region.
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PI31-NTD also contains a salt bridge formed by residues Asp48 and Arg 6 8  that 
stabilises a loop from residue 40 to 64 (Figure 4.6). The two residues are not conserved 
throughout PI31 proteins and so it is not known if this loop is maintained in a different 
way for other PI31 proteins or if it is structured differently. There is no known function 
for this loop and so it is difficult to draw any further conclusions from this interaction.
After identification o f the novel FP domain the SAM-HMM server was then applied to 
further analyse the PI31 FP domain (http://www.cse.ucsc.edu/research/compbio/HMM- 
apps/T02-query.html). This server used hidden Markov modelling (HMM) to build a 
profile of the query protein. The HMM built by the server identifies a set of positions 
that describe the conserved first-order structure in the sequences from a given family of 
proteins; this is the equivalent o f identifying the core elements o f homologous 
molecules. After building this model a multiple alignment of the sequences is 
performed. The server uses variable, position dependent, gap penalties to improve the 
quality of the alignment. The model is then used for database searching to identify 
family members and finally the model is studied directly (Krogh et al. 1994).
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Figure 4.7 -  Results from HM M  m odelling alignment
HMM modelling using PI31-NTD sequence as prey. Size of amino acid indicates the degree of 
conservation in that position. Secondary structure assignments taken from the PI31 FP domain 
structure.
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PI31 FP domain was applied to the SAM-HMM server in order to identify conserved 
amino acids that may have been mis-identified by more conventional sequence 
alignment software (Figure 4.7).
Interestingly the amino acid with the highest Z score is Trp58 followed by Pro55 and 
these residues are both in the same loop region of the protein. Unlike other residues 
implicated in the function of the domain the amino acid Trp58 is solvent accessible and 
seems to be at the bottom of a very shallow pocket that could possibly be involved in 
protein binding. Pro55 is not solvent exposed but it brings about the change in direction 
of the peptide backbone that allows the pocket to be formed and so this amino acid 
could also be important for the function of this protein (Schultz and Schirmer 1990).
Pro55
Figure 4.8 -  Structural representation o f the shallow pocket formed by Pro55 and Trp58
PI31 FP domain is represented in cartoon form. Pro55 and Trp58 are highlighted and it can be 
seen that Trp58 is a solvent exposed residue and Pro55 influences the conformation of this loop.
4.3 Topology analysis o f the PI31 FP domain
4.3.1 Structure comparison using the DALI server
Topology comparisons were carried out using several servers in order to use the 2.64A 
structure of the PI31 FP domain to obtain a greater understanding of the function of the 
PI31 protein. Structural comparison servers can be used to find structural similarity 
between proteins with little or no sequence similarity and can sometimes help with the 
elucidation of a function for a previously uncharacterised protein. This method is
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becoming more powerful as the algorithms used improve and the number of proteins of 
known structure in the database increases (Holm and Sander 1994).
The DALI server at the EBI (http://www.ebi.ac.uk/dali/index.html) did not reveal any 
proteins that have the same topology as the PI31-NTD protomer although one protein 
was revealed to have a similar topology, the E. coli protein CyaY (Cho et al. 2000) (pdb 
code: 1EW4) which is believed to be a closely related ancestor of frataxin (Figure 4.9c). 
The C-terminal domain o f human frataxin was solved by NMR (Musco et al. 2000) 
(pdb code: 1DLX) and revealed to have the same topology as CyaY (Cho et al. 2000) 
(Figure 4.9b). When comparing the topology o f PI31-NTD with CyaY using the DALI 
server it gives a Z score o f 4.5. When PI31 FP domain is compared to itself it has a Z 
score o f 32.6 and conversely a Z score o f less than 2.0 indicates the proteins are 
structurally dissimilar. The RMSD fit o f the C-alphas o f CyaY and PI31 FP domain 
used in the comparison is 3.4A and the sequence identity between PI31 FP domain and 
CyaY is 12%. These values indicate that the two proteins are not topologically identical 
but that there might be some structural similarity.
All three of the proteins have an anti-parallel beta sheet against one side o f which are 
packed alpha helices (Figure 4.9). There are however several important differences 
between the structure o f the frataxin proteins and that of PI31 FP domain. The number 
of alpha helices packing against the anti-parallel beta sheet is only two in the frataxins 
whilst there are five in PI31 FP domain and the number of strands in the beta sheet is 
five in PI31 FP domain and six in the frataxin proteins. These two large differences 
mean that the fold o f PI31 FP domain is not topologically the same as that of the 
frataxin proteins despite the similarities. The similarities between the structures of PI31 
FP domain and the frataxin proteins could have been used to obtain some information 
indicating the function of PI31 FP domain by comparison with the function o f frataxin. 
Unfortunately human frataxin, whilst implicated in the disease Friedreich’s ataxia, has 
no reported function (Musco et al. 2000).
4.3.2 Structure analysis using the ProFunc server
ProFunc (http://www.ebi.ac.uk/thomton-srv/databases/ProFunc) is a server that aims to 
predict the function o f a protein o f known structure by using both sequence and 
structural information to identify functional motifs or close relationships to previously 
characterised proteins (Laskowski et al. 2005).
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Figure 4.9 -  Cartoon representation of PI31 FP domain, frataxin and CyaY for topological 
comparison
A. PI31 FP domain protomer crystal structure. B. Frataxin C-terminal domain NMR structure. 
C. CyaY crystal structure. All structures have a topology diagram to the right of the structure and 
are coloured from blue at the amino terminus to red at the carboxy terminus.
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The sequence based analyses that ProFunc carried out were: sequence search against the 
PDB, sequence search against UniProt, sequence motif search (e.g. PROSITE (Sigrist et 
al. 2002) and Pfam (Bateman et a l  2004)), superfamily hidden Markov model search 
and gene neighbours search. In all analyses made using the PI31 FP domain sequence 
no proteins were reported.
The second set of processes applied by the server to the protein was the structure based 
analyses. These included: a secondary structure matching search (SSM) (Krissinel and 
Henrick 2004, 2005), search for surface clefts using SURFNET (Laskowski 1995), 
residue conservation mapped onto the surface o f the structure, search for DNA-binding 
helix-tum-helix motifs and finally a search for nests (an anion or cation binding site 
formed by three or more amino acids in the sequence whose ¥  -  9  dihedral angles 
alternate between the right- and the left-handed regions o f the Ramachandran plot).
Z-Score RMSD (A) Seq. ID (%) PDB entry Name
4.4 2.1 17.90 lsa8 The nmr structure of a stable and compact all-beta-sheet 
variant of intestinal fatty acid-binding protein 2
3.3 2.79 18.90 lxkp Crystal structure of the virulence factor yopn in complex 
with its heterodimeric chaperone sycn-yscb 3
2.5 3.02 17.00 ijya Crystal structure of syce 4
2.5 3.22 17.90 lry9 Spal5, a type iii secretion chaperone from shigella 
flexneri 5
2.5 2.73 12.50 lkaf DNA binding domain of the phage t4 transcription factor 
mota (aal 05-211) 6
2.5 2.92 18.90 ln5b Crystal structure of the yersinia enterocolitica molecular 
chaperone syce 7
2.4 2.97 17.90 lk6z Crystal structure of the yersinia secretion chaperone syce 
8
2.3 3.31 14.20 lsoy Solution structure of the bacterial frataxin orthologue, 
CyaY 9
2.3 2.98 17.00 112w Crystal structure of the yersinia virulence effector yope 
chaperone-binding domain in complex with its secretion 
chaperone, syce 10
2.1 3.16 16.00 lm dl Crystal structure of the yersinia enterocolitica molecular 
chaperone syce
Table 4.1 -  SSM results using PI31 FP domain to search.
The SSM search did reveal several proteins upon which it was able to superimpose the 
C-alpha chain and obtain an RMSD of less than 4 A (Table 4.1). This C-alpha 
alignment allows extensive breaks in the peptide backbone o f the protein, which reveals 
many false positives. For example the protein with the highest Z score (PDB code: 
1SA6) was an intestinal fatty acid-binding protein, which consists entirely o f beta 
strands. None o f the proteins described in Table 4.1 have the same topology as PI31 FP 
domain and, as before, the protein with topology most similar is CyaY.
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In PI31 FP domain, using the ProFunc server, no surface clefts were identified, there 
were no patches o f conserved residues on the surface, no DNA helix-tum-helix binding 
motifs and all the nests are predicted to be too shallow to have any functional 
significance.
The final analyses the server performed on the protein structure was a 3D template 
search which included: a search for enzyme active sites, ligand binding sites and DNA 
binding sites. None o f these searches produced any significant matches.
The ProFunc server provided a very thorough examination o f the PI31 FP domain 
structure with respect to other previously characterised proteins and it did not produce 
any significant hits. It appears from the searches using both DALI and ProFunc that 
PI31 FP domain contains a novel fold and further analysis will be required to elucidate 
its function.
4.4 Analysis o f the two crystallographic dimer forms
As described previously in section 4.1 there were two possible dimer formations within 
the crystal structure (Figure 4.10). In order to identify the correct physiological dimer a 
protein-protein interaction server was used to look at the features of the two possible 
dimer interfaces (http://www.biochem.ucl.ac.uk/bsm/PP/server/) (Jones and Thornton 
1995, 1996). The results o f the server analysis o f both dimer interfaces are shown in 
Table 4.2.
Protein Interface Parameter Value interface A Value interface B
Interface Accessible Surface Area (A2) 557.22 279.89
% Interface Accessible Surface Area 7.84 4.04
Planarity 1.56 1.17
Length & Breadth 25.81 & 15.42 25.92 & 10.22
Length/Breadth Ratio 0.69 0.36
Interface Residue Segments 4 3
% Polar Atoms in Interface 29.16 36.01
% Non-Polar Atoms in Interface 70.8 63.9
Secondary Structure Alpha Beta
Hydrogen Bonds 5 2
Salt Bridges 0 0
Disulphide Bonds 0 0
Gap Volume 3563.36 3691.66
Gap Volume Index 3.23 6.58
Table 4.2 -  Output data from Protein-Protein Interaction Server for the two possible 
interfaces (Jones and Thornton 1995,1996)
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Figure 4.10 -  Structural diagram  o f the two possible dimer interfaces and mutations
A. Interface A shown with the interface residue Val6 highlighted. B. Interface B shown with the 
residues Ile83 and Ile90 highlighted
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The interface accessible area is reported for only one of the protomers and the expected 
value for typical functionally relevant homodimers is 1685 A2 with a standard deviation 
of 1101 A2 (calculated for 32 known examples) (Jones and Thornton 1995) which 
means that neither o f the interfaces are within one standard deviation o f the expected 
value. Interface A has a larger interface accessible area indicating that this surface is 
more likely to be the physiologically relevant dimer interface. In order to calculate the 
planarity of the interface the best fit plane is calculated and the planarity of the interface 
is reported as a root mean square deviation from this plane. The mean value calculated 
is 3.5 with a standard deviation o f 1.7. Again both of the interfaces are more than one 
standard deviation from the expected values, indicating that both the interfaces are more 
planar than would be expected. The length and breadth provides information on the 
shape of the interface by analysis of the deviations o f the interface atoms from the 
centre of gravity o f the best fit plane previously calculated. When the length/breadth 
ratio is 1 the interface is approximately circular. The expected value o f the ratio is 0.7 
with a standard deviation of 0.2 therefore interface A is of the expected shape and 
interface B is more extended than would be anticipated. The expected number of 
hydrogen bonds within a homodimer interface is 0.7 bonds per 1 0 0  A2 with a standard 
deviation o f 0.5. Interface A contains 0.90 bonds per 100 A2 o f interface and interface 
B contains 0.71 bonds per 1 0 0  A2 o f interface so both of these values are as would be 
expected. Neither interface contains either salt bridges or disulphide bonds and so the 
interface is not likely to form a permanent complex. The final measure is of the gap 
volume which provides a measure of the complementarity of the interacting surfaces 
which is calculated using a program SURFNET (Laskowski 1995). The gap volume 
index is calculated as (gap volume / interface accessible surface area) and would be 
expected to be 2.2 with a standard deviation o f 0.9. Both PI31 interfaces are outside the 
one standard deviation range for this measure although interface A is much closer to the 
expected value than interface B.
The protein-protein interface server also produced a list o f interface residues and 
calculates their contribution to the interface accessible surface area (Table 4.3 and Table 
4.4).
In the case of interface A the major contributor to the accessible surface area is Val6  
and so this was chosen as the optimal residue to target to disrupt this dimer interface 
(Figure 4.10a). For interface B Ile83, Val85, Glu8 6  and Ile90 contribute significantly to
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the accessible surface area o f the interface. Glu8 6  is at the edge o f the accessible 
surface area and so mutation o f this amino acid would generate data that was difficult to 
analyse when looking to disrupt the dimer interface. Analysis o f the structure revealed 
that Ile83 and Ile90 were both at the centre of the dimer interface and were positioned in 
different areas o f the dimer interface and so these two amino acids were chosen for 
mutation to disrupt interface B (Figure 4.10b).
Residue Number Residue Name Interface ASA % Interface ASA
2 ALA 54.14 9.72
3 GLY 27.67 4.97
5 GLU 72.65 13.05
6 VAL 109.07 19.59
7 LEU 5.1 0.92
9 ALA 34.22 6.15
10 SER 31.53 5.66
28 TYP 27.32 4.91
31 VAL 3.78 0.68
32 THR 12.92 2.32
50 LYS 14.39 2.58
51 SER 13.92 2.5
52 GLU 71.96 12.92
53 LEU 60.74 10.91
121 HIS 17.45 3.13
Table 4 3  -  Analysis o f interface by residue for interface A
Residues to be mutated are highlighted in bold and italics
Residue Number Residue Name Interface ASA % Interface ASA
42 ASP 6.64 2.38
64 LEU 39.2 14.03
66 VAL 5.83 2.09
81 LYS 24.98 8.94
83 ILE 49.17 17.6
85 VAL 48.17 17.24
86 GLU 64.82 23.2
90 ILE 39.07 13.99
92 ASN 1.5 0.54
Table 4.4 - Analysis of interface by residue for interface B
Residues to be mutated are highlighted in bold and italics.
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The residues identified as contributing to the dimer interface are all hydrophobic 
residues. In accordance with this the analysis of the electronic surface potential o f each 
of the dimer interfaces shows that the surfaces of both of the possible dimer interfaces 
o f the PI31 FP domain are hydrophobic (Figure 4.11). There are no areas of charged 
amino acids on the surface o f the interfaces and so the most efficient way to disrupt the 
interface was to introduce a charged residue in to the interface and use the repulsion of 
the charge to disrupt the dimerisation of the PI31 FP domain. The mutation made in the 
FP domain to disrupt interface A consisted of mutating residue 6  from valine to 
arginine, which will be referred to as V6 R. A double mutation was made to disrupt 
interface B consisting o f mutating both residues 83 and 90 from isoleucine to glutamic 
acid, which will be referred to as 183,90E. The mutants were designed to have the 
maximum effect on the dimer interface but with minimum number of basepairs altered 
in the triplet code in the DNA sequence. All mutations were prepared using the 
Quikchange protocol and primers described in appendix A.
4.5 Biophysical characterisation of the PI31 FP domain
4.5.1 Analytical size exclusion chromatography of PI31 FP domain
Expression of the mutant PI31 FP domain proteins was carried out as described in 
appendix A and purified as described for His-tagged proteins. The mutant proteins 
expressed at similar levels to the wild type protein (Figure 4.12) but the introduced 
mutations I83E and 183,90E cause atypical behaviour o f the proteins when analysed by 
SDS-PAGE. This difference can also been seen when the protein is expressed in 
mammalian cells (Heike Laman). The change in charge on the surface o f the protein 
may cause the protein to appear to be larger than expected as SDS-PAGE is affected not 
only by the size and shape of the protein but also by its overall charge. The calculated 
molecular weight for all the PI31 FP domain proteins is 16.9kDa and both the wild type 
protein and V6 R mutant have an apparent size o f around 17kDa on SDS-PAGE. The 
I83E mutation gives the protein an apparent size o f 18kDa and the 183,90E double 
mutation an apparent size of just under 20kDa. The pi of wild type PI31 FP domain is 
5.14 and this changes to 5.30 and 4.93 for the V6 R and 183,90E mutations respectively 
(Bjellqvist et al. 1993). The change in pi is not large and would be unlikely to have the 
large effect on the SDS-PAGE seen and so it is possible that this is due to a 
conformational change affecting the binding of SDS to the protein.
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Figure 4.11 -  Electrostatic potential o f the surface of the PI31 FP domain
A. Electrostatic potential of the surface of PI31 FP domain when dimerised through interface A 
and the surface of the interface itself. B. Electrostatic potential of the surface of PI31 FP domain 
when dimerised through interface B and the surface of the interface itself
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Figure 4.12 -  SDS-PAGE of PI31 FP domain wild type and mutants for dimer interface
analysis
Black arrow marks the expected position of wild type PI31 FP domain.
Since some of the mutant proteins behaved aberrantly when analysed by SDS-PAGE 
analytical gel filtration was used to obtain an estimate of the molecular weight of the 
protein under native conditions. All three of the mutant proteins were analysed by size 
exclusion chromatography as described in appendix A. All o f the PI31 FP domain 
proteins produce a single symmetrical peak when analysed by gel filtration indicating 
that the sample consists of a single homogeneous species (Figure 4.13). Wild type PI31 
FP domain and 183,90E mutant are both single species under these conditions and they 
are both dimeric, with a molecular weight of around 31 kDa when compared with the 
standard proteins. Interestingly PI31 FP domain with the single V6 R mutation did not 
elute at the same position as the wild type protein. The mutant protein appeared to be 
homogeneous and eluted at a molecular weight of about 15 kDa, which strongly 
suggests that this is a monomeric form of the PI31 FP domain. Since the V6 R mutation 
disrupts interface A, which consists of the a l helix, this change in molecular weight 
indicates that the dimer interface of PI31 FP domain is through the a l helix of both 
protomers. Gel filtration analysis is performed on proteins at high concentration so 
further work was required to fully characterise the possible protein-protein interactions 
under more physiological conditions.
99
Chapter 4: Structural and biophysical characterisation o f the FP domain
V oid 6 6  4 3  3 0  1 2 .4
P131 (1-151) Wild Type
P131 (1-151) I83E.I90E
0.0 5.0 10.0 5.0 25.0
Figure 4.13 -  Comparison between wild type and mutant PI31 FP domain by gel filtration
Gel filtration performed using a Superdex 75 HR 10/30 column (Amersham Biosciences) at a rate 
of 0.4 ml/min using 20mM Tris-HCl pH 8.0, 50mM NaCl as buffer. 500|il of protein sample was 
loaded onto the column. Superposition of gel filtration traces from PI31 FP domain wild type 
(pink), 183,90E (blue) and V6R (red). Black arrows show the positions of molecular weight 
markers (in kDa). y axis is absorbance at 280nm measured in mAU and x axis is volume in ml.
4.5.2 Analytical ultracentrifugation of the PI31 FP domain
In order to establish the behaviour of PI31 FP domain under physiological conditions 
analytical ultracentrifugation (AUC) was used to analyse both wild type and mutant 
proteins. AUC is a classical method for the analysis of purified proteins in dilute 
solution and can be used to characterise the aggregation state, heterogeneity and 
thermodynamic interactions of proteins. AUC consists of the application of a 
centrifugal force with simultaneous real-time observations of the distribution of the 
protein. The resulting data can then be analysed from first principles. The main strength 
of this method is that it does not require any chemical modification of the protein and 
since there is no interaction with a matrix the proteins can be studied in solution. AUC 
experiments utilise the fact that faster sedimenting complexes are transported through a 
solution of the slower sedimenting components. Reversibly formed complexes that 
subsequently dissociate can readily re-associate during the experiment, thus permitting 
the hydrodynamic and thermodynamic characterization of even weak and transient 
interactions (Scott and Schuck 2005). For these experiments a Beckman XL-I
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ultracentrifuge was used which can measure both the absorbance and the refractive 
index gradients of the sample.
Sedimentation velocity experiments were carried out as described in appendix A for 
PI31 FP domain, PI31 FP domain V6 R and PI31 FP domain 183,90E (Figure 4.14). 
Wild type and 183,90E PI31 FP domain both have peaks at s=1.36 and s=2.65 which 
shows that there is more than one species present in both of these samples. This is not 
expected from the gel filtration data as this shows only one species (Figure 4 .14a and c). 
AUC experiments are carried out at a much lower concentration and so are more likely 
to indicate the physiological condition of the protein. V6 R PI31 FP domain has only 
one peak at s = l.36 (Figure 4.14b). This result is as would be expected from the gel 
filtration results and indicates that there is only one species within this sample. All of 
the experiments were carried out with at least two preparations of protein to ensure that 
the effects observed were not due to an individual protein preparation. The V6 R c(s) 
distribution has only one peak and so these results were modelled on a c(M) distribution 
to obtain an estimate of the molecular weight. This is not accurate as the result is 
dependent on the shape of the protein (the frictional ratio) and this is not known a priori 
for PI31 V6 R FP domain. The c(M) distribution gives the molecular weight o f PI31 FP 
domain V6 R as 18.1 kDa which is higher than predicted from the amino acid sequence 
(16.9kDa) but it is consistent with this mutation causing the protein to be monomeric. 
The c(M) distribution was plotted for PI31 FP domain wild type protein, as a 
comparison, and the value calculated for the main peak gives a molecular weight of
33.1 kDa and for the minor peak 14.8kDa which are likely to represent the dimeric and 
monomeric protein respectively (Figure 4.14d). This result indicates that the wild type 
protein is in a monomer-dimer equilibrium with the predominant species being dimeric.
Having established that there is more than one species present in both the PI31 FP 
domain wild type and the 183,90E samples a sedimentation equilibrium run was needed 
to calculate the thermodynamic properties of these two species at equilibrium. 
Sedimentation equilibrium experiments were performed as described in appendix A on 
wild type, V6 R and 183,90E PI31 FP domains at each of three concentrations and at 
three different rotor speeds.
Sedimentation equilibrium data was fitted with a model for self-association using the 
program SEDPHAT (Laue et a l 1992) and from this binding constants were 
determined. For monomer-dimer self-association, mass action means that the amount
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of dimer can be expressed as C2=Ki2ci2 (with concentrations and binding constants 
expressed in molar units), and the sedimentation equilibrium profile then follows the 
relationship expressed in Equation 4.1 assuming an ideally sedimenting system.
Equation 4.1 a(r) = q  ( ,o)6l</exp (0
2 RT ( r W ) + AT12c1(r0) 2ei^exp 2Mu 2 RT ( S - r l )
Where Mb denotes the monomer buoyant molar mass A/ = (1 - v p )  which can be predicted from 
amino acid composition.
Equation 4.1 was used by the program SEDPHAT to produce predicted sedimentation 
equilibrium curves based on the known parameters (Figure 4.15). The RMSD of the fit 
is given in Table 4.5 -  RMSD of the sedimentation equilibrium experiment and Kd for 
self-association
and these show that the fit is very good with a low RMSD for all the samples tested. 
The residuals in Figure 4.15 show that any errors in the data are small and random and 
so should not affect the binding constants calculated.
Sedimentation equilibrium analysis revealed that the monomer-dimer equilibrium 
predicted by the sedimentation velocity experiment is a good fit for both wild type and 
183,90E FP domains with a IQ of 4.85pM and 3.95pM respectively. The previously 
reported monomer-dimer equilibrium IQ for full length protein was 6.25pM 
(McCutchen-Maloney et al. 2000) which is of the same order of magnitude as the 
values for the FP domain indicating that the dimer interface is predominately through 
the FP domain. This represents only moderate binding, which is presumably why the 
protein is in dynamic equilibrium instead of a permanent dimer. Based on the binding 
constant of 6.25 pM McCuthchen-Maloney et al (McCutchen-Maloney et al. 2000) 
predicted that in intact cells nearly all PI31 would be monomeric. The monomer-dimer 
equilibrium model does produce a good fit o f the data to PI31 FP domain V6 R with the 
IQ calculated for this protein being 462M. This value is physiologically impossible 
implying that this protein does not form a dimer in solution, which fits with all other 
data for this protein presented here.
Local rmsd 0.5 mg/ml Local rmsd 0.25 mg/ml Local rmsd 0.1 mg/ml Kd
Wild Type 0.010734 (n=184) 0.008667 (n=154) 0.004149 (n=166) 4.87 pM
183,90E 0.022778 (n=229) 0.0345 (n=158) 0.013730 (n=313) 3.95 pM
V6R 0.014677 (n=202) 0.008626 (n=190) 0.009948 (n=192) 462.4 M
Table 4.5 -  RMSD of the sedimentation equilibrium experiment and Kd for self-association
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Figure 4.14 -  c(s) and c(M) distributions for PI31 FP domain proteins
A. c(s) distribution for PI31 FP domain. B. c(s) distribution for PI31 FP domain V6R. C. c(s) 
distribution of PI31 FP domain 183,90E (all c(s) distributions shown for three concentrations. D. 
c(M) distribution of PI31 FP domain (blue) and PI31 FP domain V6R (red) shown for the highest 
concentration.
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Figure 4.15 -  Typical sedimentation equilibrium data for PI31 FP domain proteins
The top box is the residuals and the lower is the experimental profile with the model fit also 
shown. A. Typical profile for PI31 wild type. B. Typical profile for PI31 183,90E. C. Typical 
profile for PI31 V6R.
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4.6 Discussion
The identification o f a common domain in PI31 and Fbxo7 indicates that the interaction 
originally described in chapter 2 may be physiologically relevant. It is possible that 
these two proteins are evolutionarily related as they are the only two proteins we have 
found to contain the FP domain and consistent with this data both proteins also contain 
a proline rich region at their C-terminus. Neither Fbxo7 nor PI31 are found in lower 
eukaryotes which indicates that these proteins have emerged late in evolution. It is not 
true that all species that contain PI31 also contain Fbxo7 for example Dictyostelium 
discoideum contains a PI31 protein but an Fbxo7 protein has not been identified. If 
these two proteins evolved together to perform a function it would be expected that they 
would be found within the same species. It is possible that while PI31 and Fbxo7 may 
interact in the cell they may also have additional functions to perform alone.
The structure based sequence alignment of the FP domain appears to show that the 
conserved residues are not functionally active residues but they do appear to be required 
for the structural integrity o f the protein. This requirement for these structurally 
important amino acids to be conserved points to the possibility that the overall structure 
of the FP domain is functionally required. It would also be interesting to examine the 
effect of mutating residues on the surface of the protein near the highly conserved Trp58 
as it is possible that this could be part of a binding surface for Fbxo7 or for the proline 
rich C-terminus of PI31 itself.
The novel a/p fold of the PI31 FP domain does not belong to any previously identified 
family of proteins. It is interesting that it has a superficially similar arrangement to 
ubiquitin (p-grasp fold), which consists of a four stranded anti-parallel P-sheet with 
three a helices packed against one side (Figure 4.16). The PI31 FP domain consists of a 
five stranded anti-parallel p-sheet with five a  helices packed against one side. However 
the topology of ubiquitin is very different to the PI31 FP domain as ubiquitin has a 
topology of PPaaPaP and PI31 FP domain o f aapppppaaa and so this similarity does 
not point to any evolutionary relationship.
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Figure 4.16 -  Structure of ubiquitin
Ubiquitin shown in cartoon representation blue at N-terminus to red at the C-terminus. (PDB 
accession code 10GW (Vijay-Kumar et al. 1987)).
Figure 4.17 -  Superposition of a subunit of T.acidophilum proteasom al subunit with PI31 FP 
domain
Alpha subunit of the T.acidophilum proteasome (green) (PDB accession code: 1PMA) superposed 
with PI31 FP domain monomer (blue). The 54 amino acids superposed have an RMSD of 3.14A 
although the topology of the structures is not the same.
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Interestingly PI31 FP domain also demonstrates superficial structural similarity with the 
20S proteasomal subunits (Figure 4.17). The superposition o f the a  subunit of 
T.acidophilum with the PI31 FP domain reveals that 54 C-alpha residues superpose with 
an RMSD of 3.14A. The topology o f the 20S proteasomal subunits and PI31 is not the 
same and so there is unlikely to be an evolutionary link between the two proteins. This 
could be very interesting as the mode of action for the reported inhibition of the 
proteasome by PI31 has not been established. It is possible that the globular FP domain 
of PI31 could mimic the proteasomal subunit and bind within the proteasome. After 
binding the unstructured C-terminus o f PI31, which was shown to be required for 
proteasomal inhibition, could be positioned inside the proteasome thus restricting access 
to the protealytically active p subunits.
The data from the protein-protein interaction servers indicated that neither interface A 
nor B were reliably within the values expected for a biologically relevant homodimer 
interface. The expected values for the homodimer interface were calculated using a 
sample set o f 32 well defined homodimers (Jones and Thornton 1995). This is not a 
large number o f proteins and so it is possible that the true values for homodimers may 
have a larger standard deviation than that calculated from this sample set. Interface A 
fits the expected parameters better than B, which indicated that this was more likely to 
form the correct solution dimer interface. The dimer o f the PI31 FP domain was shown 
in this chapter to be formed through the N-terminal a  helix of the two protomers 
(interface A) by using size exclusion chromatography and AUC analysis o f both wild 
type and mutant proteins. It appears that PI31 FP domain would be likely to be in a 
monomer-dimer equilibrium in the cell, which would have implications for the function 
of this protein.
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5 C haracterisation  o f  the P I31-F b xo7-Sk pl interaction
The interaction between PI31 and Fbxo7 was established in vitro in chapter two and 
validated by co-immunoprecipitation and yeast two-hybrid. In this chapter the 
interaction between Fbxo7-Skpl is characterised in more detail using biophysical and 
cell biology methods. A description of the experiments carried out is included as a 
flowchart in Figure 5.1.
Analysis of Fbxo7- 
Skp1-PI31 binding 
in vitro
Analysis of Fbxo7- 
Skp1-PI31 binding
Production of 
Fbxo7-Skp1-PI31 
complex using 
recombinant 
protein____
Size exclusion 
chromatography 
analysis of 
complex
GST pull-down 
using Fbxo7-Skp1 
as bait for mutant 
PI31 proteins
Analysis of 
interaction 
between Fbxo7- 
Skp1 and PI31 by 
ITC
Test for 
ubiquiti nation of 
PI31 using mutant 
proteins
Probe the 
localisation of 
Fbxo7 and PI31
Identification of 
possible 
stoichiometries for 
Fbxo7-Skp1-PI31 
complex
Identification of 
the binding 
surface on PI31 as 
the beta sheet in 
FP domain
Expression in 
tissues and cell 
lines
Immunoflourescence 
of PI31 in U20s cells
Figure 5.1 -  Flowchart of the experim ents discussed in chapter five.
5.1 PI31 mutations and characterisation of the interaction between 
PI31-Fbxo7-Skpl in vitro
5.1.1 Formation of a PI31-Fbxo7-Skpl complex
The interaction between Fbxo7 and PI31 was originally identified between recombinant, 
purified Fbxo7F2-Skpl and full-length endogenous PI31. The presence of the FP 
domain in both PI31 and Fbxo7 suggested that these domains may mediate the 
interaction between PI31 and Fbxo7. The Fbxo7F3-Skpl construct contains the FP 
domain connected to the F-box motif via a linker sequence whilst the PI31-NTD 
construct contains only the FP domain. These two constructs were used to produce 
recombinant proteins to further analyse the interaction(s) made between FP domains.
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GST-tagged Fbxo7F3-Skpl protein complex was used as bait in a GST pull-down 
(appendix A) with recombinant PI31-NTD as a potential binding partner. The P131- 
NTD that co-purified with GST-Fbxo7F3-Skpl was visualised using SDS-PAGE and 
Coomassie brilliant blue staining. The three proteins formed a complex (Figure 5.2a). 
We exploited a thrombin protease site between the GST moiety and Fbxo7 to 
specifically elute the complex from the glutathione-Sepharose and GST label.
Analytical size exclusion chromatography was used to determine the stoichiometry of 
the components in the complex (Figure 5.2c). The complex elutes from the column as 
one major peak. There is no protein in the void volume and so the current data does not 
fit with previous data from gel filtration o f Fbxo7F3-Skpl, which is surprising as this 
sample would be expected to contain aggregated Fbxo7. It is possible that the 
interaction with PI31 FP domain prevents or disrupts the aggregation o f Fbxo7. The 
peak has a shoulder at the lower molecular weight end and there are some low 
molecular weight contaminants, which have a lower molecular weight than any o f the 
components of the complex.
SDS-PAGE analysis of fractions 16 to 26 shows that PI31-Fbxo7-Skpl forms a 
complex under these conditions (20mM Tris-HCl pH 8.0 and 50mM NaCl). 
Comparison with molecular weight standards shows that the complex has an apparent 
Stokes radius (Siegel and Monty 1966) corresponding to a molecular weight o f between 
43kDa and 6 6 kDa.
The shoulder on the eluted peak from fractions 24 to 26 consists o f some Fbxo7F3 and 
also excess PI31 FP domain. This could be because excess PI31 FP domain was 
applied when the original GST pull-down was carried out or it could indicate that Fbxo7 
and PI31 interact in the absence of Skpl. There is also an indication that Fbxo7 is 
undergoing degradation although this is surprising, as the limited proteolysis experiment 
described in section 2 .1.2  did not show any further degradation to the domains used in 
this experiment.
Fractions 18-20 were pooled, concentrated to 5mg/ml and submitted to crystallisation 
trials; unfortunately no crystals were obtained.
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Figure 5.2 -  Recombinant PI31 FP domain interacts with Fbxo7F3-Skpl protein com plex.
A. GST pull down of PI31 FP domain using Fbxo7F3-Skpl as bait. Protein was eluted from the 
column by proteolytic cleavage. B. Silver stained SDS-PAGE of the fractions across the gel 
filtration profile shown in C. C. Size exclusion chromatography of PI31 FP domain-Fbxo7F3-  
Skpl complex. X-axis is volume in ml and y-axis is absorbance at 280nm measured in mAU. Gel 
filtration performed using a Superdex 75 HR 10/30 column (Amersham Biosciences) at a rate of 
0.4 ml/min using 20mM Tris-HCl pH 8.0 and 50mM NaCl as buffer. 500pl of protein sample was 
loaded onto the column.
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5.1.2 Identification of the surfaces mediating interaction between Fbxo7- 
Skpl and the FP domain of P131
The FP domain o f PI31 and Fbxo7F3-Skpl directly interact in vitro but the surface 
responsible for this interaction is unknown. Identification o f the binding surface on 
PI31 would enable a binding deficient mutant to be produced and used to study the 
function of this interaction in vivo. The FP domain o f PI31 binds to Fbxo7-Skpl, as 
does full-length P 131. Having established Fbxo7-Skpl and PI31 interact via the FP 
domain o f PI31 we investigated which interface on the PI31 FP domain mediated this 
interaction using the mutants described in chapter four. It is possible that the PI31 FP 
domain contains two protein-protein interaction interfaces. These interfaces are likely 
to be the two crystallographic dimer interfaces as described in section 4.4 and so the 
PI31 FP domain could contain the homodimer interface consisting o f the a-helix and a 
heterodimer interface through which it binds to Fbxo7-Skpl might consist of the P-sheet 
binding surface.
GST-Fbxo7F3-Skpl complex was immobilised on glutathione Sepharose resin and used 
as bait in a GST pull down. PI31 FP domain, mutant PI31 FP domain 183,90E and a 
buffer control (20mM Tris-HCl pH 8.0, 50mM NaCl and 5mM 2-ME) were used as 
prey to the bait under conditions described in appendix A. The proteins were eluted 
from the resin as described before, separated by SDS-PAGE and visualised by 
Coomassie brilliant blue staining (Figure 5.3). In the particular experiment shown in 
Figure 5.3 Fbxo7 was not as abundant as expected based on previous experiments but 
an interaction between wild type PI31 FP domain and Fbxo7F3-Skpl was detectable. 
When mutant (183,90E) P I31 was used however, no interaction with Fbxo7-Skpl could 
be seen. The stoichiometry o f this interaction does not appear to be 1:1:1 as observed 
previously. This preliminary result suggests that interface B in P I31 may mediate 
binding to Fbxo7-Skpl.
The GST pull down suggested that interface B on PI31 FP domain is the binding site for 
Fbxo7-Skpl. This experiment was not performed in physiological conditions and the 
presence of the glutathione Sepharose may have had an effect on binding. Isothermal 
titration calorimetry (ITC) is a thermodynamic technique for monitoring the heat energy 
release by the chemical process initiated by the addition o f a binding partner, and this 
method requires no chemical tagging or immobilisation of the proteins (appendix A).
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Figure 5.3 -  SDS-PAGE of GST pull down to identify the Fbxo7 binding surface on PI31
Arrows mark the expected position of Fbxo7 (blue), Skpl (green) and PI31 (black)
When proteins bind, heat is either generated or absorbed. Measurement of this heat 
allows accurate determination of binding constants (Ka), reaction stoichiometry (n), 
enthalpy (AH) and entropy (AS) providing a profile of the molecular interaction 
(Equation 5.1 and Equation 5.2). ITC is the most quantitative means available for 
measuring the thermodynamic properties of a protein-protein interaction because it 
measures the binding equilibrium directly (Wiseman et al. 1989; Pierce et al. 1999).
V0A H b[ M \ K a[
Equation 5.1 Q  =
i + * „[£ ]
Where Q=heat evolved on addition of ligand, V0=volume of the cell, AHb=enthalpy of binding per 
molecule of ligand, [M],=total macromolecule concentration including bound and free fractions, 
Ka=binding constant and [L]=ffee ligand concentration.
Equation 5.2 c = Ka[M]n
The experimental binding isotherm can be characterised by the unitless value c, which is 
dependent on the stoichiometry of the reaction (n).
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Fbxo7F3-Skpl was placed in the sample cell and wild type PI31 FP domain and 183,90E 
FP domain mutant were used as titrants. Approximately 20pM of Fbxo7F3-Skpl was in 
the cell and lOOpM of PI31 FP domain in the injectant. Figure 5.4a and b show the raw 
data in the top panels for both wild type PI31 FP domain and 183,90E mutant PI31 FP 
domain. The raw data is on the same scale and shows the significant difference between 
the wild type and mutant proteins. The profile of the mutant protein is the same as that 
for the heating o f dilution (data not shown), which strongly indicates that the mutant 
protein does not interact with Fbxo7-Skpl. The processed data for the PI31 FP domain 
183,90E mutant has a random profile that cannot be fitted to any model. This data 
indicates that the interaction between Fbxo7-Skpl requires that PI31 FP domain 
contains an intact interface B, which consists of the p-sheet of the PI31 FP domain. 
This data does not allow the analysis of the interaction interface on Fbxo7-Skpl nor 
does it mean that other domains within PI31 do not contribute to this interaction. Figure 
5.4a shows that the interaction between Fbxo7-Skpl and wild type PI31 FP domain 
produces a detectable signal which can be fitted with a smooth best-fit curve when 
modelled with the assumption that there is one binding site. It is a requirement for ITC 
data that the reaction reaches saturation (determined by the flat line at the higher molar 
ratio) and if this is the case the gradient o f the curve can be used to determine the 
stoichiometry and binding constants for the reaction. The stoichiometry of the PI31 - 
Fbxo7F3-Skpl interaction as determined by ITC is probably 1:2 (PI31:Fbxo7-Skpl) as 
n=0.444±0.006 (Figure 5.4a) indicating that one PI31 protomer interacts with two 
Fbxo7-Skpl heterodimers. This is unexpected because PI31 is in a monomer-dimer 
equilibrium in the cell (chapter 4) and so it would have seemed likely that one PI31 
homodimer would interact with one Fbxo7-Skpl heterodimer giving a stoichiometry of 
2:1 (PI31 :Fbxo7-Skpl). The Kd for the binding of PI31 FP domain to Fbxo7F3-Skpl was 
determined by ITC as 0.37|iiM, which is a 10 fold stronger interaction than the 
homodimer formation o f PI31 FP domain.
The PI31-Fbxo7-Skpl complex formed during ITC analysis was purified using size 
exclusion chromatography to remove excess PI31 and concentrated to about 5mg/ml 
prior to being used in crystallisation trials. No crystals were obtained using this 
method.
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Figure 5.4 -  ITC of Fbxo7F3-Skpl interaction with the PI31 FP domain wild type and 
183,90E
Plot of the ITC data, the top panel is raw data after removal of the contribution by the heating of 
dilution. The bottom panel consists of the experimental points (x) and the solid red line 
corresponds to the best fit curve obtained by least-squares deconvolution. A) Wild type PI31 FP 
domain as titrant. B) 183,90E PI31 FP domain as titrant. The best fit values for the wild type 
PI31 FP domain are n=0.444±0.006 and K<i=0.37|!M.
5.2 C h aracterisation  o f  the in teraction  o f  PI31 w ith  F b x o 7 -S k p l in
vivo
5.2.1 PI31-Fbxo7-Skpl interaction is required for ubiquitination o f PI31
Fbxo7-Skpl and PI31 have been shown to interact both in vitro and in vivo but the 
functional significance of this interaction has not been established. There are several 
potential functional roles for this interaction; PI31 is a substrate of an E3 ligase, PI31 is 
an E3 ligase co-factor, and PI31 is an E3 ligase localisation factor. In the former 
assumption the protein-protein interaction between an F-box protein and its substrate 
often catalyses the formation of an isopeptide bond between the substrate (or for 
polyubiquitination, ubiquitin) lysine residue and the C terminus of ubiquitin (Pickart 
2001). Analysis of the structure of the PI31 FP domain revealed several possible lysine
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residues that are exposed and therefore potential ubiquitination targets (Figure 5.5) of 
these Lys49 and Lys72 are disordered in the crystal structure. Lys49, Lys81, Lys72 and 
Lysl25 were all mutated to alanine residues in full length PI31 in the pcDNA3 
(Novagen) vector using the Quikchange protocol (appendix A) and Heike Laman used 
these constructs to produce mutant PI31 proteins to look for ubiquitination of PI31 and 
the mutants in FleLa cells. None of the lysine residues on the surface of PI31 FP 
domain are conserved and so it is possible that there is no requirement for a particular 
residue for ubiquitination. The construct for Lys49 did not produce detectable protein 
in HeLa cells because the primer sequence used to produce this construct contained an 
unintentional single base pair insertion, which introduced a stop in the sequence.
PI31-Ub
Figure 5.5 -  Identification and testing o f possible lysine residues for ubiquitination
A. Cartoon representation of the PI31 FP domain with all accessible lysine residues labelled. B. 
Over expression of His-tagged ubiquitin (Ubi-His) and PI31 in HeLa cells, His-tag pull down to 
detect ubiquitinated proteins and Western blot with the monoclonal anti-PI31 antibody to detect 
PI31. Panel below is over exposure of the section of the top panel marked with a line representing 
the ubiquitinated proteins. His-tag pull down and western blot performed by Heike Laman.
All mutant proteins except K49A are ubiquitinated to the same extent as wild type 
FLAG-tagged protein (Figure 5.5b). It is not possible to detect endogenous 
ubiquitinated PI31 in this assay (lane 1, Figure 5.5b), which is probably because the
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quantity o f protein is much lower than for the over expressed FLAG-tagged protein and 
no chemical proteasome inhibitor was included in this assay to allow the accumulation 
of ubiquitinated species including PI31. Surprisingly the over expression o f untagged 
PI31 does not allow the ubiquitination o f exogenous protein to be detected (lane 2, 
Figure 5.5b) although this may again be because the proteasome was not inhibited and 
the rapid turnover of polyubiquitinated PI31 may not allow its visualisation. To explain 
the apparent differences between untagged and FLAG tagged PI31 one hypothesis is 
that the FLAG tag itself is interfering with the ubiquitination. The FLAG tag contains 
two lysine residues and so the two FLAG tags in pcDNA3 
(MDYKDDDDKDYKDDDDK) introduce an additional four lysine residues for 
ubiquitination, which may be having an effect on the efficiency o f the ubiquitination of 
PI31 and prevent any subtle changes from the lysine mutants from being detected. 
These experiments therefore will need to be repeated using a different tag or further 
analysis of over expressed and untagged mutant proteins in the presence of proteasome 
inhibitors.
Ubiquitination of FLAG-tagged PI31 can be detected but this does not indicate that this 
ubiquitination is dependent on the interaction with Fbxo7-Skpl. The heterodimer 
mutant 183,90E disrupts the interaction between PI31 and Fbxo7-Skpl and so this 
mutation and the single mutant I83E were inserted into full length PI31 in pcDNA3 
using the Quikchange protocol and Heike Laman repeated the ubiquitination assay with 
these mutant proteins. Disruption o f the interaction between PI31 and Fbxo7-Skpl 
ablates the ubiquitination o f FLAG-tagged PI31 (Figure 5.6a) indicating that this 
interaction is necessary for FLAG-PI31 ubiquitination.
Since FLAG-PI31 is ubiquitinated and this ubiquitination requires the interaction with 
Fbxo7-Skpl, PI31 could be directly or indirectly a substrate o f the SCFFbxo7. When 
substrate proteins are polyubiquitinated through the Lys48 o f ubiquitin one possible fate 
for the substrate is for it to be targeted for destruction by the 26S proteasome (Hershko 
and Ciechanover 1998) other possible fates are signalled by monoubiquitination or by 
polyubiquitination through the Lys63 of ubiquitin. siRNA was used by Heike Laman to 
knock-down the Fbxo7 RNA levels and therefore protein levels in HeLa cells and the 
corresponding amount of PI31 protein was analysed by Western blot (Figure 5.6b). The 
siRNA depleted but did not remove all Fbxo7 in the cells but no detectable change can 
be seen in PI31 protein levels. This result could be due to several reasons, Fbxo7 may
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not be responsible for the ubiquitination of PI31 alternatively the interaction between 
PI31 and Fbxo7-Skpl is of a modest affinity (with a IQ = 0.37pM) and so the remaining 
Fbxo7 could be sufficient to allow the steady state turnover of PI31. Also the PI31 
ubiquitination may not target PI31 for destruction (Weissman 2001) but may serve a 
separate function. It may be helpful to repeat this experiment using the levels of the 
known substrate of Fbxo7, HURP, as a control to establish the efficiency of the siRNA.
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Figure 5.6 -  P I31-Fbxo7-Skpl interaction is required for PI31 ubiquitination but does not 
target PI31 to the proteasom e
A. Experiment described in Figure 5.5a repeated with mutant PI31 protein. B. Protein content of 
HeLa cells with siRNA treatment using control dsRNA and Fbxo7 dsRNA analysed by Western 
blot with anti-Fbxo7 and anti-PI31. Figure provided by Heike Laman.
5.2.2 Localisation and expression of PI31 and Fbxo7
To better understand where or when these proteins interact in vivo an investigation of 
the cellular localisation of both the proteins was carried out. Over expressed untagged 
full length murine PI31 was shown by Zaiss et al (Zaiss et al. 2002) by 
immunofluorescence to be predominately localised at the cytosolic side of the nuclear 
envelope/endoplasmic reticulum (ER) in B8 mouse fibroblasts. Heike Laman repeated 
this experiment using endogenous PI31 in U20S cells (Figure 5.7) and the localisation 
is again predominately at the ER although additional staining can also be seen. When 
Fbxo7 was over expressed (Laman et al. 2005) by transient transfection, the exogenous 
protein was localised in the cytoplasm, with small amounts being detected in the 
nucleus. Endogenous Skpl was shown by Freed et al (Freed et al. 1999) to localise at 
the centrosome and in the nucleus and cytoplasm.
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ER(DiOQ(3)) PI31 m erge
Figure 5.7 -  PI31 co-localises with the ER
The ER was visualised in fixed U20S cells by immunofluorescence staining with DiOC6(3) 
(green) and endogenous PI31 was visualised with affinity-purified monoclonal mouse anti-PI31 
antibody and donkey anti-mouse rhodamine conjugated antibody (red). Right panel shows ER and 
PI31 superposed and co-localisation appears in yellow. Immunofluorescence work done by Heike 
Laman.
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The localisation of the proteins indicates that the majority of Fbxo7-Skpl would be 
unlikely to come into contact with PI31 in the cell. During mitosis in higher eukaryotes 
the nuclear envelope breaks down and the nuclear contents are completely mixed with 
the cytosol (Alberts et al. 1989), which would temporarily bring PI31 into contact with 
Fbxo7-Skpl.
If PI31 and Fbxo7 interact within the cell it can reasonably be expected that the two 
proteins would have the same or similar tissue distributions within the body. Western 
blot analysis of tissues and cell lines revealed that PI31 and Fbxo7 are expressed in the 
same tissues at similar levels other than in the placenta and ovary where only Fbxo7 
was detected (Figure 5.8). Samples from healthy tissues were compared with cancer 
cell lines by Heike Laman and revealed that both Fbxo7 and PI31 appear to be 
expressed at higher levels in cancer cell lines than in healthy tissue with the exception 
of the proliferating HOB(6p) cell line, which is derived from normal human bone 
marrow. This difference in expression can not be confirmed as there is no loading 
control present on this Western blot and so this should be considered to be a preliminary 
result of the expression profiles of both Fbxo7 and PI31 and further work will be needed 
to characterise this using matched tissue samples. Fbxo7 was reported by Laman et al 
(Laman et al. 2005) to be an oncogene and so expression of Fbxo7 could be expected in 
cancer cell lines but there is no phenotype associated with over or under expression of 
PI31. Both Fbxo7 and PI31 are expressed in brain tissue, which is non-proliferating, 
and so more work is needed to compare the levels in tumour and non-tumour tissues to 
draw conclusions from this data.
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Figure 5.8 -  Expression of PI31 and Fbxo7 in various tissues and cell lines
Expression of PI31 and Fbxo7 in tissues and cancer cell lines. Proteins detected by Western blot 
using anti-Fbxo7 and anti-PI31 by Heike Laman.
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5.3 Discussion
The interaction between Fbxo7-Skpl and the FP domain of PI31 has been shown both 
in vivo and in vitro. It remains to be determined if the proline rich C-terminus of PI31 
contributes to the binding. The FP domain is sufficient for binding to Fbxo7-Skpl but 
the affinity for full length PI31 protein has not been shown here. It is also possible that 
in vivo this interaction is modulated by other proteins that have yet to be identified.
Fbxo7F3, SkplAH8 and P I31 FP domain proteins have predicted molecular weights of 
24.9kDa, 16.5kDa, and 16.9kDa respectively. The stoichiometry o f the three proteins in 
a ternary complex as analysed by size exclusion chromatography does not appear to be 
1:1:1 as there is less Skpl than either Fbxo7 or PI31. However the Fbxo7F3-Skpl 
protein complex used in this interaction was not purified by size exclusion 
chromatography prior to exposure to PI31 and so it is possible that there is aggregated 
Fbxo7 in the sample which can still bind PI31 in the absence of Skpl. If a PI31 FP 
domain:Fbxo7F3:Skpl complex existed as a 1:1:1 stoichiometric complex it would be 
predicted to have a molecular weight o f 58.3kDa which correlates well with the 
experimentally determined size o f about 55kDa. A 2:1:1 complex (75.2kDa), 1:2:1 
complex (83.2kDa) and a 1:1:2 complex (74.8kDa) do not fit with the experimental 
data. Although the size exclusion chromatography data suggest that a 1:1:1 complex 
forms in vitro, it is entirely possible that other stoichiometries exist in vivo. Another 
possibility raised by the excess o f PI31 FP domain and Fbxo7 in the SDS-PAGE o f the 
fractions is that the complex exists as PI31 FP domain:Fbxo7 alone. A 2:1 complex 
would be predicted to have a molecular weight of 58.7kDa and a 1:2 complex of 
66.7kDa. Both o f these values reasonably fit the range o f 43kDa to 66kDa calculated 
from the size exclusion chromatography. The ITC data also supports a 1:2 complex 
from its measurement of the stoichiometry.
PI31 and Fbxo7-Skpl interact through the heterodimer interface of the PI31 FP domain, 
which is formed by the anti-parallel p sheet. This interaction has a Kd o f 0.37pM as 
calculated by ITC, which means that this interaction is o f a higher affinity than the PI31 
FP domain dimer suggesting that Fbxo7-Skpl could successfully compete for 
monomeric PI31. This may provide a better explanation whereby two Fbxo7-Skpl 
heterodimer complexes bind to one PI31 FP domain monomer as suggested by ITC.
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Preliminary data shows that FLAG-PI31 is ubiquitinated and that this ubiquitination 
requires Fbxo7-Skpl binding through analysis of PI31 mutant defective in binding to 
Fbxo7-Skpl. Depletion o f Fbxo7 has no noticeable effect on PI31 protein levels. The 
ubiquitinated lysine residue(s) on PI31 have not been identified which could be because 
the FLAG tag interfered with the interaction or it could be that more than one lysine 
residue on PI31 can be ubiquitinated as has been observed in other proteins (Hod et al. 
1994).
PI31 and Fbxo7 have not been shown to co-localise. A crucial aspect o f validity of in 
vivo interactions is to show where and when the proteins interact. At present we do not 
understand whether PI31 and Fbxo7 can interact, one possibility is that the Ubl of 
Fbxo7 brings it into contact with the immunoproteasome where PI31 may be localised, 
or modified PI31 may be localised to the cytoplasm for Fbxo7 mediated degradation. It 
is of primary importance to address this problem with future work.
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6 Discussion
6.1 Sum m ary
One of the aims of this thesis was to structurally characterise the Fbxo7-Skpl complex 
and to identify potential substrates of SCFFbxo7. Unfortunately it did not prove possible 
within the time o f this thesis to obtain suitable diffracting crystals for structure 
determination. However biochemical work in parallel with the structural studies lead to 
the identification o f PI31 as a putative substrate for SCFFbxo7.
The identification o f a shared FP domain within both Fbxo7 and PI31 refocused our 
efforts on the structural characterisation o f the FP domain o f PI31. After overcoming 
problems encountered with obtaining experimental phases the structure of a L7M FP 
domain mutant from PI31 was solved by MAD phasing to a resolution o f 2.64A. The 
structure of the PI31 FP domain was compared to previously solved structures and 
shown to have a novel topology and to form dimers in solution predominately through 
the N-terminal a  helix.
Size exclusion chromatography and ITC were used to show that PI31 and Fbxo7-Skpl 
interact through a surface on the anti parallel P-sheet of the PI31 FP domain. It has 
been inferred from a second crystallographic dimer that the same interface within the 
Fbxo7 FP domain mediates this interaction with PI31 although this remains to be 
proven. We have not yet shown where or when PI31 and Fbxo7-Skpl might co-localise 
in the cell and so it has not yet been possible to prove a functional role for this 
interaction; ongoing studies will address these concerns. Ubiquitination o f P I31 is 
dependent on its interaction with Fbxo7-Skpl but depletion of Fbxo7 has apparently no 
noticeable effect on PI31 protein levels.
There are several questions about this interaction that remain to be addressed with 
future work:
1. When and where do PI31 and Fbxo7 co-localise and does localisation play a role 
in the function of these proteins?
2. Does Fbxo7 directly or indirectly ubiquitinate PI31 to signal its destruction in 
the cell?
3. What is the stoichiometry of the interaction between Fbxo7 and PI31 ?
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4. Is there a dominant-negative phenotype for over expression of PI31 mutant in
vivo?
5. In the longer term does PI31 or Fbxo7 inhibit the maturation or formation of the 
immunoproteasome and is the P or a interface of the PI31 FP domain required 
for immunoproteasome formation?
6. How is SCFFbxo7 regulated?
6.2 Stoichiometry o f the PI3I-Fbxo7-Skpl interaction
Results from gel filtration and ITC experiments revealed potentially conflicting data 
about the stoichiometry of the interaction between PI31 and Fbxo7-Skpl. It appears 
from the ITC data that one molecule of PI31 binds to two molecules of Fbxo7-Skpl. 
Since PI31 is in a monomer-dimer equilibrium in cells, as established by analytical 
ultracentrifugation, this stoichiometry is a little surprising. It is possible that a 
monomeric form of PI31 binds to two Fbxo7-Skpl heterodimers or that four Fbxo7- 
Skpl complexes bind to one PI31 dimer. Fbxo7-Skpl complex alone appears by gel 
filtration to have a 1:1 Fbxo7:Skpl stoichiometry, that is a single heterodimer o f 43kDa. 
This implies that either there are two Fbxo7-Skpl binding sites on each PI31 protomer 
or that PI31 induces oligomerisation of Fbxo7-Skpl. Disrupting the P-sheet surface of 
PI31 by isoleucine to glutamic acid mutations completely abolishes binding to Fbxo7- 
Skpl and so if there are two binding surfaces for Fbxo7-Skpl on PI31 (Figure 6.1) then 
there may be a requirement for binding through this P-sheet interface first in order to 
allow the second molecule to bind; i.e. binding may be cooperative.
Figure 6.1 -  Possible model for the interaction between the FP dom ains o f Fbxo7 and PI31
Model using the FP domain of PI31 to demonstrate one possible arrangement of PI31 FP domain 
(centre) interacting directly with two molecules of Fbxo7 through their FP domains.
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The monomeric form o f PI31 could be used to test this model as this mutant protein 
disrupts the a  helix homodimeric binding interface. If this interface is involved in 
binding to a second Fbxo7 FP domain analysis by ITC would show different 
stoichiometry and affinity constants. Gel filtration or analytical ultracentrifugation 
experiments could also be used to provide an estimated molecular weight of the 
complex using both wild type and mutant proteins and the stoichiometry calculated 
from this.
Structural information o f the PI31-Fbxo7-Skpl complex would address the seeming 
contradictions between the ITC and size exclusion chromatography data for the 
stoichiometry of this interaction as well as showing the molecular details of this 
interaction.
It is tempting to infer that the interaction is driven by the association between the FP 
domains of PI31 and Fbxo7 but we do not have experimental evidence for this at this 
stage. In vivo experiments will also be needed to show if the interaction between 
Fbxo7-Skpl and PI31 is through Fbxo7 alone, Skpl alone or the heterodimeric 
complex. This could be performed by co-immunoprecipitation using an Fbxo7 
construct in which the F-box domain is deleted; this would then demonstrate if  the 
interaction could proceed in the absence of Skpl binding to Fbxo7.
6.3 Localisation o f PI31
The mode of interaction between Fbxo7-Skpl and PI31 is potentially very interesting 
for studies performed in vitro but if the proteins do not co-localise in the cell the 
function of this interaction may not be physiologically relevant. We are pursuing the 
hypothesis that it is a valid interaction. It is possible that, as the other substrates of 
Fbxo7 have been shown to be cell cycle control proteins, the interaction between PI31 
and Fbxo7 could be dependent upon the stage of the cell cycle. Immunofluorescence 
studies on the proteins on cells blocked at various stages in the cell cycle would help to 
show if this is important.
Another possibility is that the interaction between Fbxo7 and PI31 occurs only in 
infected cells or cells in which IFN-y production is stimulated. IFN-y induces the 
formation and maturation of the immunoproteasome which is inhibited or blocked by 
PI31, therefore it is possible that ubiquitination of PI31 by SCFFbxo7 is triggered by viral 
attack and the release o f this cytokine. Using the mutant PI31 proteins and analysing
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MHC class I presented peptides produced only by the immunoproteasome might be 
used to test this possibility.
The majority o f Fbxo7 has been shown to be in the cytoplasm and the majority o f PI31 
in the ER however it is possible that a small but significant amount could be co­
localised and the signal masked by the higher signal from other areas in the cell. 
Density gradient centrifugation and Western blotting for Skpl, Fbxo7, PI31 and 
carefully chosen marker proteins to identify the cellular compartments could reveal if 
this possibility is true.
6.4 Ubiquitination and expression o f PI31
Although the interaction between PI31 and Fbxo7 is required for the ubiquitination of 
FLAG-PI31 the reduction o f Fbxo7 by siRNA does not affect the levels o f PI31 protein 
in the cell. One explanation for this result could be that Fbxo7 normally targets only a 
small fraction o f the total pool o f PI31 for degradation and so the global protein levels 
do not change significantly when Fbxo7 is reduced. Another possibility is that if  PI31 
is ubiquitinated and not subsequently destroyed then the ubiquitin chain may be formed 
through the Lys63 of ubiquitin and so it is not recognised for destruction by the 
proteasome. This can be tested in vivo using ubiquitin with a K48A or K48R mutation 
which are unable to form the Lys48-linked polyubiquitin chains but are still able to 
form the Lys63-linked polyubiquitin chains as well as monoubiquitination on several 
lysine residues. These post translational modifications often have alternative fates for 
the substrate protein. In vitro ubiquitination experiments using recombinant proteins 
could also reveal if  SCFFbxo7 is sufficient for the ubiquitination o f P I31. This is not a 
trivial experiment as the relevant E2 enzyme must be identified first and the 
recombinant proteins o f Fbxo7-Skpl are prone to aggregation.
If the lysine targeted for ubiquitination on PI31 can be identified it would be possible to 
analyse the phenotype that a stable PI31 protein would produce. It is possible that the 
ubiquitination o f PI31 is specific for one lysine but it has been reported that 
ubiquitination can occur on more than one lysine for some proteins (Hod et al. 1994). 
FLAG tags contain four lysine residues, which could be ubiquitination targets that are 
masking the effects o f the mutations. They are also tagging the N-terminus o f the 
protein, which is the homodimer interface and could affect its interaction with other 
proteins. It would be interesting to repeat the analysis o f the lysine to alanine mutants
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in untagged PI31; however we have not been able to detect at present if untagged PI31 
is ubiquitinated.
Fbxo7 has been reported to be the product of a proto-oncogene and so is over expressed 
in cancer cells (Laman et a l  2005). It would be interesting to look at the expression of 
both PI31 and Fbxo7 in cancer and normal tissues and to see if  the expression profiles 
of the two proteins are the same.
6.5 A n alysis  o f  th e  p ro lin e  rich region  o f  PI31
The proline rich region of PI31 was shown to be responsible for the inhibition of the 
20S proteasome in vitro (Zaiss et a l 1999; McCutchen-Maloney et al. 2000). I have 
identified a motif in the C-terminus of PI31 (residues 232-254 in human) that is 
conserved and can be found in an apparently unrelated protein in S. pombe (Figure 6.2). 
Neither a PI31 nor a Fbxo7 protein has not been found in S. pombe and there are also no 
proteins identified as containing the FP domain. This proline rich motif may have a 
functional role indicating that PI31 may have a function in lower eukaryotes that do not 
contain the immunoproteasome. The identification of this motif raises the possibility 
that the original function of PI31 is dependent on the C-terminus of the protein and that 
the function o f the globular N-terminal portion of the protein has developed more 
recently in evolution.
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Figure 6.2 -  Alignment of the C-terminal proline rich m otif identified in PI31 and yeast 
proteins.
Protein sequences obtained by searching PSI-BLAST (Altschul et al. 1997) with human PI31 and 
aligned with ClustalX (Thompson et al. 1997). Final figure produced using ESPript (Gouet et al. 
1999).
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The GYF domain of the protein CD2BP2 was recently shown to bind the motif PPGxR 
in the proline rich C-terminus o f PI31 (Kofler et a l In Press). The motif that Kofler et 
al identified is within the conserved proline rich motif identified here. The implication 
of this has yet to be elucidated but the identification of the GYF binding motif in lower 
eukaryotes may indicate an important functional role for this interaction.
To follow up these initial observations we have initiated a collaboration with the Cancer 
Research UK Cell Regulation Laboratory to explore the potential functional homologue 
of PI31 in S. pombe by over expression, deletion and tagging of this protein with GFP. 
It is hoped that this will identify a phenotype for the deletion or over expression of this 
protein and help to establish its localisation.
6.6 M odel o f  th e in teraction  b etw een  PI31 and S C F Fbxo7
In spite of the questions that remain it is possible to use the current data to produce a 
plausible hypothetical model for the functional interaction between PI31 and Fbxo7 
(Figure 6.3). From this model it is possible to make specific predictions that can be 
tested.
Im m u n op roteasom e  
a ssem b ly
Im m u n op roteasom e
MHC Class I p resentation  
o f  viral p ep tid es
Figure 6.3 -  Model o f the interaction between PI31 and SCFFbl0?
As part of the model it conceivable that in the absence of viral infection PI31 is not 
targeted for degradation and it is likely that there is no interaction between SCF1^*07 and 
PI31. Under these conditions Fbxo7 is localised in the cytoplasm and is functioning to 
maintain the protein levels of HURP and Cdk6. PI31 is localised in the ER and inhibits 
the formation of the immunoproteasome in mammals.
Viral __ ^
Infection?
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Under the conditions o f viral infection production o f IFN-y is induced and it acts as a 
signal to indirectly promote the interaction between PI31 and S C F ^ 07. This interaction 
could arise through recruitment o f SCFFbxo7 to the proteasome site where PI31 is 
localised. The Ubl domain of Fbxo7 may bring the SCFFbxo7 into contact with the 
proteasome as the S5a subunit of the 26S proteasome contains a UIM that can bind to 
Ubl domains. The degradation o f PI31 would remove its inhibitory role in the 
maturation o f the immunoproteasome and so the immunoproteasome would assemble. 
The formation o f the immunoproteasome enables the efficient production of non-self 
MHC class I peptides which are then processed and presented on the surface o f the cell 
for detection by T cells.
The tight regulation o f PI31 by SCFFbxo7 may not be readily observed without further 
work analysing the degradation o f PI31 using detailed biochemical and cell biology 
techniques. Some o f the required experiments have been outlined in this chapter.
This thesis has shown a synergy of different techniques including structure 
determination, cell biology, bioinformatics and biophysical analysis. A considerable 
amount has been learnt concerning the domain structure, evolution and potential 
binding partners o f Fbxo7 and PI31 culminating in the production o f binding deficient 
mutants. These can be used in vivo to establish a possible dominant-negative phenotype 
to probe the function o f the S C F ^ ^ -P B  1 interaction, the subject o f this thesis.
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A pp en d ix  A  M ater ia ls  and  m ethods  
A .l Reagents and enzym es
Reagents were purchased from Merck or Sigma unless otherwise stated and were of 
the highest grade available. Enzymes used in molecular biology protocols were 
purchased from New England Biolabs (NEB), unless specifically stated.
A.2 Buffers, solutions and media
The common buffers and media used are described here; when a more specialised one 
was used it is described in the appropriate section.
Name Composition
glycerol, 0.02% (w/v) bromophenol blue, 50pl/ml 
2-ME added just before use
SDS-PAGE running buffer 15. lg  Tris base, 94g glycine, 50ml 10% SDS made
SDS sample buffer 2% (w/v) SDS, 80mM Tris-HCl pH 6.8, 10% (v/v)
(lOx) up to 11 with Milli Q grade reverse osmosis water
TAE buffer 40mM Tris-acetate, 2mM EDTA
TBE buffer 90mM Tris-borate, 2mM EDTA
LB medium 5g Bacto yeast extract, lOg Bacto-tryptone, lOg 
NaCl made up to 11 with sterile water and 
autoclaved.
TB medium lOg Bacto-tryptone, 5g NaCl made up to 11 with 
sterile water and autoclaved
NZY broth 5g NaCl, lOmM MgCL, lOg NZ amine, 5g Bacto 
yeast extract made up to 11 with sterile water and 
autoclaved.
L-AGAR 6g agar added to 400ml LB. Autoclaved for 15 
minutes.
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M9 media lOx 60g Na2HP0 4  monohydrate, 30g K H 2 P O 4  
trihydrate, lOg NH4CI, 5g NaCl, 30mg CaCl2.2H20  
made up to 11 with sterile water and autoclaved.
SOC media 20g Bacto-tryptone, 5g Bacto yeast extract, 1 OmM 
NaCl, 2.5mM KC1, lOmM MgCl2, lOmM MgS0 4 , 
20mM D-glucose made up to 11 with sterile water 
and autoclaved.
DNA sample buffer (6x) 0.25% bromophenol blue, 0.25% xylene cynaol FF,
30% glycerol.
A.3 Cloning and PCR  
A.3.1 Donated constructs
The following constructs were generously provided for this work. Human cDNAs 
encoding Skpl and Fbxo7 were consecutively cloned into the expression plasmid 
pGEX-KG (Guan and Dixon 1991) to yield di-cistronic constructs which were 
provided by Heike Laman (Wolfson Institute for Biomedical Research, University 
College London, London , U K ) . This expression plasmid was adapted by Phillip 
Knowles (Structural Biology Laboratory, Cancer Research UK) to contain a TEV 
cleavage site. Human cDNAs of Cull (14-312) were cloned into pGex(KG) using the 
Ncol and Xhol restriction sites and this construct was also supplied by Heike Laman. 
Human cDNAs o f PI31 (1-151) were cloned into the expression plasmid pET-28a(+) 
(Novagen) by Neil McDonald (Structural Biology Laboratory, Cancer Research UK).
A.3.2 Vectors
PGEX-KG was used to express all Fbxo7-Skpl and Cull constructs; this system is 
discussed in section 2.1.1. The pET expression system (Novagen) was utilised for 
expression o f PI31. The pET system was originally developed by Studier and Moffatt
Potassium salts 16.5mM K2HPC>4 and 3.9mM KH2P0 4  in sterile 
water and autoclaved.
Casamino acids 0.25g casamino acids (Gibco) made up to 11 with 
sterile water and 0.22pM filtered. Used at 4ml per 1 
of NZY medium.
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(Studier and Moffatt 1986) and then commercially developed by Novagen. The 
expression plasmid pET-28a(+) contains an amino-terminal poly-histidine (His) tag 
for affinity purification, a thrombin cleavage site for removal o f the His-tag and a 
kanamycin antibiotic resistance marker. It also contains the l i l a c  promoter, which 
consists o f a lac operator sequence downstream of the 11 promoter as well as the 
promoter and coding sequence for the lac repressor (lacI), oriented so that the l i la c  
and lacl promoters diverge. FB810 cells (section A.4.1) contain a chromosomal copy 
of the gene for 11  RNA polymerase, the lacl gene and the lacUV5 promoter. When 
the pET28 vector is used in FB810 cells the lac repressor acts at both the lacUV5 
promoter in the host chromosome to prevent the transcription of the T7 RNA 
polymerase gene and at the l i l a c  promoter to block the transcription o f the target 
gene. IPTG can be used to induce the expression of T7 RNA polymerase under the 
control of the lacUV5 promoter. The T7 RNA polymerase in turn transcribes the 
target DNA in the expression plasmid. This provides a tightly controlled expression 
system whereby the concentration o f IPTG can be adjusted to optimise the expression 
of soluble target protein.
A.3.3 Oligonucleotides
Oligonucleotides were synthesised by the Cancer Research UK Oligonucleotide 
Synthesis Department and purified by ethanol precipitation. Oligonucleotides longer 
than 45 nucleotides were purified by HPLC. After closure of this facility in July 2004 
all oligonucleotides were purchased from Sigma-Genosys.
A.3.4 Plasmid purification
Plasmid DNA was purified using either a Qiagen maxiprep kit or miniprep kit 
according to the manufacturers instructions. Plasmid concentration was calculated by 
measuring the absorbance at 280nm in a Pharmacia Biotech Ultrospec2000 
spectrometer compared to a blank. Plasmid DNA was sequenced by PCR using the 
BigDye™ Terminator Cycle Sequencing kit (PE Applied Biosystems) according to 
the manufacturers instructions. Sequencing reactions were analysed by the Cancer 
Research UK equipment park by capillary sequencing using an ABI Prism 3730.
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A.3.5 Polymerase Chain Reaction (PCR)
PCR amplification (Old and Primrose 1994) was carried out using an initial cycle of 
denaturation at 95°C for 5 mins, annealing at 3°C below the Tm of the primers for 4 
mins and extension at 72°C for 4 mins. This was followed by 25 cycles of 
denaturation, annealing followed by extension for one minute at each o f the three 
steps. Reactions typically contained 0.1 pg template, lOpmole o f each primer and 2 
units o f Vent DNA polymerase in a total volume of 50pl 1 x Thermopol buffer (NEB) 
supplemented with 1.5mM MgSC>4 and 0.5mM each of dATP, dCTP, dGTP and 
dTTP. If this procedure did not succeed in producing a clean DNA product the 
Optiprime kit (Stratagene) was used to optimise the PCR conditions.
Production of all single base pair mutations used in this thesis was performed using 
the Quikchange kit (Stratagene) and primers in Figure A.l
I90E gtg gag age age atg gag etc aat gtg ctg g
I83E tc ctt gtg aaa gee gag ace gtg gag age
V6R atg geg ggc ctg gag cga ctg ttc gca teg
L7M g geg ggc ctg gag gta atg ttc gca teg gca geg ccg g
K49A ggc ggg tcc caa tga tgc gaa gtc aga act get g
K72A cct ccg gta tga gta tgc gga tgg gtc cag aaa g
K81A cag aaa get cct tgt ggc age cat cac cgt gga ga
K125A ctt cca cag gac eta ege gaa cag tga gga get t
Figure A .l -  5 ’ Primers used to create PI31 mutant proteins
3’ primers are the reverse complement of the 5’ primer in each case.
A.3.6 Restriction Digests
Restriction digests were performed using the supplied buffers at recommended 
temperatures (NEB). Typically, 1-2 units o f enzyme were used per pg o f DNA.
A.3.7 Agarose gel electrophoresis
DNA was analysed by electrophoresis on 0.8% agarose gels with 0.5pg/ml EtBr 
added and with TAE buffer if  extraction of DNA was required or TBE buffer for a 
purely analytical gel. DNA was purified from agarose gels using the Ultrafree-DA kit 
(Millipore) according to the manufacturers instructions.
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A.3.8 Ligation
Typical ligation reactions contained 50ng cut vector, 3-5 fold molar excess o f insert 
and 40 units o f T4 DNA ligase to a total volume of 10pl of 1 x T4 DNA ligase buffer.
Controls with cut vector with and without ligase were included. The reaction was left 
to incubate at room temperature for one hour and used to transform DH5a MAX 
Efficiency bacterial cells (Gibco). Uncut vector was transformed in parallel to 
monitor transformation efficiency.
A.4 Protein Expression
A.4.1 E.coli host strains
Unless stated otherwise electrocompetent BL21-(DE3 RecA') (designated FB810) 
cells were used for protein expression.
A.4.2 Transformation of chemically competent E.coli cells
Cells were thawed on ice and 1-1 Ong of the transforming DNA was added to the cells 
and mixed gently. The cells and DNA were incubated on ice for 30 minutes. The 
cells were heat shocked for 45 seconds at 41°C and returned to ice for 2 minutes. 
250pl of SOC buffer was added and the cells incubated at 37°C for 1 hour. Selection 
was carried out by spreading the mixture on to dried L-AGAR plates containing the 
appropriate antibiotic and the colonies were counted after an overnight incubation at 
37°C.
A.4.3 Transformation of electrocompetent E.coli cells
50pl o f electrocompetent cells (FB810) were thawed on ice and were mixed with 1- 
5ng o f transforming DNA. The mixture was transferred to a cooled EquiBio 2mm 
electroporation cuvette. The cuvette was then placed in an electroporator (BioRad 
Gene Pulser™) and pulsed at 2.5 V, 25pF and 200Q. 1ml of SOC media was added to 
the cuvette immediately and then plated out on selective AGAR media. The plates 
were incubated at 37°C overnight.
A.4.4 Bacterial Growth Measurement
E. coli growth was monitored by measuring the absorbance at 600nm in a Pharmacia 
Biotech Ultrospec2000 spectrometer compared to a media blank.
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A.4.5 Expression of recombinant protein in E.coli
A single colony from a fresh transformation was inoculated into 100ml o f LB media 
containing the correct antibiotic for the transforming DNA and grown overnight in a 
shaking incubator at 37°C and 220 rpm. The saturated overnight cultures were 
harvested by centrifugation in a Beckman GS-6R at 3000g for 15 minutes and the 
supernatant discarded to minimise transfer of p-lactamase to the large culture. The 
pellet was then re-suspended in fresh LB media and transferred to a 21 baffled flask 
containing 11 LB media with appropriate antibiotics. The flasks were incubated at 
37°C and 175 rpm until an OD600 o f 0.4 was reached. If the cells were to be induced 
at a lower temperature the flasks were transferred to either 18°C or 25°C and allowed 
to grow to an OD600 o f 0.6. IPTG was added to a final concentration of 250pM and 
the cells allowed to grow for 3 hours at 37°C, 4 hours at 25°C or overnight at 18°C. 
The cells were harvested in a Beckman J-6B centrifuge at 4000g for 20 minutes. The 
cell pellets were re-suspended in 35ml of LB and harvested by centrifugation in a 
Beckman GS-6R at 3000g for 15 minutes, the supernatant discarded and the pellet 
stored at -80°C.
For expression trials alternative media was used to optimise protein expression. 
When TB media was used 100ml o f potassium salts were added to 900ml o f TB 
media. When NZY buffer was used 100ml o f potassium salts and 4ml o f casamino 
acids were added to 896 ml o f NZY media.
A.4.6 Expression of Selenomethionine labelled recombinant protein in E. 
coli
Expression of Selenomethionine (Se-Met) labelled proteins was performed in 
methionine auxotroph cells, B834(DE3) cells (Novagen). For the autoclavable 
portion of the media for large scale production o f Se-Met labelled protein 23.02g of 
amino acids (not including methionine) were dissolved to a total volume o f 800ml in 
22.25mM NaOH and the solution was autoclaved. The non-autoclavable portion 
consisted o f lOg glucose, 0.5g M gSO ^FLO , lOpl concentrated H2SO4 and 50g DL- 
SeMet to a total volume of 100ml in lpM  FeCb, lpM  thiamine and 0.05pM CaCh 
and filter sterilised at 0.45pm. These two components were mixed and supplemented 
with 100ml lOx M9 salts and appropriate antibiotics to generate the complete 
medium.
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The media for overnight cultures was the same as above but the Se-Met is replaced by 
0.3mM final concentration o f methionine.
A fresh colony o f B834 competent cells transformed with the construct of interest was 
suspended in 5ml o f the media for overnight cultures as described above and 
incubated overnight at 37 °C and 220 rpm. All 5ml of the overnight culture was used 
to inoculate 0.51 cultures and these were grown as for wild type protein.
A.S Protein purification and analysis
A.5.1 SDS-PAGE
The SDS-PAGE method used was based on Laemmli (Laemmli 1970) and carried out 
basically as described by Sambrook et al (Sambrook et a l 1989). 12% resolving gel 
was used to visualise all proteins described in this thesis and consisted of 12% (w/v) 
acrylamide, 0.3% (w/v) bisacrylamide, 0.3M Tris-HCl pH 8.8, 0.1% (w/v) SDS, 
0.003% TEMED and 0.0003% (w/v) APS. The 3.8% stacking gel consisted o f 3.8% 
(w/v) acrylamide, 0.1% (w/v) bisacrylamide, 125mM Tris-HCl pH 6.8, 0.1% (w/v) 
SDS, 0.003% TEMED and 0.0003% (w/v) APS.
The TEMED and APS were added last as they induce rapid acrylamide 
polymerisation. Gels (plates 1 0 x 8  cm) were cast and run using apparatus purchased 
from Amersham Pharmacia Biotech. Samples to be analysed by SDS-PAGE were re­
suspended in SDS-sample buffer and incubated at 95°C for 2 minutes. Bead-bound 
proteins were eluted in SDS-sample buffer by boiling for 5 minutes. Gels were run in 
1 x SDS-PAGE running buffer with a limiting voltage of 100 V at the beginning of 
the run and 200 V during the second half o f the run. Electrophoresis was continued 
until the bromophenol blue dye front had just run off the bottom of the gel.
Gels were stained at room temperature for at least 5 minutes with Coomassie brilliant 
blue (0.1% Coomassie blue R350, 30% (v/v) methanol, 10% (v/v) glacial acetic acid). 
Gels were destained (45 % (v/v) methanol and 9 % (v/v) glacial acetic acid) at room 
temperature.
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A.5.2 Silver stain
Silver staining was carried out when visualisation by Coomassie brilliant blue was not 
possible using a silver stain kit from OWL Separation Systems according to the 
manufacturers instructions.
A.5.3 Purification of His-tagged proteins
Sonication Buffer: 300mM NaCl, 50mM Tris-HCl pH 8.0, lOmM Benzamadine, 
5mM 2-ME, ImM PM SF.
Wash Buffer: 300mM NaCl, 20mM Tris-HCl pH 8.0, 5mM 2-ME
Elution Buffer: 20mM Tris-HCl pH 8.0, lOOmM Imidazole, 5mM 2-ME
Storage Buffer: 20mM Tris-HCl pH 8.0, 5mM 2-ME
Frozen 1 litre cell pellets were defrosted at room temperature and homogenised using 
a wide bore pipette in 22ml o f sonication buffer. The cells were sonicated on ice 
using a MSE Soniprep 150 sonicator at 14.5pm for 1 min and then 1.5 minutes with 
cooling and end over end mixing in-between. Cell debris was pelleted using a 
Beckman Allegra 64R centrifuge at 29000g and 4°C for 30 minutes. The supernatant 
was mixed on a roller shaker at 4°C for 1.5 hours with 1 ml equilibrated Ni-NTA 
resin (Qiagen) per litre o f culture. The resin was then spun down in a Beckman GS- 
6R at 600g and 4°C for 5 minutes and washed thoroughly prior to elution. The 
protein was then dialysed overnight into its storage buffer.
Depending on the vector used affinity cleavage protease was added and allowed to 
cleave at 4°C overnight. SDS-PAGE was used to monitor the efficiency o f cleavage.
A.5.4 Purification of GST-tagged proteins
Sonication Buffer: lOOmM NaCl, 50mM Tris-HCl pH 8.0, lOmM Benzamadine, 
ImM DTT, ImM PM SF
Wash Buffer 1: lOOmM NaCl, 50mM Tris-HCl pH 8.0, ImM DTT
Wash Buffer 2: 20mM Tris-HCl pH 8.0, ImM DTT
Storage Buffer: 20mM Tris-HCl pH 8.0, ImM DTT
The cell pellet was re-suspended and treated as described for His-tagged protein 
purification to yield a soluble cell lysate containing the GST-fusion protein o f interest.
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The cell lysate was added to 100pi glutathione Sepharose matrix (Amersham 
Biosciences) per 1 o f initial culture. The lysate and resin were mixed together on a 
roller shaker at 4°C for 1.5 hours. The resin was spun down in a Beckman GS-6R at 
600g and 4°C for 5 minutes and thoroughly washed in wash buffer 1 followed by 
wash buffer 2. The resin was re-suspended in 5ml o f storage buffer.
Depending on the vector used affinity cleavage protease was added and allowed to 
cleave at 4°C overnight. Proteins remaining bound to the matrix following cleavage 
were eluted using SDS-sample buffer. SDS-PAGE was used to monitor the efficiency 
of cleavage by analysing both the proteins present in the supernatant and those 
remaining bound to the matrix following cleavage.
A.5.5 Protein Concentration
Protein concentrations were determined according to the method of Bradford 
(Bradford 1976) using Bio-Rad protein assay reagent according to the manufacturers 
instructions.
Proteins for crystal trials were concentrated to between 5 and 20mg/ml using an 
equilibrated Centricon concentrator (Amicon) in a Beckman GS-6R at 3700rpm and 
4°C. The concentrated protein was either stored at 4°C for immediate use or in 50% 
glycerol at -80°C.
A.5.6 Gel filtration
Analytical and purification size exclusion chromatography was performed using the 
AKTA HPLC machine (Amersham Biosciences) using the Superdex 75 and Superdex 
200 columns using the settings described by the manufacturer. Columns were 
equilibrated with 20mM Tris-HCl pH 8.0, ImM DTT and 50mM NaCl and calibrated 
with proteins of a known mass. The calibration o f the columns is not precise as this 
method depends on both the mass and the shape o f the protein (the Stoke’s radius) 
and so it is not possible to directly compare different proteins and obtain an accurate 
result despite being a good method for obtaining an initial estimate. Approximately 
2mg of protein was loaded on to the column for analysis of the molecular weight and 
for purification the protein was concentrated to 500pi and the entire sample loaded.
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A.6 Protein-protein interaction techniques
A.6.1 GST affinity pull-down
GST affinity pull-down experiments were performed by purifying various GST fusion 
proteins as described in 0 but terminating the protocol before proteolytic cleavage of 
the GST moiety and supplementing the storage buffer with 50mM NaCl to prevent 
non-specific binding. The GST fusion protein bound to the glutathione-Sepharose 
resin was used as bait for a variety of prey including purified recombinant proteins 
and cell lysates. These prey were incubated with the bound fusion protein for 1.5 
hours at 4°C on a roller shaker. The supernatant was then removed and the resin 
thoroughly washed using the storage buffer with 50mM NaCl.
Depending on the vector used affinity cleavage protease was added and allowed to 
cleave at 4°C overnight.
The proteins were visualised by SDS-PAGE and bound proteins analysed by mass 
spectroscopy performed by Nick Totty (Protein Analysis Laboratory, Cancer 
Research UK) or by Western blot by Heike Laman (Wolfson Institute for Biomedical 
Research, UCL).
A.7 Biophysical techniques
A.7.1 Isothermal Titration Calorimetry
An ITC instrument consists o f two identical cells composed o f a highly efficient 
thermal conducting material surrounded by an adiabatic material. Heaters located on 
both cells and jackets are activated when necessary to maintain identical temperatures 
between the components. The macromolecule is placed in the sample cell and the 
reference cell is filled with water. During the injection o f the titrant into the sample 
cell the time dependent input of power required to maintain equal temperatures in the 
sample and reference cell is recorded. The heat absorbed or evolved during a 
calorimetric titration is proportional to the fraction o f bound ligand and so the 
accuracy o f the initial concentrations o f the macromolecule and titrant are vital to the 
experiment.
ITC was carried out with the help of Sarah Westcott (Molecular Enzymology 
Laboratory, Cancer Research UK) using the MicroCal ITC equipment according to
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the manufacturers instructions and using methods described in Pierce et al (Pierce et 
al. 1999). All proteins analysed were dialysed into the same storage buffer consisting 
of 20mM Hepes pH 8.0, 50mM NaCl and ImM 2-ME. Fbxo7-Skpl complex purified 
by gel filtration was loaded into the cell and PI31-NTD injected by a syringe. 
Approximately 20juM o f Fbxo7F3-Skpl was in the cell and lOOpM of PI31 FP domain 
in the injectant. Analysis o f the results was performed using UNICORN software 
provided by MicroCal using the one binding site model. Protein concentration was 
calculated using the NanoDrop spectrophotometer to accurately measure the OD280 of 
the protein, as precise protein concentration is critical for correct analysis o f the ITC 
results.
All proteins analysed by ITC were purified by size exclusion chromatography and 
dialysed into the same buffer prior to measurement of their molar concentration. The 
experiments were carried out at 30°C with 28 injections each of lOpl measured with 
stirring and all settings were constant for both wild type and mutant experiments. 
Data corrected for heating o f dilution were fitted using a nonlinear least square curve- 
fitting algorithm (MicroCal) with three floating variables: stoichiometry, binding 
constant and change in the enthalpy o f interaction, which assumes one non­
competitive binding site.
A.7.2 Analytical Ultracentrifugation
AUC experiments were performed with the help of Jane Sandall (Molecular 
Enzymology Laboratory, Cancer Research UK) on PI31-NTD and mutant proteins. 
All proteins were stored and analysed in a buffer containing 20mM Tris-HCl pH 8.0, 
50mM NaCl and 5mM 2-ME. All AUC experiments were performed using a 
Beckman XL-I analytical ultracentrifuge using both absorbance and interference data 
according to the manufacturers instructions. Protein parameters used for data analysis 
and the calculation o f initial experimental parameters were calculated using the 
program SEDNTERP (Laue et a l  1992). Data was analysed using the AUC machine 
software and the programs SEDFIT and SEDPHAT (Schuck 2000) using the model 
monomer-dimer equilibrium in the final analysis.
There are two different methods to obtain data from AUC experiments and each is 
needed to obtain a full characterisation of the protein. Firstly a sedimentation velocity 
experiment was carried out to obtain an initial characterisation of the purity o f the
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sample. This experiment consisted of the application of a centrifugal force and the 
analysis o f the time-course o f the sedimentation process. Secondly a sedimentation 
equilibrium experiment was performed to establish the thermodynamic interactions of 
the proteins using the application of a centrifugal force that permits the diffusion to 
balance the sedimentation such that a time-invariant equilibrium gradient can be 
observed.
The sedimentation process is governed by three factors: gravitational force, buoyancy 
and hydrodynamic friction and from the balance of these three forces the Svedberg 
equation is obtained (Equation A .l). This equation describes a relationship between 
the three directly measurable quantities for a single protein component: the 
sedimentation coefficient (obtained from the migration of the sedimentation boundary 
with time in a sedimentation velocity experiment), the diffusion coefficient (obtained 
from the spread o f the sedimentation boundary with time in sedimentation velocity), 
and the molar mass (obtained from the exponential gradient in sedimentation 
equilibrium).
s  M ( \ -  v r )
Equation A.1 —  = -------------------
D  R T
Where s is the sedimentation coefficient (measured in units of Svedberg, with 1 S = 10'13 sec), D 
is the diffusion constant, M is the protein molar mass, v is the effective protein partial-specific 
volume (which can be predicted from amino acid sequence (Laue et al. 1992)), r is the distance 
from the centre of rotation, R is the gas constant and T is the absolute temperature.
The major parameter obtained from the sedimentation velocity experiment is the 
sedimentation coefficient (s) described in Equation A.2.
1 dr m
Equation A.2 s = —---------= —
(0  r dt f
Where s is the sedimentation coefficient, co2r is the centrifugal field, r is the radius, t is time of 
sedimentation, m is buoyant molecular mass an d /is  the frictional coefficient of the protein.
The approach used to analyse the sedimentation velocity data was to describe it as a 
differential sedimentation coefficient distribution c(s), which describes a 
superposition of sedimentation boundaries of many species with different 5-values 
(Balbo and Schuck In Press). The distribution c(s) and residuals o f the fit were used 
to assess if the c(s) model was adequately describing the data. If the distribution
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contained a single major peak, it was transformed to a molar mass distribution c(M) 
that allowed estimation o f the molar mass o f the main species (Schuck 2000).
The theoretical description o f reversible protein interactions is conceptually simple in 
sedimentation equilibrium conditions because chemical equilibrium and mechanical 
sedimentation equilibrium can be achieved simultaneously. This then requires only 
equilibrium thermodynamics to describe the model because the mass action law 
applies across the cell. In contrast, sedimentation velocity is governed by 
thermodynamics but also by the reaction kinetics and hydrodynamics making the 
theoretical description more complex (Balbo and Schuck In Press).
Sedimentation equilibrium experiments utilise the fact that at lower rotor speeds the 
transport of sample down the centrifuge cell is balanced by diffusion back up the cell 
due to the creation of a concentration gradient. Sedimentation equilibrium is 
established when no change in the concentration distribution o f any component is 
detectable.
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A p p en d ix  B  X -ra y  crysta llography m ethods and theory
B .l Protein crystals
B.1.1 Crystallisation
The basic strategy for crystallisation is to bring a protein solute to a limited degree o f 
supersaturation (Ducruix and Griege 1992).
There are three discrete zones where the solution is supersaturated (Figure B .l):
1) Precipitation zone where the excess o f protein molecules separate from solution 
to form amorphous aggregates.
2) Nucleation zone where the excess of protein molecules aggregate in a crystalline 
form.
3) Metastable zone where well ordered crystals of a large size can be grown 
providing nucleation has already taken place.
Two techniques for setting up crystal trials were used to find the optimum path through 
phase space (Figure B .l); vapour diffusion (either using sitting or hanging drops) and 
microbatch (either using paraffin oil (Chayen et a l 1990) or A l’s oil (1:1 silicon and 
paraffin oil) (D'Arcy et al. 1996)).
In both sitting and hanging drop vapour diffusion experimental setups (Figure B.l a) 
typically a 1-5 pi drop of sample was mixed with a l-5pl drop of reservoir solution. The 
initial precipitant concentration in the drop was therefore lower than that in the 
reservoir. In order to reach equilibrium the reservoir draws water from the sample drop 
increasing the concentration o f precipitant and protein solute in the drop. Both sitting 
drops and hanging drops sample the same area of phase space through the nucleation 
and metastable zones.
Microbatch experiments sample a different area of phase space to vapour diffusion 
(Ducruix and Griege 1992) as equilibrium is reached rapidly. For all microbatch 
experiments lp l o f protein was mixed with lpl of crystallization solution and placed 
under oil. When the drop is placed under paraffin oil (Figure B .lb) very little 
evaporation is possible and so the concentration of the protein is constant. When Al’s 
oil is used (Figure B .lc) water can permeate the oil allowing evaporation and 
concentration o f the sample over time.
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Figure B .l - Phase diagram and crystallisation techniques
A. Vapour diffusion set-up for hanging and sitting drops. B. Microbatch using paraffin oil. C. 
Microbatch using Al’s oil. Each point on the curves corresponds to a relative concentration at 
which the solution is in equilibrium with the precipitating agent. Arrows show the path through 
phase space for each type of experimental set-up. Set-up diagrams adapted from the Hampton 
website (http://www.hamptonresearch.com).
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B .l.2 Crystal packing and space groups
A crystal is a three dimensional periodic array of molecules characterised by a repeating 
unit, the unit cell, that can be translated to generate its crystal lattice. The 
crystallographic unit cell is described by the vectors a, b and c and by the length of 
these vectors (a, b and c) and the angles between them (a, p and y) which are called the 
unit cell parameters and describe the lattice symmetry. In addition to the translational 
lattice symmetry a unit cell can also have additional internal symmetry such as screw 
rotations, mirror planes, centres o f symmetry (inversion centres) and rotation inversion 
axes (Drenth 1994). The lattice symmetry and internal symmetry together define the 
space group o f the crystal. Proteins are made o f chiral L-amino acids, which precludes 
symmetry elements with inversion or mirror operations and so the combination of 
symmetries found in protein crystals are limited to only 65 out o f a possible 320 
possible space groups (Ducruix and Griege 1992; Hahn 1996). The smallest portion of 
the crystallographic unit cell which can be used to generate the complete unit cell by 
applying the whole set o f symmetry operations of the specific space group is called the 
asymmetric unit (AU).
B .l.3 Characterisation of the crystal
With the knowledge of the space group and the unit cell constants the Matthews co­
efficient (Vm) can be calculated to estimate the number o f molecules o f protein and the 
solvent content in the asymmetric unit (AU) o f the crystal (Matthews 1968).
VEquation B.l Vm = --------
1  1  j l  !-TM x Z
Where Vm = Matthews co-efficient, V = Volume of unit cell (A3), M = molecular weight of protein 
(Da) and Z = No. of molecules in the unit cell (No. asymmetric units x No. molecules in 
asymmetric unit)
The range for Vm for protein crystals is typically found to be between 1.66 and 4.0 
corresponding to solvent contents o f 25% to 70% when assuming the partial specific 
volume of the protein is 0.74ml/g. Using this it is possible to calculate Vm assuming the 
number o f molecules per AU = %, Vi, 1, 2, 3 etc and from this narrow down the possible 
values. If Vm falls far outside the range then the number o f molecules per AU assumed 
is likely to be incorrect because the packing of the molecules is either impossibly dense 
or too distant to form a 3D-lattice.
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B.2 X-ray diffraction by crystals
B.2.1 How X-rays interact with a crystal lattice: Bragg’s law and the Ewald 
construction
X-rays are scattered by the electrons within the atoms that make up proteins. A charged 
particle that interacts with an electromagnetic wave experiences a force, which causes it 
to oscillate. This causes it to act as a new source of electromagnetic radiation and so 
‘scatter’ the incident radiation. This interaction can only be observed if the dimensions 
of the particle are o f the same order of magnitude as the wavelength o f the radiation; 
therefore X-ray radiation with a wavelength in the range o f 1-1.5 A can be used to study 
the structure o f matter at atomic resolution.
In order to observe constructive interference the X-rays must scatter in phase in a 
relationship described by Bragg’s law (Equation B.2).
Equation B.2 2d  sin 6  = nX
Where 0 = angle of diffraction, X = wavelength, n = integer value and d = inter-planar spacing 
between atoms
Bragg’s law states that diffraction spots will only be observed at the angle o f incidence 
at which the path length between the wave scattered from each plane is equal to an 
integer number o f wavelengths. This relationship means that every atom contributes to 
every diffraction spot. The resolution of the X-ray diffraction pattern is the minimum 
inter-planar spacing (dmin) o f a set of planes from which the diffraction can be observed.
Rearrangement o f Bragg’s law reveals that 0oc(l/d) which means that it is easier to 
represent the diffraction data using a reciprocal lattice based on 1/d which varies as 
sin0. This reciprocal lattice can be used to describe the unit cell edges as a/h, b/k and c/1 
where h, k and 1 are integers and are called the Miller indices. The notation (hkl) is used 
to describe the plane defined by the h, k and 1 Miller indices. The space described by 
the Miller indices is referred to as reciprocal space.
The Ewald construction is a theoretical method to help understand diffraction from a 
crystal. This construction uses the Bragg equation re-written in vector form (Equation
B.3).
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Equation B.3 S =  S -  So
Where S is the scattering vector which also defines a reciprocal lattice point in the diffraction and 
| s | = | s0 | = 1/A.
Only when the vector triangle given by Equation B.3 and described in Figure B.2 is 
satisfied does diffraction occur. The Ewald sphere is only applicable if the direction of 
the beam is parallel to s for the orientation of the crystal. Providing these conditions are 
satisfied diffraction occurs whenever a point of the reciprocal lattice lies exactly on the 
Ewald sphere.
Figure B.2 -  The Ewald sphere
The sphere has a radius MX, the centre of the reciprocal lattice is at O, s0 indicates the direction of 
the incident beam and s indicates the direction of the scattered beam. This is a 2-dimensional 
representation of the sphere adapted from Drenth, J (Drenth 1994)
Each lattice point (reflection) can be characterised by the phase, amplitude and the 
position o f the lattice point in reciprocal space. This relationship is described as the 
structure factor ( F h k i )  and is described in Equation B.4. In order to interpret Equation
B.4 for the position h k l  the phase of each reflection must be known but this information 
cannot be measured directly and this is known as the phase problem.
Equation B.4 p  ^  =  \ p hkJ\ Q X p [ ia (h k l )]
Where IFhul is the structure factor amplitude and a  {hkl) is its phase
Protein crystals have a unit cell much larger than the wavelength o f the radiation used 
and so in order to measure data for all reflections the crystal is rotated to bring 
successive reflections into a diffracting position. The rotation method was employed 
for all data collection in this thesis and is where the crystal is rotated about a single axis
reciprocal
lattice
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(cp) through a narrow, defined angle (Acp) during each exposure to the X-rays. All 
reflections that satisfy the Bragg equation over this angle are recorded as diffraction 
spots on a single image.
B.2.2 X-ray sources and detectors
The X-rays used for protein crystal diffraction are typically generated by two different 
sources, either rotating anodes or synchrotrons.
Rotating anodes produce X-rays by focusing an accelerated beam of electrons in a 
vacuum onto a metal anode, typically copper. When the beam hits the metal most of the 
energy is liberated as heat, however some electrons will absorb a small amount of the 
energy and move to a higher energy state. When the excited electrons return from the 
higher orbitals to their normal energy state the energy is released in the form of X-ray 
radiation o f a characteristic wavelength. The wavelength is dependent on the two 
orbitals between which the transition of the electron occurs. There are typically two 
wavelengths emitted from a copper anode (K<x= l .54 A and Kp=l .39 A). The Kp peak is 
filtered out and radiation focussed, using mirrors, onto the protein crystal (Drenth 
1994).
Synchrotron radiation sources produce X-rays by utilising the fact that charged particles 
travelling at relativistic speeds emit radiation in the X-ray range when they undergo a 
change in direction. In a synchrotron electrons at 2-6 GeV are forced by dipole magnets 
to adopt a curved path causing a constant change in direction and therefore a constant 
source of X-rays (Sweet 1998). Synchrotrons produce white radiation from which 
specific wavelengths can be chosen using a monochromator. Helliwell (Helliwell 1997) 
discusses experimental considerations.
The intensities o f all the diffracted X-rays need to be measured in order to determine a 
crystal structure. A detecting device is required to measure the position and intensity of 
the diffracted beams. Accurate measurement of the diffraction pattern was performed 
using either a MAR storage phosphor-based image plate or a charge-coupled device 
(CCD).
B.2.3 Cryo-crystallography
Exposure o f protein crystals to X-ray radiation causes damage due to the interaction 
between the molecules in the crystal and the beam. Energy is dissipated in two ways: it
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produces heat through the thermal vibrations of the molecules and it provides the energy 
to break the bonds between atoms. The mechanisms for producing reactive radicals are 
direct (i.e. damage to the poly-peptide bonds) or indirect (reactive H* or OH* formed 
by the destruction o f a water molecule). The thermal energy within the crystal can 
allow these free radicals to diffuse through the crystal causing further damage. At cryo 
temperatures ( 1 0 0  K) these reactive particles are immobilised in the crystal and cause 
less secondary damage (Garman 1999). Garman and Doublie (Garman and Doublie 
2003) discuss experimental consideration and procedures.
The high water content o f protein crystals means that cryo-protectant agents (e.g. 
glycerol, PEG 400 and N-paratone) have to be employed to avoid the destructive effects 
o f crystalline ice formation during freezing.
B.2.4 Data collection
During data collection two factors influencing the completeness o f data must be 
considered: 1) the symmetry o f the reciprocal lattice and 2 ) the accuracy of the 
measured reflections which depend on factors such as the exposure time, crystal 
diffracting power and characteristics o f the detector and X-ray source. The redundancy 
of the dataset is also important because when a reflection is measured several times its 
value can be determined with greater accuracy. The number of times each reflection is 
measured is referred to as the multiplicity of the dataset.
While theoretically the diffracted X-rays should form a sharp spot on the detector in 
practice various factors cause it to have a finite size. For example the incident radiation 
has some divergence and all parts of the crystal are not in the same orientation as 
described in the Ewald construction. X-rays from rotating anodes are parallel within a 
small angle (0.2-0.40), which is improved for synchrotron radiation (-0.001°), and 
crystals are composed o f small mosaic blocks slightly mis-oriented with respect to each 
other (Dauter 1999). The wavelength of the radiation is also imprecise and so all these 
effects cause the diffraction from a particular reflection to be spread over a range of 
crystal rotation. This means that some reflections come into a diffracting position 
during one exposure and finish during the next; these are known as partial reflections.
All of the considerations for a complete dataset were taken into account for each 
specific experimental setup in this thesis by using the STRATEGY option within the
148
References
Mosflm program (Leslie 1992) to calculate the initial oscillation cp angle, oscillation 
range and the number o f images needed to obtain a complete dataset.
B.2.5 Processing data in Mosflm
X-ray diffraction data consists of many images each containing the intensity and 
position o f many reflections. The aim of data processing is to integrate this raw data 
into a three-dimensional representation of the reciprocal lattice points with their 
measured intensities. Several program suites are available to process X-ray diffraction 
data; however in this thesis only Mosflm (Leslie 1992) was used.
The first stage in data processing is obtaining an accurate estimate for the unit cell and 
space group o f the crystal, this is done using a process called autoindexing based on a 
one-dimensional Fast Fourier Transform (FFT) method (Powell 1999). Using several 
images can further improve this estimate by refining the cell parameters, the crystal to 
detector distance, parameter defining the orientation of the crystal with respect to the 
incident beam and the mosaic spread o f the crystal independently o f all detector 
parameters and distortions by a process called post-refinement. After calculating these 
parameters the whole dataset is integrated to produce a file containing a list of 
reflections and their intensities after applying a correction for the effects o f polarization 
and the Lorentz correction (which is a geometrical correction dependent on data 
collection technique).
B.2.6 Scaling and analysing the data
The program SC ALA (Evans 1993, 1997) was used to scale both reflections and 
datasets together; it also removes the effects o f beam fluctuation and mechanical errors. 
SCALA produces scaled intensities for the unique indexed reflections and also outputs 
statistically useful values that can be used to analyse the data quality and the integration. 
Data quality can be judged using the statistical indicator Rmeas, which is derived from a 
comparison of the intensities. This gives an average ratio o f the spread o f intensities of 
the multiply measured symmetry equivalent reflections to the estimated value o f the 
reflection intensity (Equation B.5) (Diederichs and Karplus 1997).
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Equation B.5 R,meas
h  i
1 ”*
Where nh is the multiplicity, I h =  —  ^  I h . and I h f is intensity o f  the ith measurement o f  the h
reflection.
The program TRUNCATE was used to convert the averaged intensities into a file 
containing structure factors. The structure factors are not on an absolute scale and so 
the Wilson plot (French and Wilson 1978) is used to estimate both an absolute scale and 
temperature factor for a set o f observed structure factors. It is assumed that all atoms in 
the cell have the same isotropic thermal motion and therefore that Equation B .6  is valid; 
however this assumption can only be used for data with a resolution of 3 A or higher.
Where\Fhkl | = observed intensities, f 0 = atomic scattering factor of each atom in the unit cell, 
C=linear scale factor and B=temperature factor
B.3 Phase determ ination by SIR and SAD
The electron density in a crystal can be obtained by calculating the Fourier summation 
in Equation B.7.
Equation B.7 p (x , y , z )  = —- | exp[- 2m(hx + ky + lz)+ ia w ]
^ hkl
Where \Fhjd | = structure factor amplitude of reflection (hkl) including the temperature factor,
V=volume of the unit cell, p = electron density, a = phase angle and x,y,z are the co-ordinates of 
the atom in the unit cell.
The structure factor amplitude can be obtained directly from diffraction data but no 
information is available for the phase angles. Two methods to solve the phase problem 
were used for the PI31-NTD structure determination; Single Isomorphous Replacement 
(SIR) which requires the attachment of heavy atoms to the protein molecules in the 
crystals and Single Anomalous Diffraction (SAD) which depend on the presence of 
strong anomalously scattering atoms within the protein.
Equation B.6
2
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One useful tool in obtaining experimental phase information is the Patterson function 
which is a Fourier summation that does not require any phase information and relies on 
the square of the structure factor amplitude as can be seen from Equation B.8 .
Equation B.8 P { u v w )  =  ^ ~ Y ){F hkit c o s[2;t(/7w +  k v  +  /w)]
V  hki
Where P(uvw) is the Patterson function of u,v,w relative co-ordinates in Patterson space
In general the Patterson function will have a zero value because the vector will be zero 
as one or both ends will be at zero electron density. It will only have positive value if 
both ends are at atomic positions. For N atoms in a unit cell there will be N2 peaks in 
the Patterson map which is obviously a prohibitively large number to interpret for 
proteins however it can be used to find the location of a limited number of heavy atoms 
(Drenth 1994).
B.3.1 Heavy atom derivatives to solve the phase problem
SIR experiments require both data from a native protein crystal and a crystal o f at least 
one heavy atom derivative, which is isomorphous to the native crystal (having the same 
cell dimensions and orientation o f molecules). This isomorphism means that the 
intensity differences between the native and the derivative are due to the heavy atoms 
and not to any other changes within the crystal.
The known data in an SIR case are the amplitudes o f F p  and F PH (structure factors of the 
native protein and the heavy atom replacement protein respectively). Their phase 
angles are not yet known; however for each reflection there is a difference in | F | 
described in Equation B.9 and Figure B.3.
Equation B.9 =  \^ ph \ ~  \^p \
This means that the Patterson map with the coefficients (a If^ ) 2 will give a map of the 
heavy atom arrangement in the unit cell.
The high solvent content o f protein crystals means that solutions of heavy atoms can be 
soaked into the protein crystal to produce derivatives. This is a trial and error process 
with variables including solubility of heavy atom compounds in the crystallisation 
solution, soaking time and concentration of the heavy atom compound (Ducruix and 
Griege 1992).
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A. B.
R R
Figure B.3 -  Argand diagram  showing structure factors for SIR and SAD
A. The structure factor triangle for isomorphous replacement. B. Structure factor triangles for 
anomalous scattering, the structure factors Fp(-), FPH(-), Fh(-) and F” H(-) have been reflected with 
respect to the horizontal axis and combined with the structure factors for reflection (h, k, 1). These 
diagrams have been reproduced from Drenth (Drenth 1994).
B.3.2 A nom alous d iffrac tio n  to solve the phase problem
Diffraction is caused by electrons surrounding the atomic nucleus and is represented by 
the atomic form factor y°(0). If X-rays provide electrons with the energy required to 
leave an energy shell an anomalous signal is observed which can be expressed as a 
complex number and is dependent on the wavelength i f  + i f '). / '  is proportional to the 
atomic absorption of X-rays and/  follows the derivative of this. The full atomic form 
factor is shown in Equation B.10.
The atomic absorption increases with atomic number and as the energy of the X-rays 
approach the resonant energy o f excitation of orbital electrons. As the energy moves 
below such a value the absorption diminishes rapidly (Hendrickson and Ogata 1997).
When the atomic form factor is real F(h,k,l)=F(-h,-k,-l) and <p(h,k,l)=-cp(-h,-k,-l); this is 
known as Friedel’s law. The effect of anomalous scattering is that this law no longer 
applies, and so differences between intensities of Friedel pairs can be used as a means to 
obtain the phase angle for each structure factor using the difference described in 
Equation B.l 1 and shown in Figure B.4.
Equation B.10 /(M = /o(0)+/’W+«/"W
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Equation B . l .  A |F | |_  =
Where \Fph (+)) represents the amplitude of the structure factor for a reflection (h, k, 1) and 
|Fph (“ ]j is the amplitude for the reflection (-h, -k, -I).
This means that the Patterson map with the coefficients (a \f \anof  will give a map of the 
heavy atom arrangement in the unit cell.
A multiple anomalous diffraction (MAD) dataset contains data from the same crystal at, 
usually, three different wavelengths, the peak, the inflection and the remote wavelength 
(Figure B.4) in order to maximise the information from obtained from the anomalous 
signal (Hendrickson and Ogata 1997). Single anomalous diffraction (SAD) datasets are 
generally collected at the peak wavelength where time, radiation damage or other 
limitations prevent a MAD dataset from being collected. SAD data can be used to 
obtain phases; however the data must be of good quality to ensure an accurate 
anomalous signal (Dauter et al. 2002) and additional methods such as density 
modification are required to overcome the phase ambiguity (Dodson 2003).
X-ray w avelength in A
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Figure B.4 -  T h e o r e t ic a l/ a n d / '  plot for Se K edge
Plotted using the server http://www-ssrl.slac.stanford.edu/absorb.html (Brennan and Cowan 1992). 
Arrows mark the position of the wavelengths for: A) inflection B) peak and C) High energy 
remote.
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Identification o f the heavy atom sites and estimation of phases from either isomorphous 
replacement or anomalous data were performed using SOLVE (Terwilliger and 
Berendzen 1999) or SHELXD (Schneider and Sheldrick 2002) using automated 
Patterson searching, cross-vector matching and quality control methods. All work using 
the program SHELX reported in this thesis was performed by Judith Murray-Rust 
(Structural Biology Laboratory, Cancer Research UK).
Having obtained experimental amplitudes and experimental phases based on a subset of 
atoms it is theoretically possible to produce an electron density map. However in 
practice early electron density maps from SIR and anomalous scattering are very noisy, 
and so density modification is applied to recognise and reduce errors in the phase 
estimate. When the map has been corrected phases are re-calculated and re-combined 
with the experimental phases. This can yield a better map and can also be used to solve 
the phase ambiguity in a SAD or SIR experiment. The programs RESOLVE 
(Terwilliger 2000) and DMMULTI (Cowtan 1994) were used in this thesis to perform 
density modification and solvent flattening. RESOLVE uses a maximum likelihood 
approach to density modification while DMMULTI allows data to be combined from 
two different crystals for density modification. The program uses Wang solvent 
flattening, density averaging and histogram matching (comparing experimental density 
distribution to a standard map at that resolution).
After density modification the protein structure can be built and refined. Programs O 
(Jones et al. 1991) and COOT (Emsley and Cowtan 2004) were both used in this thesis 
for building the structure. Knowledge o f the position o f the Se substructure using the 
anomalous signal also helped with the original chain tracing of the molecule.
B.4 Refinement
The goal o f refinement is to maximise the correlation between the correct 
stereochemical model and the observed structure factors. This is measured by two 
factors known as Rf** and Rfree and these are defined in Equation B.12. The Rfree takes a 
random subset o f 5% of the reflections and excludes them from refinement therefore 
offering a method o f cross-validation (Brunger 1992).
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hklczT
Z
Equation B.12 _ hklcJ
Z f * A" '  ZK
Where T is the subset of reflections used for cross validation
Refinement programs use a target function in order to obtain the best possible model. 
The program used for refinement in this thesis was REFMAC 5.0 (Murshudov et al. 
1997) which employs a maximum likelihood function using Bayes’ theorem which says 
that the best model is that most consistent with the observations. Restrained refinement 
was performed in this thesis, which means that the a priori information about 
macromolecular structures (bond length, bond angles, planarity etc) was used as 
additional information within the refinement.
At the low resolution (2.64A) o f PI31-NTD there were not enough observations per 
parameter to perform anisotropic refinement using anisotropic displacement parameters 
(ADPs) however these parameters can be modelled as those o f a set o f rigid bodies 
using TLS parameters (Winn et a l 2001; Winn et al. 2003). TLS parameters model the 
translation, rotation and screw-rotation of a rigid body and output a matrix that takes 
into account anisotropic behaviour. The output of TLS refinement in REFMAC was 
analysed using the program TLSANL (Howlin et al. 1993).
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